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Adverse reactions or lack of therapeutic efficacy are commonly encountered challenges when
prescribing pharmaceutical drugs to patients. These undesirable outcomes highlight the large
amount of interindividual variability in drug responses, and can often be attributed to differ-
ences in drug metabolism and clearance rates among patients. Patient age and current medica-
tion usage are two variables that can increase or decrease the expression and activity of drug
metabolism by cytochrome P450 enzymes (CYPs), thus impacting responses to other drugs.
Neonates, infants, and children, express CYP enzymes at different levels than adults due to
immature liver functions, and this causes drug responses to differ in pediatric populations. Be-
cause infants and children are not typically included in clinical drug trials, there is a significant
knowledge gap in understanding how CYP expression and liver function may be impacted by
drug treatment in early postnatal life. Antiepileptic drugs (AEDs) are commonly administered
to newborns, infants, and children suffering from acute seizures or chronic epilepsy, however
these medications are known to induce the expression of drug-metabolizing CYPs. This work
has explored the consequences of exposure to two AEDs, phenobarbital and phenytoin, on the
expression and activity of drug-metabolizing CYPs in the liver during postnatal development
in mice. Short-term, as well as long-term, effects on gene and protein expression profiles and
enzymatic activities were evaluated. Our results demonstrate that responses to AED treatment
differ significantly in neonatal mice compared to adults in terms of CYP inducibility and liver
functions that were altered. Additionally, exposure to AEDs at neonatal ages may cause per-
manent effects on gene and protein expression in the liver in adulthood, which could impact
drug efficacy and susceptibility to liver diseases later in life. These differential effects may
be due to epigenetic modifications that are susceptible to alteration by drug treatment in the
maturing liver that does not occur in the fully differentiated adult liver. Overall, these studies
highlight a critical need for a better understanding of pharmacokinetic regulation in pediatric
populations, as drug responses in adults cannot be used for accurate prediction or extrapolation
of drug responses in infants and children.
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Chapter 1
Introduction
In the current, traditional model of clinical healthcare, patients that are diagnosed with a spe-
cific disease or condition are often all prescribed the same medication at the same dosage, with
little regard for individual factors and differences. Whereas this system of medical interven-
tion is successful for some patients, an even greater proportion of patients experience either
no therapeutic efficacy or potentially dangerous adverse side effects. It is estimated that most
major drugs are efficacious only in 25-60% of patients [1]. Additionally, more than two million
cases of adverse drug reactions (ADRs) are reported each year and account for nearly 5% of
total hospital admissions in the United States. Reactions to drugs can be life threatening, and
cause 100,000 deaths annually [2]. Many genetic, physiological, and environmental factors
synchronously play a role to determine how a patient will respond to drug treatment. Under-
standing these individual factors and implementing them into a more personalized model of
therapeutic medical intervention could improve the number of patients that respond positively
and without side effects to drug treatment.
1
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1.1 Drug Responses in Pediatric Populations
Age is a significant factor known to affect drug response, yet the majority of therapeutic medi-
cations are developed and subjected to clinical trials in adult patients only to characterize their
efficacy and safety. Due to ethical and technical constraints, drugs simply are not usually tested
in pediatric or geriatric populations before being approved and reaching the market. Infants
and children, in particular, often demonstrate highly differential effects from adults to the same
drug treatment due to immature renal and hepatic function [3]. Because of the lack of sufficient
testing in pediatric populations, clinicians are left to extrapolate adult efficacy and toxicity data
to their young patients. However, dose extrapolation from adults to neonates and children is not
straight-forward and presents a major clinical challenge. Pediatric patients are not just small
versions of adult patients, and dosing cannot be adjusted based solely upon bodyweight. The
composition of bodily water and fat, plasma proteins, drug clearance rates, and hormone levels
change rapidly throughout postnatal development and play a significant role in drug disposition
[4]. All of these factors should be considered collectively when selecting a dosing regimen for
a pediatric patient, however they are largely overlooked in today's clinical practice.
Due to insufficient clinical testing in neonates and children, approximately 45% of drugs admin-
istered to pediatric patients are used off-label, without proper dosing guidelines and disposition
profiles. Off-label drug use is associated with unforeseen side effects and a higher rate of ad-
verse reactions. ADRs are unfortunately common in infants and children, and nearly half of
total reported ADRs from populations of all ages occur in children under the age of four [5].
Infants younger than the age of one are considered to be the most susceptible to ADRs [6].
Whereas drug reactions in younger patients tend to be non-life threatening, with skin rash and
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gastrointestinal disturbance being the most common, up to 10% of reported pediatric adverse
effects are serious enough to cause hospitalization [7]. The classes of drugs most frequently
associated with adverse side effects include antibiotics, antipyretics, and non-steroidal anti-
inflammatories. Anticonvulsants and antineoplastic agents, while not as commonly utilized,
are known to cause the more severe ADRs in neonates and children [8].
Off-label drug usage in children increases the risk of unanticipated and unpredictable side ef-
fects. Drug responses in pediatric patients often differ greatly from responses in adults, com-
plicating the extrapolation of adult drug data to children. The toxicity and efficacy profile of a
given drug can vary depending on the age of the patient. For example, at toxic doses, the an-
tibiotic chloramphenicol will cause aplastic anemia in adults. In newborns, however, chloram-
phenicol toxicity presents as Gray baby syndrome, and causes vomiting, gray coloring of the
skin, and hypotension [9]. On the contrary, younger patients may also be resistant to the effects
of a drug because of immature drug clearance function. Neonates treated with acetaminophen
for pain management and fever reduction, for example, appear to be more resistant to toxicity
than adults. Acetaminophen is notorious for causing hepatotoxicity if taken in large enough
doses due to accumulation of the toxic drug metabolite, however this adverse event is rarely
reported for infant populations [10]. The goal of drug therapy is the same for pediatrics as it
is for adults: to maximize therapeutic efficacy while minimizing toxicity. However, efficacy
and toxicity varies drastically between children and adults, even when they are treated with
the same drug at the same dose. There is a serious need to further understand the mechanisms
that underlie differential drug responses based upon age and postnatal developmental stage.
Identifying the physiologic factors and cellular mechanisms that contribute to drug responses
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in children is imperative to decrease ADRs and develop a more personalized model of pediatric
medicine.
1.2 Drug-Drug Interactions
A drug-drug interaction (DDI) occurs when the administration of one drug alters the efficacy
or toxicity of another drug taken concurrently. In an increasingly medicated population where
taking several therapeutic drugs at once is increasingly common, DDIs are a significant cause
of variability in drug responses between people. Polypharmacy, or the use of multiple medica-
tions simultaneously, is especially prevalent in geriatric and chronically ill populations due to
comorbidities, and significantly increases DDI risk in these patients [11]. The adverse effects of
drug interactions can range from mild, such as gastrointestinal disruption, to severe, including
arrhythmia, hepatoxicity, hemorrhage, and even death [12]. Approximately 1% of total hospi-
tal admissions are due to adverse effects caused by DDIs [13]. Additionally, drug interactions
present a clinical challenge if they attenuate the efficacy of another medication. Many medica-
tions that are known to interact with the action of other drugs are well-documented and physi-
cians are advised to avoid certain drug combinations. For example, the interaction between
the anticoagulant warfarin and many antibiotics is widely known. Antibiotics are commonly
prescribed medications, and can alter the metabolism of warfarin as well as the gut microflora
that produce vitamin K. Both of these factors increase the efficacy of warfarin, and can cause
dangerous excessive bleeding in patients. Accordingly, the dose of warfarin is typically de-
creased in patients that are taking an antibiotic concomitantly [14]. Despite our knowledge on
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drug combinations that can cause adverse effects and efforts to avoid them, many patients still
experience unexpected and undesirable drug responses as a result of DDIs.
Pediatric patients are also highly susceptible to adverse events caused by DDIs, perhaps even
more so than adults. Although polypharmacy tends to be less common in younger populations
due to fewer comorbidities, 50-75% of hospitalized children are exposed to potential DDIs [15].
The most common types of prescription drugs indicated in pediatric drug interactions are opi-
oids, antibiotics, neurologic agents, gastrointestinal agents, and cardiovascular agents. In chil-
dren that experience clinically serious DDIs, the most frequently reported adverse events are
respiratory depression, bleeding risk, QT interval prolongation, central nervous system depres-
sion, and hyperkalemia [16]. Significant drug interactions can also occur with over-the-counter
medications, such as ibuprofen, which are routinely given to children without physician consult.
Due to the lack of clinical drug testing in pediatric populations, physicians are left to extrapo-
late adult dosing and DDI data to infants and children. Even though multiple studies indicate
pediatric patients cannot be treated as ’small adults’ in terms of drug pharmacokinetics, most
methods of pediatric dose adjustments are based on simple algorithms that extrapolate doses
from adult data based on body weight, height, or body surface area. However, one algorithm is
not appropriate to use for determining equivalent doses for all stages during postnatal develop-
ment. Additionally, utilizing more sophisticated physiologically based pharmacokinetic model-
ing (PBPK) requires robust input data, which is typically unavailable in sufficient amounts from
infant and children populations [4, 17]. There is still a critical need to understand other fac-
tors that contribute to enzyme induction, DDI development, and pharmacokinetic differences
in newborn, infant, and child populations to better determine drug selection and dosage.
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1.3 Aim of the Project
There is a serious lack of adequate clinical drug testing in pediatric populations. However, it
is unlikely that all clinical trials will involve more infants or children due to ethical, technical,
and financial constraints. Sufficient data on pediatric responses to existing drugs is also usually
limited or not even available. The extrapolation of adult clinical data and dose selection to
infants and children is currently flawed, and pediatric drug responses can be unpredictable
and unique from adult responses. Developing a deeper understanding of the mechanisms that
cause pediatric drug responses to differ from adult drug responses is key to preventing ADRs
and DDIs in younger patients in the absence of thorough clinical testing. Making informed,
developmental stage-appropriate decisions for drug choices and dosing regimens can improve
precision medicine in pediatric patient populations.
The goal of this research was to examine the induction of hepatic CYP enzyme expression and
activity in response to drug treatment during postnatal maturation. A mouse model was uti-
lized to investigate the long-term alterations to drug metabolism and CYP expression follow-
ing exposure to two pharmaceutical compounds, phenobarbital and phenytoin, at the neona-
tal age. Acute CYP induction in response to drug treatment was compared across a range
of ages beginning at the neonatal stage and extending through adulthood. The differences in
short-term enzymatic responses between neonates and adults were also examined. To better
understand the molecular mechanisms that contribute to the regulation of CYP expression at
different ages during postnatal maturation, a proteomic study was implemented and changes in
post-transcriptional modifications were revealed.
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The results generated from this research will provide fundamental data to developmental phar-
macological researchers, as well as pediatric clinicians, on how drug responses can differ de-
pending on age and stage of postnatal maturation. Although the majority of this work was
performed in a mouse model, the information can be utilized as proof of a concept that may
one day be validated in humans.
Chapter 2
Literature Review and Background
2.1 Pharmacokinetics and Drug Responses in Adults
The pharmacokinetic and pharmacodynamic properties of a drug determine its effect in the
body. Pharmacokinetics involves characterizing the absorption, distribution, metabolism, and
excretion of drug compounds in relation to their plasma concentration over time. Pharmacody-
namics is focused on studying the physiologic effects of a drug on the body, such as receptor
binding and biological outcomes [18]. Genetic, physiological, and environmental factors can
all have an impact on a drugs pharmacokinetic and pharmacodynamic profile in a particular
patient. Genetic factors, such as mutations or single nucleotide polymorphisms (SNPs), may
affect the expression of proteins that are either drug targets, or enzymes involved in drug clear-
ance. Physiologic factors including age, sex, and comorbidity, and environmental factors in-
cluding additional medication usage, toxicants, and diet, can also influence concentrations of a
drug in the circulation and impact drug response [19, 20]. To create the most favorable response
8
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to a therapeutic agent while minimizing adverse effects, it would be beneficial to incorporate
all factors that may impact pharmacodynamic and pharmacokinetic properties when selecting
a drug and dose for an individual patient.
The biological processes involved in pharmacokinetics are particularly variable among patients
[21]. In order for drugs to be therapeutically efficacious while also minimally toxic, their
plasma concentrations must be maintained within a therapeutic range. Alterations to the ab-
sorption, distribution, metabolism, or excretion of a drug will affect bioavailability and, ulti-
mately, patient response. Absorption can be influenced by food intake and the permeability of
the intestinal wall. Distribution is largely dependent on a persons body weight and composition.
Kidney function and the expression of drug transporters contribute to determining the rate of
elimination. Drug metabolism, however, can be considered the process that has the widest range
of interindividual variation. The liver is responsible for the majority of metabolism and is often
regarded as the most important organ in biotransformation, although the kidneys and intestines
also play roles in metabolizing ingested compounds. Hepatic drug metabolism is heavily in-
fluenced by factors such as sex, age, diet, disease state, circadian rhythm, and polypharmacy,
which all significantly contribute to drug disposition [22].
2.1.1 Hepatic Drug Metabolism
The majority of xenobiotic metabolism, or biotransformation, occurs in the liver. This process
is intended to protect the body from potentially harmful exogenous chemicals by increasing
their solubility for efficient excretion in the urine. Endogenous compounds, such as steroids,
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also undergo metabolism in the liver to allow the conversion into their active forms or elim-
ination via degradation. Nearly all oral pharmaceutical drugs will undergo biotransformation
by enzymes in the liver to facilitate their detoxification into drug metabolites, and this is re-
ferred to as first-pass metabolism [23]. The overall process of drug metabolism is divided into
three phases that ultimately enhance the water solubility of a compound in order for it to be
efficiently excreted out of the body. Phase I of drug metabolism is catalyzed mainly by cy-
tochrome P450 enzymes (CYPs), which belong to a family of oxidases that introduce reactive
or polar groups to the chemical structure of their substrate compounds via oxidation, reduc-
tion, or hydrolysis reactions. Reductases, flavin-containing monooxygenases (FMOs), perox-
idases, monoamine oxidases, dehydrogenases, and carboxylesterases also contribute to phase
I of metabolism. Phase II enzymes, including UDP-glucoronosyltransferases (UGTs), sulfo-
transferases (SULTs), N-acetyltransferases (NATs), and glutathione S-transferases (GSTs), are
responsible for conjugating the modified drug compound to other polar compounds to further
increase molecular polarity. During phase III, the now hydrophilic drug metabolites are elimi-
nated from the liver via proteins belonging to the ATP-binding cassette (ABC) and solute carrier
(SLC) families of transporters. Metabolites and any unmodified drug compounds can then be
excreted from the body in the urine [24].
The efficacy or toxicity of a drug is largely dependent on the rate of hepatic drug metabolism
in a patient as this process determines bioavailability. Slower rates of metabolism cause an
increased concentration of the parent drug compound in circulation and a delay in excretion of
drug metabolites. High concentrations of active drug compound in the blood are important for
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its therapeutic efficacy, however excessive levels can lead to toxicity. On the other hand, ele-
vated rates of metabolism decrease the concentration of parent drug compound in the circulation
while increasing the amount of drug metabolites produced. This becomes problematic if the
parent compound is the active form of the drug, because plasma concentrations will fall below
the therapeutic range and a patient might experience a lack of efficacy. The buildup of metabo-
lites can also lead to adverse side effects if they are toxic. In some cases, drug metabolites are
responsible for eliciting the therapeutic effect and drug compounds must undergo biotransfor-
mation to reach their active forms. If so, decreased rates of metabolism could cause attenuated
drug efficacy while increased rates could cause the drugs effects to be excessive [25].
2.1.2 Cytochrome P450 Enzymes
The hepatic CYPs are oxidase enzymes that utilize heme as a cofactor to catalyze monooxyge-
nase and hydroxylation reactions. They are responsible for the metabolism of exogenous drugs,
environmental toxins, and dietary components, as well as the biosynthesis and degradation of
endogenous steroids, lipids, and vitamins. Most life forms, including primates, rodents, ca-
nines, plants, fungi, and bacteria, express CYP enzymes in some amount, and approximately
60 CYP genes have been identified in humans. The individual enzyme isoforms are classi-
fied according to their family number and a subfamily letter, followed by a number to identify
the specific enzyme. All mammals share the same 18 CYP gene families, but the number of
subfamilies and enzymes in each family may differ depending on the organism [26].
Enzymes belonging to the CYP1, CYP2, and CYP3 families contribute most significantly to
the metabolism of pharmaceutical drugs. Approximately 80% of currently marketed drugs are
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substrates for CYP enzymes and will undergo phase I metabolism, which accounts for nearly
50% of overall drug elimination [27]. Drug compounds may be substrates for multiple CYP
isoforms, and one isoform may be responsible for metabolizing hundreds of different substrate
drugs. In contrast, other isoforms have stringent specificity and only bind one or two substrates.
CYP3A4 is often considered to be the most important CYP in terms of drug metabolism due
to its involvement in the biotransformation of more than 50% of medications on the market,
from antidepressants to chemotherapeutic agents to statins. It is also the most abundant iso-
form in the liver, accounting for 30-40% of the total hepatic CYP abundance . Approximately
25% of clinically utilized drugs are metabolized by CYP2D6 and include antipsychotics, beta-
blockers, opioids, and anti-arrhythmics. CYP2C19 metabolizes up to 10% of current clinical
medications, most notably antiepileptic drugs, antidepressants, and proton-pump inhibitors.
Also a member of the CYP2C subfamily, the enzyme CYP2C9 is known to metabolize up to
100 marketed drugs, including non-steroidal anti-inflammatories (NSAIDs) and the anticoag-
ulant warfarin. CYP2B6 has far fewer substrates than the previously mentioned CYPs, but
this isoform plays a significant role in the metabolism of the antidepressant bupropion, the
antiretroviral efavirenz, and even nicotine [28].
Environmental toxicants and dietary compounds can also undergo metabolism by CYP en-
zymes. CYP2E1 is responsible for the majority of the metabolism of acetaminophen and
anesthetic medications, but also plays a large role in the detoxification processes of ingested
caffeine and ethanol. CYP1A2 is also known to metabolize caffeine as well as various other
drugs including antidepressants [28].
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CYP enzymes also play important roles in the biosynthesis and degradation of many endoge-
nous compounds. Whereas CYP2D6 appears to metabolize drugs exclusively, most drug-
metabolizing CYPs are also responsible for the metabolism of steroid hormones, fatty acids,
retinoids, prostaglandins, cholesterol, and bile acids produced by the body [29]. Bile acids,
which are products of cholesterol catabolism necessary for fat digestion and absorption, are
metabolized by CYP3A4 to prevent their accumulation and associated toxicity Chen et al.,
2014). On the other hand, CYP7A1, CYP8B1, and CYP27A1 are responsible for synthesizing
bile acids from cholesterol, although these enzymes do not play a major role in drug metabolism
[30]. Endogenous steroids also undergo extensive metabolism by CYP enzymes either for their
activation or degradation. CYP2B6 catalyzes testosterone 16- and 16-hydroxylation, and has
shown to be differentially expressed in male and female liver samples [31]. CYP3A4, 2C9, and
2C19 also metabolize testosterone, along with various other hormones including progesterone
and estradiol [32]. Members of the CYP4 family are responsible for fatty acid metabolism and
regulate lipid catabolism and storage in the liver [33]. Taken together, CYP enzymes are key
players in maintaining the homeostasis of energy utilization, hormone signaling, and nutrient
uptake within the liver and throughout the rest of the body. However, their activity varies widely
among patients [34].
Due to their roles in the metabolism of endogenous compounds and essential nutrients, alter-
ations to the activity of certain CYPs have been implicated in various diseases. Because CYPs
are so prevalent in the liver, it makes sense that many CYPs are involved in the pathogenesis
of hepatic disorders such as alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD),
steatohepatitis, and hepatocellular carcinoma. Enhanced CYP2E1 activity, in particular, has
Chapter 2 14
been associated with with alcoholic liver disease as well as NAFLD, due to the creation of re-
active oxygen species that damage cellular membranes and mitochondria [35]. CYPs are also
highly expressed in the kidney, brain, cardiovascular system, and lungs, and their altered ex-
pression has also been implicated in diseases of these organs as well [36–38]. CYP expression
activity levels not only determine patient responses to drug treatment, but they may also play a
large role in the etiology of the diseases themselves.
2.1.3 Cytochrome P450s in Drug-Drug Interactions
While CYP enzymes are responsible for the detoxification of exogenous drug compounds, their
gene expression and protein function can simultaneously be modified by the administration
or ingestion of other xenobiotics. Certain medications, as well as dietary components and
other environmental chemicals, have the ability to induce or inhibit CYP enzymatic function.
Because of this, concomitant usage of therapeutic drugs with the ability to alter CYP activity is
a major contributor to the cause of DDIs. Compounds known as inducers enhance CYP activity
by increasing the amount of CYP enzymes present via the up-regulation of gene transcription.
Inducers tend to induce specific CYP isoforms rather than CYP activity as a whole. DDIs occur
when an inducer medication is administered at the same time as a victim drug that is a substrate
for the induced CYP. The increased rate of metabolism of the victim drug can cause attenuated
therapeutic efficacy due to increased active drug compound clearance. Adverse side effects
may also occur due to a buildup of drug metabolites that are toxic. On the other hand, certain
medications require bioactivation by CYP enzymes to achieve their therapeutically active form.
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Induced CYP activity, in this case, would enhance therapeutic efficacy and could also lead to
unwanted side effects [39].
CYP activity can also be decreased by drug administration via protein inhibition mechanisms.
In this case, metabolism of substrate drugs taken simultaneously would be down-regulated.
Increases in toxic side effects are possible due to excessive circulating concentrations of the
active drug compound and slowed clearance. Therapeutic efficacy may also be attenuated if the
drug requires bioactivation by CYPs to reach its biologically functional form [40].
2.2 Pharmacokinetics and Drug Responses in Infants and
Children
The process of selecting medications and dosing regimens for pediatric patients must differ
from that of adult patients due to significant alterations in drug clearance during postnatal de-
velopment. The mechanisms involved in drug clearance vary drastically during the first few
years of life and must be taken into consideration. It is also necessary to evaluate drug clear-
ance based on a pediatric patients age, rather than categorizing all infants and children into one
pediatric category [41]. The population of pediatric patients is further broken down into specific
age groups based upon FDA Guidance from 1998 (Guidance for Industry: General Considera-
tions for Pediatric Pharmacokinetic Studies for Drugs and Biological Products). Neonates are
classified as ranging from birth to 1 month, infants are 1 month to 2 years, developing chil-
dren are 2-12 years, and adolescents are 12-16 years. Overall growth and the development and
maturation of organs occurs rapidly during the first two years of life, while body composition
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continues to change throughout childhood and adolescence. Body size, the volume of distribu-
tion, and drug clearance processes have a large impact in determining a drugs pharmacokinetic
profile and are therefore dependent upon age and stage of development. Expression of proteins
that are pharmacological drug targets and disease pathogenesis may also change throughout
postnatal childhood development, and could therefore affect a compounds pharmacodynamics
as well. All of these factors contribute to determining drug response and therapeutic efficacy at
specific pediatric ages, however the effects are poorly understood [42].
All aspects of drug clearance involving the absorption, distribution, metabolism, and excretion
of ingested compounds have been proven to be altered in pediatric populations in comparison to
adults. Absorption determines the onset of drug action as well as the effective dose and can be
influenced by gastric pH and intestinal permeability, both of which are altered in infants [43].
Neonates and infants have significantly higher gastric pH levels than adults that can increase
the bioavailability of acid-labile drugs, while reducing the bioavailability of drugs of weaker
acidity, such as phenobarbital and phenytoin [44]. Differences in intestinal permeability and the
expression of intestinal transporters that allow the passage of drug compounds from the intesti-
nal lumen into circulation also affect the bioavailability of many medications in newborns and
infants [3]. Following absorption, compounds are distributed to different compartments within
the body according to physiochemical properties. Drug distribution is impacted by protein
binding in the plasma, and neonate and infants tend to have lower concentrations of proteins,
such as albumin, in their blood than adults. This decreases protein binding and increases the
amount of free, unbound drug compounds in the circulation [45]. Changes in body composition
also affect distribution. Infants have higher volumes of total body weight and lower volumes of
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total body fat than adults, and this alters the volumes of distribution for water- and fat-soluble
drugs [3].
Metabolism, as previously discussed, has a significant impact on drug efficacy and toxicity.
Members of phase I and phase II metabolic enzymes are not be fully expressed in neonates
and infant livers, and therefore drug metabolism capabilities may be reduced. The ontogenic
expression of P450 drug metabolizing enzymes, in particular, during postnatal ages will be
outlined in more detail in later sections. There are also perinatal forms of drug-metabolizing
enzymes that are enriched specifically in the fetus and immediately after birth, while absent
in adults. These metabolic differences affect the plasma concentration of administered drugs,
along with their metabolites, which could produce age-specific toxicities [46]. Finally, excre-
tion is largely dependent upon kidney function along with renal blood flow. Renal excretion
is highly variable in neonates and infants, and can occur at rates higher or lower than those of
adults depending on the drug [47].
2.2.1 Postnatal Liver Maturation
At birth, the liver does not possess the fully mature metabolic capabilities that are seen in adults.
The fetal and neonatal liver acts as a hematopoietic organ, generating blood cells. During the
first several years of life, the neonatal liver undergoes a postnatal developmental process that
allows it to transform from a proliferating, hematopoietic organ into a differentiated, metabolic
organ. The complete process takes up to five years in humans, but occurs most rapidly during
the first two years of life [48]. During the beginning of this period of postnatal growth, the liver
is responsible for producing hematopoietic cells and is in a state of rapid cellular proliferation
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so it can grow in size along with the rest of the body. The hepatocytes also differentiate si-
multaneously at this time to achieve mature gene expression profiles and enzymatic activities.
Because of this, neonatal and infant livers have limited metabolic capabilities and are often
more sensitive to drug treatment than adults due to lowered rates of drug clearance [49].
This process of postnatal liver maturation is remarkable in that cell proliferation and differ-
entiation occur simultaneously. However, the cellular mechanisms regulating this process are
relatively understudied. There is limited research regarding the biological pathways, transcrip-
tion factors, and signaling events that orchestrate both hepatic growth and maturation during
the postnatal stage. The Wnt/-catenin signaling pathway has been shown to be involved in
postnatal liver growth and cell proliferation, and is necessary for the liver to increase in size
[50]. The yes-associated protein (Yap) and the hippo kinase pathway have also been proven
to regulate postnatal liver growth, cell proliferation, and the expression of genes involved in
hepatic bile acid and retinoic acid metabolism [51, 52]. Several studies have also demonstrated
that the Notch signaling pathway, along with the ligand Jag, play a critical role in hepatic bil-
iary duct formation and differentiation during early postnatal life [53, 54]. On the other hand,
transcription factors E2F7 and E2F8 have been shown to regulate liver growth by controlling
excessive cell proliferation and suppressing hepatic tumor formation during postnatal develop-
ment [55]. Insulin signaling is known to be an important pathway in mammalian organ growth
and development in general, and studies have demonstrated the varying expression of insulin-
like growth factors 1 and 2 (IGF1; IGF2) during postnatal liver development, possibly due
to regulation by the CCAAT-enhancer binding protein (C/EBP ) [56]. The liver is responsi-
ble for producing circulating IGFs, and IGF2 is considered to be most abundant in fetal and
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early postnatal life, while IGF1 is believed to be the predominant form in adults [57]. Several
nuclear receptors, including hepatocyte nuclear factor 4 (HNF), pregnane X receptor (PXR),
constitutive androstane receptor (CAR), and aryl hydrocarbon receptor (AhR) are shown to be
activated at different points during postnatal development and contribute to liver differentiation
by inducing the transcription of mature hepatocyte-specific genes, including drug-metabolizing
enzymes, xenobiotic transporters, and albumin.
The expression of cellular components involved in epigenetic gene transcription regulation also
change in the liver throughout postnatal development. Long non-coding RNAs (lncRNAs) have
recently been acknowledged for their roles in regulating gene and protein expression. Many
hepatic lncRNAs were shown to be enriched at different stages during postnatal development,
and their expression levels were highly correlated with the expression of their neighboring
coding genes involved in regulating hematopoiesis, cell proliferation, and metabolism [58, 59].
2.2.2 Ontogeny of Cytochrome P450s
The majority of CYP enzymes are expressed at significantly lower levels at birth and during
the first few years of life than in adults. In fact, the fetal and neonatal liver is considered to
only have 30-60% of the total CYP content of adults. Therefore, newborns and infants are
considered to have overall significant reductions in CYP-mediated drug metabolism. During
postnatal liver maturation, each CYP isoform appears to follow a distinct pattern of ontogenic
regulation in which its transcription, expression, and activity varies depending upon age. Three
groups of CYP gene expression patterns appear and consist of the CYPs that are enriched during
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the neonatal period but become undetectable in adults, the CYPs that increase in expression
quickly after birth, and the CYPs that become up-regulated during adolescence [60, 61].
As previously stated, most hepatic CYPs involved in drug metabolism are expressed at very
low levels in newborns at birth. During the first two years of life, expression of these enzymes
increases rapidly with age. Expression may then steadily increase throughout childhood and
adolescence until adult expression levels and full enzymatic activity are achieved. CYPs that
follow this postnatal developmental pattern include CYP1A2, 3A4, 2C9, and 2C19. All of these
isoforms are nearly undetectable in the liver in the fetus and immediately after birth. CYP1A2
becomes detectable between one and three months of age, and is expressed at 30% of adult
levels at age one. Between two and three years of age, enzymatic activity is comparable to that
of adults. The CYP2C isoforms increase in expression more rapidly after birth, reaching 30%
of adult values by one month of age, and 50% of adult values by five months of age. Expression
then slowly rises to adult levels over the next few years and may not be fully mature until age
10 [62, 63]. Like CYP1A2, CYP2E1 is expressed at around 40% of adult levels by age one, but
also might not reach levels comparable to adults until age 10 [64]. CYP3A4 expression rapidly
increases during the first month after birth as well, and reaches 50% of adult values between 6
and 12 months of age. Interestingly, the literature also suggests that CYP3A4 activity might be
higher in infants after one year of age than in adults [65]. The expression pattern of CYP2B6 is
unique in that it appears to be expressed more highly immediately following the perinatal stage
during the first one to three months of life than in adults. In infants aged one year or older,
levels decrease and become more comparable to those of adults [66].
Fetal forms of CYP enzymes also exist in which the highest levels of expression occur during
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gestation in the fetal liver and immediately after birth. CYP3A7 is the best-studied example
of this. This isoform is considered to be the fetal form of the CYP3A family of enzymes. Its
expression is highest in the fetal liver and in newborns, but quickly decreases to undetectable
levels within the first few months of life. This decrease in CYP3A7 expression correlates well
with the increase of the expression of the adult isoforms CYP3A4 and CYP3A5 during infant
development, and the CYP3A postnatal switch has been well documented in the literature.
In mice, the Cyp3a switch is associated with a change in epigenetic histone modifications.
Suppression of the fetal Cyp3a16 during postnatal liver maturation coincided with increased
repressive H3K27me3 and decreased H3K4me2 in the gene. Simultaneously, the expression of
the adult isoform Cyp3a11 increased during postnatal maturation and coincided with increased
levels of H3K4me2 within the gene [67]. This suggests that epigenetics and play a significant
role in regulating the developmental expression patterns of CYP enzymes.
Several genetic and environmental factors have been shown to affect the natural ontogeny of
CYP activity during postnatal development. For example, formula-fed infants were shown to
gain CYP1A2 and CYP3A4 metabolic activity more rapidly than infants that were breastfed
(Blake et al., 2006). At six months of age, infants that are formula-fed clear caffeine from their
systems more rapidly than infants that are breastfed [68]. The specific components of infant
formula also seem to have an impact on CYP ontogeny, with infants fed soy-based formulas
having higher levels of CYP3A activity [69]. Depletion of the nuclear farnesoid X receptor
(FXR) in mice appeared to delay or attenuate the expression of many CYPs during postnatal
maturation, indicating a possible role of bile acids in regulating CYP ontogeny [70]. A further
discussion of the endogenous factors that contribute to orchestrating the changes in postnatal
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expression of CYP enzymes and activity are discussed in later sections. l
2.2.3 Induction of Cytochrome P450s in Pediatric Populations
The process of CYP enzymatic induction is normally studied in the context of the fully mature,
adult liver. In this case, induction is a process that is temporary and reversible, and induced CYP
expression returns to basal levels once the inducer drug is discontinued and completely cleared
from circulation. Induction in the context of the neonatal, infant, and child liver during postnatal
maturation is an understudied area and not well understood. However, pediatric patients are
still exposed to a wide range of drugs that have capabilities to induce CYP expression, and the
outcomes of enzyme induction during stages of postnatal liver growth and differentiation are
relatively unknown.
Very few studies have investigated whether the inducibility of CYPs varies with age, espe-
cially during postnatal development. One study showed that the inducibility of hepatic drug-
processing genes during mouse postnatal development was age-dependent and correlated with
the basal expression of the enzyme. However, this study only examined induction at the mRNA
level, and produced transcriptional induction via administration of direct nuclear receptor lig-
ands, not pharmaceutical drugs [71]. Another study compared the inducibility of hepatic car-
boxylesterases, which also play a role in drug metabolism, between neonatal and adult mice.
In response to phenobarbital treatment, the carboxylesterases tested were induced to a greater
extent at the mRNA, protein, and catalytic levels in neonates than in adults. The induction
at the neonatal age also caused more rapid hydrolyzation of clopidogrel and the accumulation
of plasma lipids, indicating significant functional consequences [72]. There is a clear need to
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further examine the inducibility of specific CYP isoforms at various ages during postnatal de-
velopment in response to drug treatment, as this may greatly affect the efficacy and toxicity of
other medications that are administered concurrently to pediatric patients.
2.2.4 Use of Antiepileptic Drugs in Pediatric Patients
Neonatal seizures occurring in newborns immediately after delivery are a fairly common oc-
currence, with a frequency of three cases per 1,000 live births in the United States. Child-
hood epilepsy is also a common disease affecting pediatric populations at all ages of postna-
tal development. Treatment of these disorders involves the administration of one or multiple
antiepileptic drugs (AEDs) to prevent and control seizures that could be detrimental to brain
development [73]. A wide variety of AEDs can be prescribed to children suffering from either
chronic epilepsy or an acute seizure episode and include the first generation AEDs (carba-
mazepine, phenobarbital, phenytoin, clonazepam, and valproic acid), second generation AEDs
(felbamate, gabapentin, lamotrigine, and topiramate), and the most recently developed third
generation AEDs (lacosamide, perampanel, retigabine, stiripentol). However, most second and
third generation AEDs are not approved for pediatric use and are prescribed to infants and chil-
dren off-label [74, 75]. Neonates generally clear AEDs at much slower rates than older patients,
presumably due to low levels of hepatic CYPs. On the contrary, infants and younger children
have higher clearance rates of AEDs than adults and often require dosage adjustments, which
we can hypothesize is due to the changing expression of CYPs in the liver during this period
of postnatal development [76]. Additionally, many AEDs are well known to cause CYP induc-
tion and are implicated in common DDIs, which becomes problematic as epileptic patients are
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frequently treated with multiple medications to control seizures and other comorbidities [77].
AEDs also have narrow therapeutic plasma concentration windows and are prone to causing
adverse side effects in patients. Overall, the usage of AEDs comes with several risks, and the
chance of adverse effects increases even more significantly in pediatric patients [78].
AEDs that are considered first-line therapy for treating neonatal seizures include phenobar-
bital, phenytoin, diazepam, and lorazepam, with phenobarbital and phenytoin being the most
commonly used clinically [79]. Simple and partial seizures in infants and children are also
commonly treated with phenobarbital and phenytoin, and these drugs are considered first-line
therapy for treating generalized and infant febrile seizures as well. However, newer AEDs are
beginning to be preferred due to the lower occurrence of adverse effects. Unfortunately, second
and third generation AEDs are more expensive, and families without health insurance or those
living in poorer countries are often left to use the more inexpensive AEDs such as phenytoin
and phenobarbital to treat their children. Additionally, phenobarbital appears to remain the
most effective treatment option [80].
Phenobarbital (trade name Luminal) was first used clinically in 1904 and is on the World Health
Organizations List of Essential Medicines. It is a barbiturate drug that prevents convulsions
and induces sedation by increasing the activity of the inhibitory neurotransmitter GABA and
blocking glutamate excitatory signaling. Treatment with phenobarbital begins with a loading
dose of 20 mg/kg bodyweight, followed by subsequent maintenance doses of 3-5 mg/kg. Serum
concentrations of 40 g/ml are desirable for therapeutic efficacy in adults, however it has been
shown that concentrations up to 100 g/ml are more desirable to prevent seizures in infants.
Phenobarbital is metabolized primarily by CYP2C9 in the liver, with smaller contributions
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by CYP2C19 and CYP2E1. In adults and neonates, the half-life of the drug is around 100
hours, however in young infants, the half-life is decreased and may only be around 60 hours.
Phenobarbital is also a potent inducer of CYPs, specifically CYP2B6, via the activation of CAR.
Enzymes in the CYP2C and CYP3A families are also induced by phenobarbital treatment.
Because of this, phenobarbital is implicated in many DDIs and often causes adverse effects in
patients [81].
Phenytoin (brand name Dilantin) is often better tolerated than phenobarbital for seizure treat-
ment and is frequently preferred over phenobarbital for the treatment of neonatal seizures be-
cause of this. It is also on the World Health Organizations List of Essential Medicines and is
inexpensive compared to other AEDs. Phenytoin is also occasionally used for the treatment
of arrhythmias. It exerts its therapeutic effects through a different mechanism of action from
phenobarbital by blocking voltage gated sodium channels to prevent repetitive firing of action
potentials in neurons in the brain. A loading dose of around 20 mg/kg is also recommended
for pediatric patients [82]. Phenytoin is metabolized by CYP2C9 and CYP2C19 in the liver,
although it has a much shorter half-life (10-15 hours) than phenobarbital. Because CYP2C9
and 2C19 are barely expressed in the newborn patient, the half-life of phenytoin is prolonged
relative to older infants and adults. However, the elimination rate of the drug is higher in infants
and children than it is in adults, perhaps due to the lack of CYP2C9-mediated metabolism or
variability in the inducibility of the enzyme. Because of this, phenytoin doses in pediatric pa-
tients must be 50-100% higher than in adult patients to achieve comparable therapeutic plasma
concentrations [83]. Like phenobarbital, though, phenytoin is also a potent inducer of CYPs in
the liver, particularly CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4. The mechanism
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by which phenytoin causes enzyme induction, however, is not well understood, although it is
thought that CAR activation is also involved [77, 84].
Because phenobarbital and phenytoin are potent inducers of general CYP activity in the liver,
they are implicated in many DDIs, especially with co-administered AEDs. In hospitalized
children with epilepsy, phenobarbital and phenytoin are among the most common causative
agents of DDIs. Phenobarbital and phenytoin treatment can reduce serum concentrations of
the commonly co-administered AEDs valproic acid and lamotrigine by over 50%, which may
attenuate efficacy and warrant dosage adjustments. In children, other DDIs with pain-reducing
agents, antimicrobials, and immunosuppressants are most frequently reported [85].
Both phenobarbital and phenytoin are considered first-line therapies for the treatment of seizures
in newborns, and are commonly used for the treatment of epilepsy in children. Because of this,
these are the AEDs we have focused on for the duration of this research. Both drugs also ac-
tivate the CAR nuclear receptor indirectly to induce CYP expression and drug metabolism in
the liver. A previous study has shown direct CAR activation at the neonatal age can cause per-
manent changes to drug metabolism in the liver of mice [86] via epigenetic memory, so it is
critical to investigate the consequences of CAR-activating drug exposure during postnatal life.
Whereas they are similar in the fact that they can both activate CAR to induce CYP activity in
the liver, they still have unique pharmacokinetic profiles, chemical structures (Figure 2.1), and
mechanisms of action. Phenobarbital is also known to activate CAR via its action on the epider-
mal growth factor receptor (EGFR) (Figure 2.2), while the mechanism for CAR activation by
phenytoin is not understood. It would therefore be beneficial to study them separately to better
understand whether they have different effects on CYP induction during postnatal development.
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FIGURE 2.1: Chemical structures of phenobarbital and phenytoin. Obtained from Pub-
Chem (pubchem.ncbi.nih.gov).
2.3 Mechanisms of Cytochrome P450 Regulation
2.3.1 Genetic Polymorphisms
Heritable changes to the genetic sequence of drug-metabolizing CYP genes can both enhance as
well as suppress their enzymatic activity. Copy number variants (CNVs) and single nucleotide
polymorphisms (SNPs) within the gene promoter typically encompass gain-of-function vari-
ants that increase the number of functional gene copies, thus up-regulating the rate of substrate
metabolism. On the other hand, loss-of-function polymorphisms typically affect CYP gene
splicing and expression, rather than transcription, and act to down-regulate enzymatic activity.
The phenotypes associated with specific polymorphisms are referred to using the terms poor
metabolizer, intermediate metabolizer, extensive metabolizer, and ultrarapid metabolizer. Ex-
tensive metabolizers are considered the normal phenotype and represent the majority of the pa-
tient population. Poor metabolizers carry polymorphic alleles that do not code for a functional
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FIGURE 2.2: Direct and indirect pathways leading to CAR activation by xenobiotics in
mouse. Upon activation, CAR dissociates from heatshock protein 90 (hsp90) and cytoplas-
mic CAR retention protein (CCRP) in the cytoplasm and translocates to the nucleus where it
associates with transcriptional coactivator CREB-binding protein (CBP)/p300 (not pictured).
The complex binds to response elements (PBREM) in the promoter of target genes, includ-
ing Cyp2b10, to up-regulate transcription. Activation of CAR can either be direct, as through
the direct binding of the ligand TCPOBOP, or indirect, as through the binding of phenobarbi-
tal (PB) to the epidermal growth factor receptor (EGFR). PB antagonizes EGFR, which leads
to activation of RACK-1 and protein phosphatase 2A (PP2A), which dephosphorylates CAR,
leading to its activation and translocation into the nucleus [87].
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CYP protein, and these patients typically require smaller doses of a drug. Intermediate metabo-
lizers, while similar to poor metabolizers, usually carry deficient alleles that attenuate metabolic
capacity rather than abolish it completely. Ultrarapid metabolizers carry gain-of-function poly-
morphic alleles and have a greater capacity for metabolic activity and sometimes require higher
drug doses to achieve therapeutic effect. However, if the drug requires metabolism to receive its
active form (i.e. prodrugs), ultrarapid metabolizers may require lower doses to avoid toxicity,
while poor metabolizers may require higher doses to achieve therapeutic efficacy [28].
Many SNPs in drug-metabolizing CYP genes have been identified and their resulting metabolic
phenotypes are known and occasionally utilized clinically. CYP2B6 is highly polymorphic, and
the CYP2B6*6 allele, which is associated with a 50-75% decrease in hepatic protein, has the
greatest frequency in patient populations. This variant causes decreased clearance of efavirenz,
nevarapine, and 5-methadone, which is associated with resulting adverse effects due to toxicity
and drug discontinuation [88]. On the other hand, CYP2B6*4 and *22 variants, while less com-
mon, cause increased CYP2B6 activity, which leads to up-regulated clearance and decreased
efficacy of buproprion, efavirenz, and selgiline [31].
Strong phenotype-genotype correlations have been found for the CYP2C19 gene, in which
the *2 and *3 null alleles abolish metabolic activity. Proton-pump inhibitors (PPIs) such as
omeprazole and lansoprazole, which increase pH in the stomach, depend on the genotype of
the CYP2C19 gene for their efficacy. PPIs actually tend to work better in poor metabolizers, as
the drug remains in the circulation for longer and increases gastric pH more significantly [89].
On the contrary, the antiplatelet drug clopidogrel requires bioactivation by CYP2C19 for its
therapeutic action. Poor metabolizers, in this case, have a higher risk of adverse cardiovascular
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events due to attenuated efficacy. A black box warning has even been given by the FDA for this
drug warning about decreased efficacy in patients with the loss-of-function allele variants [? ].
CYP polymorphisms have also been shown to make an impact on AED metabolism, efficacy,
and toxicity. Patients treated with phenytoin that carry variations in the CYP2C9 allele associ-
ated with decreased activity are at greater risk of adverse skin and nervous system effects due to
higher plasma concentrations of the drug [90]. Genetic testing prior to initiating AED treatment
is not typical, however. Instead, physicians are encouraged to routinely monitor plasam levels
of both phenytoin and phenobarbital and adjust dosing accordingly [91]. Whether this is a safe
and effective method for dosing pediatric epileptic patients is unknown.
Many genetic polymorphisms in CYP genes have been identified and produce clinical con-
sequences recognized to make an impact in drug responses. However, these genetic variations
only account for 10-30% of the inter-individual variability observed in CYP metabolism among
patients [92]. Other factors beyond the underlying DNA sequences in CYP genes must be con-
tributing to determine the extent of CYP enzyme activity in a patient.
2.3.2 Nuclear Receptors
Nuclear receptors are unique signaling proteins in that they act as both sensors of chemical
ligands as well as transcription factors that directly affect the activation or repression of gene
transcription. All nuclear receptors share a common structure that consists of a ligand binding
domain and a DNA binding domain. Various nuclear receptors have been well-characterized
for their roles in the regulation of CYP gene transcription. Nuclear receptors tend to remain in
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the cytoplasm of the cell until they become activated by an endogenous or exogenous chemical
ligand. Following activation, they translocate into the nucleus and bind to specific response el-
ements in the promoters of the target genes. Nuclear receptors are able to recruit various other
co-activator or co-repressor proteins that can then manipulate chromatin architecture to facil-
itate or suppress transcription of their target genes. Enzyme induction occurs predominantly
via the action of nuclear receptors, however basal enzyme expression may also be under the
control of constitutively active nuclear receptors that remain bound to the promoter regions of
the target genes.
The pregnane X nuclear receptor (PXR), encoded by the NR1I2 gene, and the constitutive an-
drostane nuclear receptor (CAR), encoded by the NR1I3 gene, in particular, control the induced
expression of multiple CYPs involved in drug metabolism and have been implicated in many
DDIs. Both form a heterodimer with the retinoid X receptor (RXR) upon activation, then bind
to response elements within the DNA to up-regulate the transcription of target CYP genes. PXR
can be activated by a variety of xenobiotics, including synthetic glucocorticoids, antiglucocor-
ticoids, antibiotics (e.g. rifampicin), antifungals, and herbal extracts (e.g. St. John’s Wort), as
well as endogenous compounds such as steroids. This receptor recruits several co-activators,
including steroid receptor co-activators (SRC-1 and SRC-2) and PPARγ co-activator (PGC-1α)
to facilitate up-regulated transcription of target genes (e.g. CYP3A4) [93]. CAR is activated
by several xenobiotics such as AEDs (e.g. phenobarbital) and endogenous steroids such as
androstanes. This receptor has also been shown to have high constitutive activity even in the
absence of ligands, although CAR is still typically thought to be important in CYP induction in
response to drug treatment. CYP2B6 is most commonly used as an example of a CAR target
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gene, however CAR can also influence the transcription of many other drug-metabolizing en-
zymes and transporters. CAR also plays an important role in the regulation of gluconeogenesis,
lipid metabolism, and bile acid homeostasis within the liver [94]. Many CYPs, such as CYP2B,
2C, and 3A enzymes, have shown both PXR- and CAR-dependent induction, while others, such
as CYP1A enzymes, are only induced by CAR activation [95].
While PXR and CAR are perhaps the best studied nuclear receptors in terms of CYP-mediated
drug metabolism, several other nuclear receptors play roles in regulating CYP expression in the
liver. The aryl hydrocarbon receptor (AhR) can be activated by enivornmental hydrocarbons
such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to up-regulate the expression of CYP1A
and 1B enzymes. The glucocorticoid receptor (GR), which also has target genes including
CYP1A and 1B enzymes, can be activated by the drug dexamethasone. The vitamin D receptor
(VDR), activated by vitamin D3 and lithocholic acid, has been shown to affect the expression of
many drug metabolizing genes, including CYP3A4, 2B6, and 2C9. The hepatocyte nuclear fac-
tors (HNF1 and HNF4) have also been considered master regulators of CYP gene expression,
especially under basal conditions [96]. These receptors have also been implicated in regulat-
ing the expression of other hepatic nuclear receptors involved in drug metabolism regulation,
including PXR and CAR, suggesting the expression of all nuclear receptors are coordinated in
a type of cross-talk network that cooperatively orchestrates overall liver function [97].
2.3.3 Epigenetic Modifications
Modifications to the chromatin landscape of CYP genes can up- or down-regulation their tran-
scription, and thus have significant affect on the amount of CYP mRNA and protein present
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in the liver. This often leads to clinically relevant changes to CYP activity, drug clearance,
and drug response. DNA methylation, histone methylation, and histone acetylation have all
been shown to play extensive roles in regulating the expression of relevant drug-metabolizing
CYPs, and understanding the mechanisms offers insight into how the expression of CYPs may
be controlled under different circumstances [98].
DNA methylation is perhaps the best defined epigenetic process known to regulate the expres-
sion of many CYP and other drug-metabolizing genes. DNA methylation is typically associated
with transcriptional repression and the down-regulation of target genes. The mechanism in-
volves the addition of a methyl group to cytosine pyrimidine rings in CpG dinucleotides in the
promoter region or gene body, and is catalyzed by DNA methyltransferase enzymes (DNMTs).
This facilitates long-term gene silencing via the formation of heterochromatin, which prevents
the binding of transcription factors and allows the binding of certain co-repressors [99]. DNA
methylation has been shown to regulate the expression of certain phase I, phase II, and phase III
transporter genes, and is associated with determining the transcription of CYP1A2, CYP2D6,
and CYP2E1. Hypermethylation of CYP2D6 and CYP2E1 was associated with increased liver
injury rates due to a decreased ability to clear toxic metabolites of anti-tuberculosis drugs [100].
The acetylation of histones, catalyzed by histone acetyltransferase enzymes (HATs), is con-
versely associated with active gene transcription, as the attached acetyl groups facilitate open
chromatin structure that allows the binding of transcription factors. Histone acetylation has
been implicated as a mechanism in the induction of CYPs in response to drug treatment, par-
ticularly involving the activation of the CAR nuclear receptor. Chemically inhibiting histone
deacetylase enzymes (HDACs), which remove acetyl groups thus repressing gene transcription,
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have been shown to up-regulate the expression of several CYPs, including CYP2B1, CYP2B2,
CYP2B6, and CYP3A4, through the recruitment of CAR [101, 102].
Histone methylation may have either activating or repressing effects on transcription. This
process involves the addition of methyl groups to certain lysine residues on histone tails, and
depending on the lysine that is methylated, transcription of the target gene may be up- or down-
regulated. For example, histone 3 lysine 4 methylation (H3K4me3), is associated with increases
in transcription and the reaction is catalyzed by the Su(var)3-9, Enhancer of zeste, Trithorax-
containing (SET) family of histone methyltransferases. On the other hand, histone 3 lysine
27 methylation (H3K27me3) is associated with transcriptional repression, and this reaction is
catalyzed by the Enhancer of zeste 2 (EZH2) methyltransferase. Both of these marks are im-
plicated in regulating the expression of the CYP3A4 gene. In response to rifampicin treatment,
which activates PXR, increases of H3K4me3 and decreases in H3K27me3 are observed in the
promoter region of CYP3A4, and correlates with up-regulated expression of the gene [103].
Taken together, epigenetic modfications to the chromatin of drug metabolizing enzymes work
synchronously to affect the expression of CYPs within the liver. Understanding the pathways
that contribute to altering hepatic DNA methylation, histone acetylation, and histone methyla-
tion will enable a better understanding of CYP regulation and how factors that alter epigenetics
may affect drug responses.
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2.3.4 Hormones
Endogenous factors, such as steroid hormones, can also influence the expression and function
of CYPs by altering transcriptional regulation via endocrine signaling and the activation of nu-
clear receptors. Certain pharmaceutical drugs may act as direct hormone agonists or synthetic
analogs, whereas other drugs can modulate the bodys endocrine function and change the lev-
els of circulating hormones. In either case, it is important to understand the effects steroid
hormones have on drug-metabolizing CYP activity and the pathways through which they alter
CYP expression. Alterations to CYP activity can then not only change the rate of exogenous
drug metabolism, but also affect the rate of subsequent steroid hormone metabolism and energy
homeostasis.
Differences in the expression of several drug-metabolizing enzymes exist between males and
females, and this can be attributed to the role of sex hormones in determining constitutive levels
of CYP gene expression. The female hormone 17β-estradiol is known to enhance CYP2B6 and
CYP3A4 expression and this explains why the expression of these enzymes is typically higher
in females than in males, and is increased even more significantly during pregnancy [104].
Progesterone, another predominantly female hormone, has also been shown to up-regulate the
expression of CYP2B6 and CYP3A4 in the liver [105]. Additionally, since many CYPs also
play roles in hormone synthesis and metabolism, this provides a feedback mechanism which
regulates hormone homeostasis within the body [106].
Growth hormone, also known as somatostatin, exerts its effect by binding to the membrane
growth hormone receptor (GHR), and is also partially responsible for the differences in CYP
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expression between males and females. In the adult male, the secretion of growth hormone from
the pituitary gland occurs in an episodic manner, which is characterized by a few large bursts
of growth hormone secretion throughout the day that are separated by longer intervals devoid
of the circulating hormone. Females, on the other hand, have circulating growth hormone
profiles that are more continuous, characterized by numerous, smaller bursts of growth hormone
secretion throughout the day. In both sexes, a similar amount of growth hormone is released
per day in total, but the difference lies in the pattern of secretion. These patterns play a role in
determining basal and induced levels of drug-metabolizing CYPs in the liver. Growth hormone
appears to have a repressive effect on CYP expression, and has been shown to suppress CYP2B
induction in response to phenobarbital treatment [107].
Glucocorticoids, which include the stress hormone cortisol, also have an effect on the basal and
induced expression of CYPs in the liver that can provide an explanation as to why CYPs ex-
hibit circadian patterns of expression. The level of circulating cortisol follows circadian rhythm
and is normally highest in the early morning and lowest around midnight. The cellular effects
of cortisol and other glucocorticoids are exerted through binding to the glucocorticoid nuclear
receptor (GR), which is then able to bind to the promoter of target CYP genes to induce their
transcription. The GR appears to be necessary for the maximal induction response of CYP2B,
CYP2C, and CY3A enzymes in response in inducer treatment, as well as for determining con-
stitutive expression levels. It has also been reported that activation of GR also enhances the
action of PXR and CAR in inducing the expression of CYP2B, CYP2C, and CYP3A enzymes.
Because of this, GR has been described as a master regulator of CYP expression due to its abil-
ity to directly affect the transcription of drug-metabolizing CYPs after its activation, as well as
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regulate the functions of other nuclear receptors involved in CYP induction [108].
2.4 Regulation of Cytochrome P450s During Postnatal Mat-
uration
As previously mentioned, CYP enzyme induction is considered a temporary and reversible
event, and metabolic activity returns to constitutive levels once the inducing drug is ceased
and fully cleared from the body [77]. While this is a documented fact in adult patients, it
is not thoroughly understood whether CYP induction during neonatal or infant ages causes
permanent alterations to enzyme expression and activity. Numerous studies have suggested
that inducing CYP expression at young ages may have lasting effects on the expression and
function of these enzymes in adulthood. The liver is undergoing rapid cellular proliferation
and differentiation in the years following birth, which is accompanied by significant changes to
the epigenetic landscape. Manipulating epigenetic changes during this time by administering
inducer drugs may have permanent consequences on liver function. Therefore, it is pertinent to
gain a better understanding of how CYP induction in neonates, infants, and children can affect
drug metabolism in the long-term.
Histone modifications have also been implicated in regulating the basal expression of CYPs
in the liver during the period of postnatal maturation. As previously discussed, specific CYP
enzymes follow dinstict ontogenic patterns during the first several years of life. Adult CYP
isoforms increase in expression over time, while fetal and neonatal isoforms simultaneously
decrease in abundance. Associations between the enrichment of certain histone marks in the
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promoters of CYP genes and CYP mRNA expression levels have been observed during post-
natal liver maturation in mouse. During the first five days following birth, the fetal isoform
of Cyp3a has high mRNA expression and is associated with high levels of the active histone
mark H3K4me2 in its promoter. By the adult age, mRNA of the fetal enzyme is practically
undetectable, and enrichment of the repressive histone mark H3K27me3 becomes enriched in
the promoter region instead. These cellular events occur correlate with low mRNA expression
of the adult Cyp3a isoform during the neonatal age and no enrichment of the activating histone
mark in this gene. By the adult age, however, the adult Cyp3a increases in expression by 6-
fold, which correlates with a 5-fold increase in H3K4me3 enrichment in the promoter region of
the gene [67]. Since this study was performed in the absence of any drug treatment, this data
shows that epigenetic modifications in CYP genes are highly plastic during postnatal matura-
tion, and are changing in response to endogenous signaling. Similar findings have also been
found for the role of histone modifications in the regulation of Cyp2d enzyme otogeny [109].
The consequences of disrupting or interfering with the endogenous regulation of CYP ontogeny
by histone modifications have not been thoroughly studied and warrant future investigation.
2.4.1 Neonatal Phenobarbital Exposure and Permanent Changes to Cy-
tochrome P450 Expression
Beginning as early as 1981, many studies have documented the potential for early postnatal ex-
posure to specific drugs, dietary components, and environmental toxicants to alter the metabolic
and detoxification processes in the adult liver. Initial evidence of this phenomenon was first ob-
served in the enzymatic activities of hepatic microsomes prepared from the livers of adult rats
Chapter 2 39
that were exposed to various compounds during the first five days following birth. The admin-
istration of phenobarbital, methadone, or testosterone to the neonatal pups altered their hepatic
monooxygenase capabilities and increased CYP activity in adulthood. These landmark studies
suggested that CYP-dependent metabolism may be subjected to permanent manipulation by
exogenous compounds early in life [110–114].
With the discovery of individual CYP isoforms, subsequent research throughout the 1990s val-
idated the previous observations by focusing on alterations in the expression and activity of
specific enzymes following neonatal exposure to various compounds. Phenobarbital has been
the most commonly utilized inducing agent, and the permanent effects on CYP activity follow-
ing early life exposure to this drug have been reported in multiple studies. The expression and
activity of hepatic CYP2B and CYP2C enzymes were found to be higher in adult rats that were
exposed to phenobarbital as neonates, which then had a functional effect on steroid hormone
metabolism [115, 116]. This phenomenon was thought to be a consequence of altered growth
hormone secretion during development caused by phenobarbital, which ultimately affected the
expression of CYPs in the adult liver [117]. Adult animals that were exposed to phenobarbital
early in life also had greater extents of CYP induction when re-challenged with phenobarbital
in adulthood, suggesting neonatal exposure increases the sensitivity of the adult liver to enzyme
induction [118, 119]. Aside from changes in CYP expression, rats that received phenobarbi-
tal as neonates also demonstrated higher rates of liver tumorigenesis and a reduced lifespan
compared to control animals [119].
A more recent study from our own laboratory has also confirmed that neonatal phenobarbital
exposure in mice is capable of causing permanent alterations to CYP expression in adulthood.
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In addition, this work examined the role of the dose of phenobarbital and the age of exposure in
producing long-term changes to Cyp2b10, Cyp2c29, and Cyp3a11 expression in the liver. Fol-
lowing a single dose of phenobarbital five days after birth, all three CYP isoforms were overex-
pressed in both male and female mice at 60 days after birth when compared to control animals.
This effect was found to be dose-dependent in that the greater the dose of phenobarbital given,
the larger the extent of CYP overexpression. The effect was also found to be age-dependent, in
that the earlier the age of phenobarbital exposure, the larger the extent of CYP overexpression
in adulthood. If mice were given phenobarbital at ages older than day 15, significant alterations
to CYP expression in adulthood were no longer apparent, suggesting a window of sensitivity
exists in which the neonatal liver is susceptible to enzymatic programming [120].
2.4.2 Neonatal Exposure to Other Drugs and Permanent Changes to Liver
Function
A few additional xenobiotics have also been tested for their potential to cause permanent effects
on adult CYP-mediated metabolism if administered during postnatal development. Lindane,
an organochlorine compound used for the treatment of lice and as an insecticide, caused the
overexpression of CYP1A and CYP2B enzymes in adult rodents following neonatal treatment
[121]. Neonatal exposure to tamoxifen, an estrogen receptor modulator used for breast cancer
therapy, caused increased levels of CYP2A1 in adult male rats only. In females, however, a low-
ered expression of CYP3A9 was observed [122]. Exposing neonatal rodents to diethylbisterol,
a synthetic estrogen once used in various female hormonal therapies, caused decreased CYP3A
expression and increased CYP1A and CYP2B expression in adult males only [123]. Taken
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Species
Drug 
administered
P450s Permanently 
Altered
Expression ↑ or 
↓
Level of 
Quantification
Reference
Rat (male) Phenobarbital 2B ↑ Protein
(Zangar et 
al., 1993)
Rat (male) Diethylstilbestrol 2C6 ↑ Protein
Rat (male) Diethylstilbestrol 3A2 ↓ Protein
Rat Phenobarbital 2C7 ↑ RNA, protein, activity
(Agrawal 
and Shapiro, 
2000)
Rat Phenobarbital 2C6, 3A1, 3A2 ↑ RNA, protein
(Agrawal 
and Shapiro, 
2003)
Rat Phenobarbital
2C7, 2C6, 2B1, 2B2, 
3A1, 3A2
↑ RNA, protein, activity
(Agrawal 
and Shapiro, 
2005)
Rat Phenobarbital 2B1, 2B2 ↑ RNA, protein, activity
(Agrawal 
and Shapiro, 
1996a)
Mouse Phenobarbital 2B10, 2C29, 3A11 ↑ RNA, protein, activity
(Tien et al., 
2015)
Rat Lindane 2B1, 2B2, 1A1, 1A2 ↑ RNA, protein
(Johri et al., 
2008)
Rat (male) Tamoxifen 2A1 ↑ Protein, activity
(Kawai et al., 
1999) 
Rat (female) Tamoxifen 3A9 ↓ RNA
Rat (male) Tamoxifen 2C11 ↓ Protein, activity
Rat 17β-estradiol 3A ↑ Activity
(Murakami 
et al., 2004)
FIGURE 2.3: Summary of studies that demonstrate long-term alterations in hepatic CYP
expression, activity, and/or induction following neonatal administration of specific drugs.
together, these studies suggests clear gender-dependent effects following neonatal exposure to
various xenobiotics. Additionally, most of the xenobiotics that have been tested are either syn-
thetic steroid hormones, or resemble steroid hormones in their chemical structure. This also
implies a significant role in circulating hormone levels in regulating CYP ontogeny and ex-
pression during postnatal development, which can then have lasting effects on liver metabolism
into adulthood. A table summarizing all rodent studies that found altered CYP expression in
adulthood following neonatal drug exposure can be found in Figure 2.3.
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Although the focus of this research is on drug-metabolizing CYP enzymes in the liver, there are
several other studies that examined long-term alterations to CYPs involved in other metabolic
processes or located in other organs. CYP8B1 is responsible for regulating cholesterol metabolism
through its involvement in bile acid synthesis. Following neonatal exposure to the glucocorti-
coid drug dexamethasone in rats, CYP8B1 levels were lowered and resulted in impaired hepatic
lipid secretion once the animals reached adulthood [124]. CYP activity in the brain has also
been shown to be modified by neonatal drug exposure. Cerebral expression of CYP1A and
CYP2B enzymes were up-regulated in adults that received treatment with lindane during the
perinatal period [121]. Treatment with the selective serotonin reuptake inhibitor, fluoxetine, for
the first 16 days following birth caused rats to have elevated CYP4A expression in their adult
brains, which altered cerebral arachidonic acid metabolism [125, 126]. A summary of all the
discussed work regarding neonatal drug exposure and permanent alterations to CYP expression
can be found in Figure 2.3. Together, these studies indicate that CYP regulation in general
is quite sensitive during early postnatal life and may be particularly susceptible to exogenous
modification with permanent effects. The mechanisms behind this phenomenon are just be-
ginning to become elucidated, however they undoubtedly involve underpinning changes to the
epigenetic landscape.
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2.4.3 Nuclear Receptors and Neonatal Imprinting
The term “imprinting” can have two different meanings in the field of biology. Genomic im-
printing refers to the phenomenon that causes certain genes to be expressed in a parent-of-
origin-specific manner, as a result of particular DNA or histone methylation patterns that re-
press gene transcription on one allele [127]. This project, however, will refer to the concept
of neonatal imprinting, which describes a phenomenon of developmental programming that
produces delayed effects as a result of neonatal exposure to a specific exogenous compound or
environmental stimulus. This type of imprinting requires a specific time window of sensitivity
and organ plasticity during early postnatal, or even prenatal, life in which exposure must occur
[128]. During this window of sensitivity, organogenesis occurs and tissues undergo extensive
differentiation as epigenetic markers are installed on the genome to facilitate specialized gene
expression. Exposure to compounds that alter how the epigenetic modifications are placed can
cause lifelong disruptions to gene expression, causing programmed alterations to organ func-
tion [129].
The mechanisms that underlie neonatal imprinting involve influencing the proteins involved in
creating histone modifications and DNA methylation during postnatal windows of sensitivity in
which organs still exhibit plasticity. As discussed in previous sections, DNA methylation, his-
tone acetylation, and histone methylation have strong influence in determining whether a gene
in transcriptionally repressed or activated. In adulthood, when organs are fully developed and
differentiated, epigenetic modifications that result from an environmental exposure are usually
transient and short-lived. However, during periods of tissue growth and maturation when organs
still exhibit plasticity, epigenetic modifications have the possibility of becoming permanent, to
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offer a type of cellular memory for later gene expression and exposure response later in life
[130]. Upstream of the specific epigenetic modifications, however, are the transcription factors
that bind to target genes and recruit the co-activator proteins to facilitate the addition or removal
of the epigenetic modifications. It is still not well understood how certain compounds that affect
transcription factor binding influence neonatal imprinting during postnatal development.
The concept of neonatal imprinting, although still elusive, has been described in various or-
gans in response to a variety of environmental exposures. Several studies have demonstrated
permanent changes in chromatin structure and histone modifications in different tissues fol-
lowing postnatal exposure to specific xenobiotics that cause the activation of nuclear receptors,
which also act as transcription factors. Endocrine disruptors, in particular, have been shown to
play a significant role in neonatal imprinting in multiple organs due to their ability to activate
the nuclear estrogen receptor (ER) [131]. Rats exposed to bisphenol A (BPA), an endocrine
disruptor found in plastic, during the first five days of life exhibited markedly up-regulated ex-
pression of secretaglobin (Scgb2a1), a secreted protein involved in inflammation, tissue repair,
and tumorigenesis, in their prostate at age day 70. The increase in gene expression correlated
with persistently enriched H3K9 acetylation and H3K4 methylation and decreased methyla-
tion in the CpG island upstream of the genes transcription start site, which facilitated increased
transcription. The overexpression and enhanced secretion of secretaglobin in adulthood could
subsequently have implications in prostate cancer risk and also affect the efficacy of drugs
that bind to the protein [132]. The expression of other genes in the prostate cancer pathway
were not found to be altered in adults following neonatal BPA exposure until the adult animals
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were re-challenged with a stimulus. In this case, when testosterone was administered in adult-
hood, other genes within the prostate cancer pathway exhibited an exaggerated response to the
hormone due to neonatal BPA exposure, even though there was no difference in their basal
expression in the absence of testosterone administration [133].
Neonatal exposure to genistein, an endocrine disruptor found in dietary soy, and diethylbisterol,
both of which bind the ER, also caused permanent changes to gene expression and inductive re-
sponses in adulthood by altering the epigenetic landscape. The promoters of genes in the uterus
remained permanently hypomethylated following treatment, and lead to increased gene tran-
scription in adults. Responses to re-challenges with estrogen in adulthood were exaggerated,
and included up-regulated secretion of lactoferrin, a protein found in breastmilk [134, 135]. To-
gether, these studies on neonatal programming following endocrine disruptor exposure had sev-
eral mechanistic factors in common: 1) the activator of a nuclear receptor, 2) altered response
to hormone stimulation, and 3) up-regulated protein secretion. Whether this phenomenon can
occur with the activation of other nuclear receptors that play a role in hormone signaling is
worth investigating.
Endocrine disruptors and the ER have also been shown to play a role in the neonatal pro-
gramming of gene expression in the liver through permanent epigenetic alterations. Diethyl-
stilbestrol administration at the neonatal age activated the ER and permanently altered hepatic
gene expression through the activity of small heterodimer partner (SHP), which plays a role
in transcriptional repression. Adult mice exhibited decreased Cyp7a1 and Cyp8a1 expression
and increased Cyp7b1 expression, which altered bile acid synthesis and homeostasis perma-
nently. Additionally, neonatal exposure to diethylstilbestrol caused decreased levels of CAR
Chapter 2 46
and PXR in adult livers, which in turn reduced the expression of Cyp3a4, Cyp2b10, and other
hepatic transporters [136]. In terms of neonatal imprinting in the liver and permanent effects on
CYP-mediated drug metabolism, no studies have established the role of pharmaceutical drugs
that are able to activate PXR or CAR, however. Limited research utilizing non-pharmaceutical
compounds that directly bind nuclear receptors to cause their activation has shown that CAR
and PXR activation during postnatal liver development can permanently alter hepatic gene ex-
pression in adulthood via persisting epigenetic modifications. A landmark study using a mouse
model was able to establish persistent induction of Cyp2b10 and Cyp2c37 in the livers of adult
mice that received treatment with TCPOBOP, a direct murine CAR ligand, at the neonatal age.
As a result, the adult mice showed a decrease in efficacy of zolaxamine, a compound that
induces sleep, due to enhanced drug metabolism. Permanent increased enrichment of H3K4
methylation and decreased H3K9 methylation in the promoter region of the Cyp2b10 gene ac-
companied the long-term changes in CYP mRNA expression. The permanent overexpression
of CYPs and associated histone modifications were abolished, however, in knockout mice that
lacked CAR, suggesting this nuclear receptor was necessary to produce the lasting effects of
neonatal imprinting by TCPOBOP [86].
Since the study with TCPOBOP and permanent alterations to CYP2B10 and CYP2C37 expres-
sion in 2012, only one other project has looked at neonatal nuclear receptor activation and the
effects on CYP expression in the liver in adulthood. In this case, mice were treated with either
PCN, a direct murine PXR ligand, or TCPOBOP, in the neonatal stage, and the mRNA expres-
sions of all genes in the liver were measured and compared in adulthood. Neonatal exposure
to TCPOBOP resulted in persisting up-regulation of Cyp2b10 and Cyp2c29 along with other
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xenobiotic-processing enzymes and transporters. On the other hand, Cyp4a enzymes were sig-
nificantly down-regulated. Neonatal exposure to PCN resulted in persisting up-regulation of
Cyp2b10, Cyp2b13, Cyp2a, and Cyp2c55 and various other enzymes involved in metabolism,
and a decrease in Cyp4a expression as well [71]. This suggests that there can be overlap in
nuclear receptor signaling and the subsequent permanent changes to gene expression that re-
sult. However, this also indicates that there may also be specificity in which genes become
imprinted as a result of the specific nuclear receptor that becomes activated at the neonatal
age. Additionally, this study found that both PCN and TCPOBOP treatment during early post-
natal development caused permanent down-regulation of the nuclear peroxisome proliferator-
activated receptor (PPAR) in adult livers. PPAR regulates hepatic lipid metabolism and induces
expression of CYP4A enzymes when activated [71]. This also suggests that nuclear receptor
activation in the neonatal age has the potential to impact the expression of target genes, as
well as other nuclear receptors and transcription factors, permanently, which can affect organ
function in its entirety.
Phenobarbital appears to be the prototypical, clinically relevant drug administered to neonatal
animals to elicit the persistent up-regulation of drug-metabolizing P450s. Other studies have
utilized compounds that directly bind nuclear receptors to also elicit permanent changes to the
same enzymes. However, the link between postnatal nuclear receptor activation by pharma-
ceutical drugs and altered CYP-mediated drug metabolism in adulthood has not yet been well-
established. Pediatric patients are regularly exposed to many other drugs besides phenobarbital
that produce CYP enzyme induction for indications such HIV, tuberculosis, and seizures, as
summarized in Figure 2.4.
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FIGURE 2.4: Drugs administered to pediatric patients with the ability to activate nuclear
receptors to induce CYP activity. GCR = glucocorticoid receptor
It is also possible for mothers that are taking medications that cause enzyme induction to pass
through breastmilk to her infant. Additionally, all of the discussed studies were concepts only
shown in rodent models, which will eventually need to be put to the test in humans. One study
has shown that formula-fed infants have higher levels of CYP1A2 activity and clear caffeine
from their systems more rapidly than breastfed infants at six months of age, and the authors
concluded this was due to components of the formula activating the AhR, which regulates
CYP1A2 induction [137]. Therefore, it may be possible for nuclear receptor activation caused
by pharmaceutical drugs administered to pediatric patients to program, and permanently alter,
CYP expression and drug metabolism in humans. However, future studies utilizing additional
pharmaceutical inducers are absolutely necessary to generalize this phenomenon.
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2.5 The Mouse as an In VivoModel for Studying Drug Metabolism
So little is known about the regulation of drug metabolism in pediatric patients simply because
they are not usually included in clinical trials that determine pharmacokinetic profiles. This
is due to obvious ethical, financial, and technical constraints, and it is not likely that pediatric
patients will be used regularly in clinical trials in the future. Epidemiological studies in infants
and children that compare different lifestyle, environmental, and genetic factors to alterations
in CYP activity exist, however it is impossible to eliminate all confounding variables. Liver
biopsies from healthy children are also extremely difficult to obtain, and an in vitro cell model
representative of a true infant or child hepatocyte does not exist. Therefore, studies in animals
remain as our best option for understanding the regulation of CYP expression in response to
drug induction during early postnatal development.
This study, in particular, utilizes the C57Bl/6 mouse as a model organism. The mouse is an
ideal model for postnatal developmental studies for several reasons. First, the short lifespan
enables us to examine the effects of early life drug exposure on metabolism in adulthood over a
relatively short period of time. Mice also give birth to large litters than usually contain between
six and twelve pups, in our experience. This allows us to include both vehicle control- and test
compound-treated pups within the same litter, which decreases inter-litter variability and helps
to diminish confounding factors. Finally, mouse genetics are well-defined and widely manipu-
lated as evidenced by the seemingly infinite amount of genetically modified mouse models that
have been engineered. Mice that lack functional nuclear receptors, such as PXR and CAR, are
readily available to further study the effects of CYP induction at postnatal ages in the absence
of these key signaling molecules. Chimeric mouse models that express the humanized forms
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of PXR and CAR also exist, and can be utilized to study compounds that are specific to the
activation of human nuclear receptors.
While phenobarbital is an indirect activator of both human and murine CAR, the nuclear recep-
tor is activated by different compounds and drugs in each respective species, with only a few
that are common. Unfortunately, this is a regular problem when attempting to use the mouse as
a model to study human drug metabolism. Many compounds that activate the murine form of a
nuclear receptor do not activate the human form of a nuclear receptor, and vice versa. There are
also differences in the enzymatic substrates between human and murine CYP orthologs. How-
ever, no model organism or system is a perfect representation of the human body. This section
will discuss the similarities in CYP-mediated drug metabolism between mice and humans, as
well as the challenges that will need to be considered when extrapolating the data from mouse
drug metabolic studies to clinically relevant conclusions in humans.
2.5.1 Human and Mouse Orthologous Cytochrome P450 Genes
CYP enzymes have been genetically conserved across all species and appear to have originated
from a single ancestral gene approximately 1.36 billion years ago. All gene members of the
CYP superfamily contain highly conserved regions of amino acids, with smaller variations in
primary amino acid sequences between species. This gives rise to orthologous CYPs, in which
isoforms from different species may be designated as belonging to the same subfamily due to
conserved regions, while the slight differences in the rest of the sequence are acknowledged by
assigning a unique isoform number to the gene name [138].
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Mice, in general, possess higher relative amounts of hepatic enzymes than humans when mea-
sured as the concentration of CYP enzymes per gram of bodyweight. Thus, drug metabolism
and clearance is considered to be more rapid in the mouse than in the human. Mice also have
a greater number of total CYP genes than humans (93 versus 57, respectively). Forty pairs
of orthologous CYP genes between the two species have been identified, and they encode for
enzymes that perform similar functions and share common substrates [139, 140]. Differences
between the activities of orthologous CYPs can exist however, and in some cases drug sub-
strates are unique to each species. This becomes a challenge when utilizing a mouse model to
characterize a compounds predicted pharmacokinetic profile and identify the enzymes respon-
sible for its metabolism and clearance in a human. This project, however, is not attempting to
characterize the metabolism or clearance of any compounds. We are attempting to establish
a proof of concept, which argues that CYP regulation and induction during postnatal develop
differ from that in later ages of adulthood. Therefore, we believe the use of a mouse model is
appropriate at this stage of research. The concept, of course, will need to be validated eventu-
ally in humans. A list of human drug-metabolizing CYPs and their corresponding orthologs in
mouse that we will use for our studies have been listed (Figure 2.5), along with probe substrate
drugs that are clinically used to measure enzymatic activity.
In order to extrapolate the data from this project to relevant human scenarios, we first must
understand the postnatal ontogeny of CYP expression in mice as it relates to humans. As
described previously, individual CYP isoforms follow distinct patterns of expression throughout
the course of postnatal liver maturation in humans. Our laboratory has previously performed
RNA-sequencing (RNA-seq) on mouse liver samples collected at various ages of postnatal
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FIGURE 2.5: Human and mouse orthologous CYP enzymes and their substrates. Human
drug-metabolizing CYPs have been listed with their corresponding accepted murine ortholo-
gous enzyme. Probe substrates for each enzyme typically utilized to evaluate enzymatic activity
rates (based on FDA guidance) have also been listed.
development (Figure 2.6). This allowed us to quantitatively measure the absolute amounts of
each CYP isoform in the liver across the neonatal, infant, child, adolescent, and young adult
stages [141]. Like human CYP expression patterns, the ontogenies of murine CYP expression
also appear to belong to one of three categories: fetal/neonatal enriched, adolescent enriched,
and adult enriched [60].
In general, most drug-metabolizing CYPs belonging to the subfamilies Cyp1, Cyp2, and Cyp3
are expressed at low levels before and immediately following birth, similar to humans. Through-
out postnatal maturation, the expression of these CYPs increases, with expression levels compa-
rable to those of adult mice attained by day 30 of age. Further examination of the expression of
individual murine CYPs throughout postnatal development also reveals similarity to postnatal
CYP ontogeny in humans. Murine Cyp2c29, 2e1, and 3a11 enzymes are the most abundant of
the drug-metabolizing CYPs expressed in the adult mouse liver, which correlates with relative
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FIGURE 2.6: Ontogeny of murine drug-metabolizing CYPs following during postnatal
liver maturation. RNA-seq was performed on livers from male C57Bl/6 mice collected on
different days following birth (x-axis) to evaluate gene expression throughout postnatal matu-
ration. Data are displayed as the mean of three liver samples ± S.E.M for each time point
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abundance of CYPs in humans. The enzymes Cyp2d22 and Cyp3a11 appear to reach their max-
imal expression at the age of day 30, however the other enzymes shown in the figure (Cyp1a2,
2b10, 2c29, and 2e1) actually appear to be expressed at higher levels in late adolescent stages
between the ages of day 20 to day 45, than in fully mature adults. This would suggest that drug
metabolism catalyzed by these enzymes might occur at faster rates in adolescent stages than in
adults, at least in mice. However, this also correlates well with the fact that the half-lives of cer-
tain drugs are actually lower in human children than in adults, suggesting faster drug clearance
during childhood [3]. Both phenobarbital and phenytoin, which are primarily metabolized by
CYP2C enzymes in humans, have shorter half-lives in infants and children compared to adults,
suggesting higher activity of CYP2C enzymes in pediatric populations.
During postnatal liver maturation in the mouse, there is also a switch in the expression of
the Cyp3a family of enzymes, similar to what occurs in humans. In humans, CYP3A7 is
considered the fetal/neonatal enzyme of the subfamily, and is most highly expressed in the
fetal liver during gestation and for several months after birth. As the infant develops, CYP3A7
expression decreases while CYP3A4, the predominant adult enzyme, increases in expression.
A similar pattern is seen in the developing mouse liver. Cyp3a16 is considered the murine
fetal/neonatal Cyp3a enzyme, and it is expressed most highly during gestation and for the first
20 days followning birth (Figure 2.7). At later ages, its expression of Cyp3a16 is repressed
as it becomes practically undetectable in the adult liver, while the Cyp3a11 enzyme increases
in expression and becomes the predominantly expressed Cyp3a enzyme once the liver is fully
matured. Because of this, high expression of Cyp3a16 in the mouse liver is a sign that the organ
is still undergoing the maturation process [142].
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FIGURE 2.7: Repression of murine fetal CYP isoform Cyp3a16 during postnatal liver
maturation. Ontogeny of Cyp3a16 expression throughout postnatal development is shown at
various days following birth (x-axis). Data are displayed as the mean of three liver samples ±
S.E.M.
The nuclear receptors CAR and PXR that contribute to the regulating CYP expression in re-
sponse to induction may also be expressed at slightly higher levels during the human postnatal
development phase compared to adult [? ]. However, the variability among liver samples from
pediatric patients is quite large and it is difficult to draw concrete conclusions. In mice, how-
ever, we can observe slightly higher expression of Car and Pxr during neonatal ages before
day 20 (Figure 2.8). Whether this is biologically significant and/or contributes to the ontogenic
regulation of CYPs is relatively unknown. It is difficult to extrapolate murine data on Car and
Pxr function to relevant conclusions for human CAR and PXR, though, due to very distinct
differences in receptor ligands between the species. This results from differences in the amino
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FIGURE 2.8: Ontogeny of murine nuclear receptors Car and Pxr during postnatal liver
maturation. Expression of Pxr and Car in the livers of mice collected at different days follow-
ing birth (x-axis) determined by RNA-seq. Data are presented as the mean of three livers ±
S.E.M.
acid sequences in the ligand binding domains in each species. For example, human PXR is acti-
vated by the administration of the drug rifampicin to induce CYP3A4 expression, while murine
PXR is not activated by rifampicin. Instead, prenenolone 16 α-carbontrile (PCN) is considered
a direct murine-specific Pxr ligand used to induce Cyp3a11 expression. In terms of CAR, the
chemical CITCO is used as a direct human CAR ligand to induce CYP2B6 expression. While
this compound does not activate Car in mouse, the chemical TCPOBOP is often utilized as a
direct murine Car ligand [143] to induce Cyp2b10 expression.
2.5.2 Inter-Species Age and Dose Extrapolation
In terms of studying developmental pharmacology utilizing the mouse as a model, it is critical
to understand how different ages in mouse correlate with ages in humans, and how doses of a
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compound compare between the species. Mouse and human ages cannot be directly extrapo-
lated, as mice develop at an accelerated rate compared to humans.
On average, the lifespan of a mouse is approximately two years, and we consider the average
lifespan of a human as 80 years. When taking the entire lifespan of each species into account,
nine mouse days is roughly equivalent to one human year. This conversion is not very useful
during postnatal development, however a variety of factors can be evaluated to estimate how
a certain age in mice might correlate to humans. First, young mice are typically weaned from
their mother between 21-28 days of age, while human babies are usually weaned between the
ages of 6-12 months. This indicates that human infants are weaned much earlier in life in
comparison to mice and this must be considered when studying postnatal development. During
the period of postnatal development prior to weaning, one human year is equivalent to roughly
57 mouse days. Conversely, mice reach puberty much sooner in life following weaning than
human children. By age day 42, mice are considered to have attained puberty, however puberty
does not occur in humans until 12-16 years of age. Based on this, one human year is equivalent
to only three mouse days approximately during the pubertal phase. Finally, mice at the age
of day 60 are considered fully matured adults, while humans are typically considered fully
matured (growth-wise) around age 20 [144]. Based on these developmental landmarks, we
have utilized the following mouse ages as representation of specific phases of human postnatal
development: day 5-10: neonatal; day 15: infant; day 20: child; day 30: adolescent; day 45:
young adult; day 60: adult. In terms of CYP ontogeny, the most drastic changes occur within
the first year of life in humans, which would correlate with the first 10 days of life in mice.
Drug dosage also must be adjusted in mice to make valid conclusions based on clinical doses
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utilized in humans. Mice are considered to metabolize xenobiotics more quickly than humans,
so doses based on bodyweight are typically higher in mice to achieve the same efficacy or
toxicity. The FDA offers a simple equation to convert human doses to equivalent doses in a
variety of species. To estimate the dosage in mouse, the human dose is simply multiplied by
12.3 [145]. So for example, a dose of 20 mg/kg bodyweight of a drug in a human would be
equivalent to a dose of roughly 246 mg/kg bodyweight of the same drug in a mouse. This
equation is only validated for adult human dose conversions, however [146]. In the following
studies, we converted suggested pediatric doses in humans to developmental mouse equivalent
doses using the same formula since a pediatric-specific inter-species dose equivalence formula
does not exist.
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Neonatal Phenobarbital Exposure and
Drug Interactions in Adulthood
3.1 Introduction
Polypharmacy-induced DDIs significantly raise the risks for decreasing therapuetic efficacy and
increasing adverse reactions, with particularly higher risks for the elderly, children, and female
populations [147]. Approximately 50% of the population aged over 65 years now takes at least
five different medications, with 35-60% of these elderly patients exposed to a potential DDI,
and 5-15% suffering clinically significant adverse reactions [148]. Additionally, it is estimated
that close to 50% of hospitalized patients under the age of 21 are also exposed to potential DDIs
[16].
59
Chapter 3 60
On the basis of their mechanisms of action, DDIs are classified into two main categories (phar-
macokinetic or pharmacodynamic) based on their origin. Pharmacokinetic DDIs occur when
one drug alters the absorption, distribution, metabolism, or excretion of another drug admin-
istered concomitantly. Altering any of these processes can increase or decrease the concentra-
tions of a drug or its metabolites in the circulation. Certain drugs possess the ability to up-
or down-regulate the rate at which another drug is metabolized, leading to significantly lower
or higher plasma concentrations of the drug or its metabolites. These types of interactions are
common, owing to the induction of many CYPs responsible for the biotransformation of 80%
of prescription drugs.
Induction of CYPs in response to drug treatment occurs shortly after the inducing drug is taken,
with a delay depending on the half-life of the drug. Induction is considered to be tempo-
rary in adults, in whom CYP expression levels will return to basal levels once the inducing
drug is discontinued and excreted [149]. However, a large body of work from Dr. Bernard
Shapiro’s laboratory has demonstrated that neonatal exposure to the AED phenobarbital may
cause lifelong alterations to the basal and induced levels of CYP enzyme expressions and ac-
tivities [116, 117, 119]. Recently, research in our laboratory has demonstrated that neonatal
exposure to phenobarbital can cause a permanent elevation of the activities of several CYPs in
the adult mouse liver and that this effect is dependent upon two key factors: the age at which the
mouse is exposed to the drug in early life, and the dose at which phenobarbital is administered
[120]. Phenobarbital is still considered the first drug of choice for treating acute seizures in
newborns, which occurs in two-three out of every 1,000 live births in the United States [150],
and is widely administered to babies and children across the globe. It is also a known inducer
Chapter 3 61
of CYP2B6, 2C9, 2C19, and 3A4 in humans, and Cyp2b10, 2c29, and 3a11 in mice [151].
Treatment at earlier ages with high doses of phenobarbital produced a permanent induction of
CYP enzymes in adults in mice, however whether the efficacy of other drugs administered in
adulthood is impacted has not yet been studied.
This study aims to determine whether treatment with the CYP-inducing drug, phenobarbital,
early in life can affect the efficacy of a drug taken later in life. Omeprazole (brand name
Prilosec OTC) is a proton-pump inhibitor (PPI) commonly utilized to treat gastric ulcers, gas-
troesophageal reflux disease (GERD), and heartburn by increasing the pH of the stomach. PPIs
are some of the most commonly prescribed drugs and are usually available over the counter
[152]. Omeprazole was chosen as a probe drug to test for changes in efficacy in adult mice
following neonatal exposure to phenobarbital for two reasons. First, its efficacy can be easily
assessed by measuring the pH of gastric contents following a daily dosing regimen. Secondly,
omeprazole is known to be primarily metabolized by CYP2C19 and 3A4 in humans [153, 154].
The metabolism of omeprazole has also been shown to be altered when co-administered with
phenobarbital [155]. Although the CYP enzymes that mediate the primary metabolism of
omeprazole in mice have not yet been defined, we are hypothesizing that omeprazole is metab-
olized by Cyp2c and Cyp3a enzymes in the mouse as well, particularly Cyp2c29 and Cyp3a11,
both of which are induced by phenobarbital. Investigating whether neonatal phenobarbital ex-
posure affects the ability of omeprazole to increase stomach pH in adults can give insight into
how drug treatment in early life can impact drug interactions later in life, even if two drugs are
not administered at the same time. This knowledge may prompt a re-evaluation of how DDIs
in the clinic are viewed and predicted. In order for a DDI to occur, it may not be necessary for
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two drugs to be taken concomitantly.
3.2 Materials and Methods
Chemicals. Phenobarbital sodium salt, omeprazole, and Tween-20 were purchased from Sigma-
Aldrich (St. Louis, MO).
Animals. The use of animals in this study was approved by the Institutional Animal Care and
Use Committee at the University of Connecticut. C57Bl/6 mice (Jackson Laboratories, Bar
Harbor, ME) were bred and housed under standard conditions in the Animal Resources Facility
at the University of Connecticut according to the animal care guidelines provided by the Amer-
ican Association for Laboratory Animal Science. The specific timing of drug treatment for
each experiment is outlined in the figures. Phenobarbital was dissolved in phosphate-buffered
saline (PBS) and administered intraperitoneally to animals at a dose of 200 mg/kg. This dose
of phenobarbital was chosen based on our previous publication showing that a single dose of
200 mg/kg phenobarbital could permanently induce CYP enzymes in mouse [120]. Three con-
secutive doses of omeprazole dissolved in PBS supplemented with 1% Tween-20 were also
administered to mice intraperitoneally at a dose of 150 mg/kg. This dose was selected based on
previously described efficacy to inhibit the gastric H+/K+-ATPase pump in mice [156]. Only
male mice were used in this study to avoid variability in CYP expression based on estrous
cycles in adult females.
Gastric pH Measurement in Stomach. One hour after the final dose of omeprazole (or vehicle
control) was administered, adult mice were anesthetized with isoflurane and an incision was
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made into the stomach. An Orion 9863BN micro-pH electrode was placed in the middle of the
stomach and the pH of gastric liquid was measured using a previously described protocol [157].
Mice were then sacrificed and livers were harvested and stored at -80 °C.
Real-Time Quantitative PCR. Total RNAs were isolated from liver tissue without gall blad-
ders using TRIzol reagent according to the manufacturers protocol (Life Technologies, Guil-
ford, CT). RNA concentrations were measured using a NanoDrop spectrophotometer (Nan-
oDrop Technologies, Wilmington, DE) at a wavelength of 260 nm. The integrity of RNA was
evaluated using an Agilent 2200 Tape Station (Agilent Technologies, Santa Clara, CA). To ob-
tain cDNA, reverse transcription was performed using iScript Reverse Transcription Supermix
according to the manufacturers protocol (Bio-Rad, Hercules, CA). RT-PCR was performed us-
ing a CFX-96 thermocycler system (Bio-Rad) with TaqMan gene expression assays for Gapdh,
Cyp2c29, and Cyp3a11 (Thermo Fisher Scientific, Waltham, MA). Relative gene expression
was quantified using the Ct method with normalization to Gapdh.
Western Blotting. Total cellular proteins were isolated from liver tissue using RIPA buffer
according to the manufacturers protocol (Life Technologies). Protein concentration was deter-
mined by the Qubit Protein Assay Kit (Life Technologies). Extracted proteins were diluted to a
concentration of 40 g/mL and were separated on a 12% SDS-PAGE gel using an electrophore-
sis system (Bio-Rad), then electro-blotted onto a PVDF membrane with a transfer system (Bio-
Rad). The membranes were blocked with 5% non-fat milk at room temperature for one hour
followed by incubation with the primary antibody against Cyp3a11 (1:1000 dilution) (Millipore
Corporation, Bedford, MA). Gapdh antibody (Sigma-Aldrich) was used as a loading control for
normalization (1:3000 dilution). Immunoreactive bands were detected by chemiluminescence
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using corresponding horseradish peroxidase-conjugated secondary antibodies (1:3000 dilution
(Sigma-Aldrich)).
Statistical Analysis. Data are presented as mean ± S.D. with n = 3 for each treatment group.
Statistical analyses were performed using GraphPad Prism 6 software. Comparisons between
control and treatment groups were evaluated using Students t-test and a p-value of < 0.05 was
considered statistically significant, provided a power of 80% if the mean between control and
treatment groups were greater than 2-fold and standard deviation was less than 30%.
3.3 Results
3.3.1 Omeprazole inhibits the gastric proton-pump to increase pH in the
stomach of adult mice.
A control experiment (Figure 3.1A) was performed to examine the efficacy of omeprazole in
inhibiting proton-pump activity in the adult mouse stomach. Adult mice that received PBS
as a vehicle control had a gastric pH of 2.4 ± 0.2 in an unfasted condition. Adult mice that
received omeprazole for three days had a gastric pH of 4.5 ± 0.2 also in an unfasted state
following the final treatment (Figure 3.1B). This indicates that omeprazole efficiently blocked
the activity of gastric proton-pumps to reduce the amount of acid released into the stomach
and significant raised the pH (**p < 0.01). Expression of Cyp2c29 and Cyp3a11 mRNAs and
Cyp3a11 protein in livers were also were also measured by RT-qPCR and Western blotting,
respectively (Figure 3.1C, D, E). Because an antibody specific to Cyp2c29 was not available,
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the expression of Cyp2c29 protein could not be determined. No differences in gene expression
of either Cyp3a11 or Cyp2c29 were observed following omeprazole treatment. These results
show that treatment with omeprazole does not induce or repress Cyp3a11 and Cyp2c29 gene
transcription.
3.3.2 Concurrent administration of phenobarbital and omeprazole tem-
porarily reduces efficacy of omeprazole in adult mice.
A potential interaction between phenobarbital and omeprazole in adult mice was investigated
utilizing the experimental design illustrated in Figure 3.2A. Mice in the omeprazole control
group had a gastric pH of 4.0 ± 0.1, which was comparable to our earlier results. Mice in
the co-treatment group that received phenobarbital and omeprazole concurrently had a gastric
pH of 3.5 ± 0.1, which was significantly lower (***p < 0.001) than the control group. This
indicates that administering phenobarbital at the same time as omeprazole results in a DDI that
attenuates the efficacy of omeprazole in increasing gastric pH in the stomach (Figure 3.2B).
However, administering phenobarbital several days before beginning treatment with omepra-
zole does not adversely affect the action of omeprazole. Mice in this post-treatment group had
a gastric pH of 4.2± 0.1 following the final dose of omeprazole, which showed no statistically
significant difference to the gastric pH in the control group. This suggests that in adult mice, the
efficacy of proton-pump inhibition by omeprazole is not affected by a previous administration
of phenobarbital, and phenobarbitals potential to cause drug interactions may only be transient.
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FIGURE 3.1: Omeprazole increases gastric pH without altering CYP expression in adult
mice. (A) A schematic of animal treatment. Adult mice were treated with either vehicle control
(PBS, n = 3) or 150 mg/kg omeprazole (OME, n = 3) for three consecutive days at the ages of
days 57, 58, and 59 after birth. At age day 60, gastric pH was measured and livers were
collected for gene expression analysis. (B) Gastric pH with mean S.D. in the mouse stomach 1
hour after the final treatment of PBS or OME. (C) Relative fold changes of mRNA of CYP2C29,
(D) mRNA of CYP3A11, and (E) protein of CYP3A11 in the liver of mice treated with either
vehicle or omeprazole. **p < 0.01. GAPDH; glyceraldehyde 3-phosphate dehydrogenase.
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FIGURE 3.2: Concurrent administration of phenobarbital (PB) and omeprazole (OME)
results in a drug-drug interaction and reduces omeprazole efficacy in adult mice. (A) A
schematic of animal treatment. Adult mice in the OME control group (n = 3) were treated
with three consecutive doses of 150 mg/kg/day omeprazole (OME) at ages day 57, 58, and 59
after birth. Adult mice in the PB/OME co-treatment group (n = 3) received a single dose of
200 mg/kg phenobarbital together with a dose of 150 mg/kg omeprazole at day 57, followed
by two more treatments with just omeprazole on days 58 and 59. Mice in the PB/OME post-
treatment group (n = 3) received a single dose of 200 mg/kg phenobarbital at age day 57, then
three consecutive doses of 150 mg/kg/day omeprazole were initiated three days later, beginning
at age day 60. In all cases, gastric pH and liver collection were performed 1 hour following
the final treatment of omeprazole. (B) Gastric pH represented as mean ± S.D. in the mouse
stomach at 1 hour after the final omeprazole treatment. (C) Relative fold changes of mRNA of
CYP2C29 and (D) CYP3A11 and (E) protein expression of CYP3A11 in the mouse liver. ***p
< 0.001
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To exclude an effect on proton-pump activity by phenobarbital treatment, a group of mice
was treated with phenobarbital only and then gastric pH was measured. These mice had a
gastric pH of 2.7 ± 0.3 in an unfasted condition, and this was not a statistically significant
difference from the gastric pH of the control group. Gene expression of Cyp2c29 and Cyp3a11
in the liver was also determined by RT-qPCR following the completion of omeprazole treatment
(Figure 3.2C, D, E). Compared with the omeprazole control group, expression of both Cyp2c29
and Cyp3a11 mRNAs were significantly induced to 7.3 ± 0.9− (***p < 0.001) and 12.6 ±
0.8− (***p < 0.001) fold higher, respectively, in the co-treatment group of mice that received
phenobarbital and omeprazole concurrently. Mice that received phenobarbital three days prior
to beginning omeprazole treatment had no significant induction in either Cyp3a11 or Cyp2c29
mRNA expression following the final dose of omeprazole. Correlating changes in Cyp3a11
protein were also observed. These results indicate that phenobarbital-mediated CYP induction
in adult mice is not long-term, and induced levels of Cyp3a11 and Cyp2c29 mRNAs will return
to normal at least six days after phenobarbital treatment is ceased.
3.3.3 Neonatal administration of phenobarbital reduces the efficacy of
omeprazole in adulthood.
For these experiments, neonatal mouse pups were administered phenobarbital at day 5 of age
and were then treated with omeprazole in adulthood as previously described in the prior exper-
iments (Figure 3.3A). Neonatal treatment with vehicle control (neo vehicle/adult OME) did not
affect omeprazoles ability to inhibit proton-pump activity and gastric pH in adult stomach was
consistently 4.5 ± 0.2. Mice that only received phenobarbital as neonates and no omeprazole
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in adulthood (Neo single-PB/adult vehicle) had gastric pH levels of 2.3 ± 0.8, consistent with
un-fasted high stomach acidity in adult mice from the previous experiments. This indicates that
neonatal exposure to phenobarbital does not affect gastric pH in adulthood. However, mice that
were treated with phenobarbital as neonates then challenged with omeprazole as adults (neo
single-PB/adult OME), however, had significantly lower gastric pH levels (3.6 ± 0.1, **p <
0.01) than adult mice that received omeprazole and the vehicle control as neonates (4.5± 0.2).
Mice that received multiple doses of phenobarbital as neonates (Neo multi-PB/adult OME) ex-
hibited even lower gastric pH levels after omeprazole treatment in adulthood (3.1 ± 0.2, **p
< 0.01) (Figure 3.3B). These observations suggest that phenobarbital exposure at the neona-
tal stage reduces the efficacy of omeprazole in adulthood to inhibit gastric proton-pumps to
increase the pH of the stomach. This indicates a type of unconventional DDI, in which prior
phenobarbital treatment is still able to decrease the efficacy of omeprazole as if they were ad-
ministered concomitantly, when in reality significant time elapsed between the administrations
of both drugs.
Based on our hypothesis, the decrease in omeprazole efficacy in adulthood could be caused by
increased rates of drug metabolism due to the permanent induction of CYPs caused by pheno-
barbital exposure at the neonatal age. Therefore, we measured the expression of Cyp3a11 and
Cyp2c29 in the livers of these mice as well. The administration of phenobarbital to neonates
caused the expression of Cyp3a11 and Cyp2c29 mRNA to be up-regulated in adulthood fol-
lowing both vehicle and omeprazole treatment (Figure 3.3C, D). Cyp3a11 protein was also
overexpressed in these animals (Fig. 3.3E). Administering multiple doses of phenobarbital
to neonates also appeared to increase the variability of expression of the CYPs in adulthood
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FIGURE 3.3
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FIGURE 3.3: Neonatal administration of phenobarbital causes a long-term drug-drug
interaction and reduces efficacy of omeprazole in adult mice. (A) A schematic of animal
treatment. Mice in the neo vehicle/adult OME control group (n = 3) received vehicle (PBS) at
the neonatal age of day 5 and three consecutive doses of 150 mg/kg/day omeprazole (OME) at
the adult ages of day 57, 58, and 59. The mice in the neo single PB/adult vehicle group (n =
3) received a single dose of 200 mg/kg phenobarbital (PB) at age day 5 and three consecutive
doses of vehicle PBS at ages day 57, 58, and 59. Mice in the neo single PB/adult OME group (n
= 3) received a single dose of 200 mg/kg phenobarbital at age day 5 and three consecutive doses
of 150 mg/kg/day omeprazole at ages day 57, 58, and 59. Mice in the neo multi PB/adult OME
group (n = 3) received three consecutive doses of 200 mg/kg/day phenobarbital at ages day 5,
6, and 7 followed by three consecutive doses of 150 mg/kg/day omeprazole at ages day 57,
58, and 59. In all groups, gastric pH and liver collection were performed 1 hour following the
final treatment of omeprazole. (B) Gastric pH represented as mean S.D. in the mouse stomach
1 hour after final treatment of omeprazole. (C) Relative fold changes of mRNA of CYP2C29
and (D) CYP3A11 and (E) protein expression of CYP3A11 in the livers. *p < 0.05 and **p <
0.01.
compared to mice that only received a single dose of phenobarbital as neonates.
3.4 Discussion
This study presents a case in which drug treatment at the neonatal age was able to affect the
activity and efficacy of a different drug administered much later in adulthood. Omeprazole
is a medication utilized to inhibit gastric proton-pumps to decrease stomach acidity and raise
pH levels. When phenobarbital and omeprazole are administered concurrently in adulthood, the
efficacy of omeprazole is attenuated and gastric pH levels do not increase as significantly as they
do in the absence of phenobarbital. When phenobarbital is administered during the neonatal
stage, there still appears to be an interaction between the two drugs even when omeprazole is
administered much later in adulthood. This observation challenges the current definition of a
DDI, and suggests that perhaps two drugs do not need to be administered concurrently for an
interaction to occur if one of the drugs is administered at the neonatal age. We hypothesize
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that this is due to the inducer drug, phenobarbital, permanently up-regulating the expression
and activity of Cyp3a11 and Cyp2c29 after treatment during neonatal life, which alters the
metabolism of omeprazole in adulthood, increasing the rate of its clearance and thus lowering
its efficacy.
Phenobarbital, along with several other first-generation antiepileptic and sedative drugs, is
known to cause induction of several different CYP enzymes in the liver of both rodents and
humans [78]. Because of this, physicians are currently aware of the risk of DDIs with many
commons medications in patients prescribed phenobarbital [85]. However, the current clini-
cal practice only takes DDIs into considerations when multiple drugs are administered at the
same time. Historical usage of drugs in previous weeks, months, or years is not a consideration
for DDI risk, as most cases of drug-mediated CYP induction are temporary and expression of
the enzymes return to normal once the inducer drug is discontinued. Whereas this is true for
adults, our findings suggest that CYP induction at the neonatal age can lead to permanent con-
sequences on drug metabolism later in life. This could eventually lead to a change in how DDI
risk is evaluated and significantly impact the clinical practice.
Studies from Dr. Bernard Shapiros laboratory have demonstrated that permanent induction of
CYP expression in the adult rat liver can be achieved when neonates are exposed to phenobar-
bital [116, 117, 119]. A previous study from our own laboratory confirmed this observation
in mice, and also further illustrated that the phenomenon was dependent on both the dose of
phenobarbital administered, and the age at which the drug was given [120]. In our current
study, we additionally showed that the permanent induction of CYPs resulting from neonatal
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phenobarbital exposure may be associated with a significant decrease in the efficacy of gas-
tric proton-pump inhibition by omeprazole administered in adult life. Other prior studies have
shown that neonatal treatment with compounds that induce drug-metabolizing CYPs may af-
fect the action of other compounds in adulthood. For example, neonatal phenobarbital exposure
decreased sleep time in vivo in adult rats treated with hexobarbital [119], and neonatal expo-
sure to the constitutive androstane receptor ligand TCPOBOP decreased paralysis time in adult
mice treated with zoxazolamine [86]. However, neither hexobarbital nor zoxazolamine are cur-
rently used as pharmaceutical medications. Omeprazole, on the other hand, is a very commonly
utilized drug across patient populations, and our study has shown that its efficacy can also be
affected by prior phenobarbital exposure at the neonatal age.
This study presents a set of observational experiments used to establish a concept in a rodent
model. This concept of long-term, unconventional DDIs resulting from neonatal drug expo-
sure will need to be confirmed in additional models with a wider range of inducer and victim
pharmaceutical compounds. The efficacy of midazolam, another sleep-inducing agent, could
easily be measured and is metabolized primarily by CYP3A enzymes. Other drugs that induce
CYP expression and activity, such as phenytoin and dexamethasone, could also be adminis-
tered at the neonatal age to determine whether this phenomenon is restricted to phenobarbital
or if other inducers are capable of producing similar effects in adult drug metabolism. Effective
dose ranges and exposure-sensitivity windows will also need to be established for each drug.
Conversely, if neonatal exposure to additional inducer drugs does not permanently alter CYP
expression into adulthood, it may be worth investigating what makes phenobarbital unique and
able to produce permanent changes to hepatic metabolic function.
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Furthermore, the underlying molecular mechanisms also need to be explored for an expla-
nation of how neonatal drug exposure is capable of permanently altering the expression and
metabolic activity of CYP enzymes. Epigenetic mechanisms, including DNA methylation,
histone modifications, and microRNAs, have been implicated in regulating the expression of
drug-metabolizing enzymes in both neonatal and adult livers [92, 98, 158]. Additionally, phe-
nobarbital treatment does not only cause changes in the gene expression of CYP enzymes.
Many drug-metabolizing enzymes are transporters are altered following phenobarbital treat-
ment, however it is unknown whether all of these are permanently impacted following neonatal
exposure as well.
Chapter 4
Long-term Effects on the Liver
Transcriptome Following Neonatal
Phenobarbital Exposure
4.1 Introduction
Drug metabolizing enzymes (DMEs) and transporters are expressed at high levels in the liver
in both constitutive and induced states. DMEs are responsible for modifying xenobiotic sub-
strates that enter the body through metabolic reactions that increase the solubility of the com-
pound to facilitate eventual excretion. Phase I enzymes catalyze hydrolysis, reduction, and
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oxidation reactions, whereas Phase II enzymes conjugate water-soluble groups to the mod-
ified compounds. Phase III transporters provide systems of both influx and efflux to trans-
port compounds in and out of hepatocytes. The cytochrome P450 family of enzymes (CYPs)
are monooxygenases that make up the majority of enzymes responsible for phase I oxidative
metabolism. Their substrates consist of a wide variety of both endogenous and exogenous sub-
stances in addition to pharmaceutical drugs, including environmental toxicants, dietary compo-
nents, and endogenous hormones. Following phase I metabolism, phase II enzymes carry out
conjugation reactions to facilitate detoxification and consist mainly of transferases, including
UDP-glucuronyltransferases (UGTs), sulfotransferases (SULTs), N-acetyltransferases (NATs),
glutathione S-transferases (GSTs), and methyltransferases. Finally, the modified compounds
can be effluxed out of the hepatocyte via ATP-binding cassette (ABC) and solute carrier (SLC)
phase III transporters. The expression of phase I and II enzymes and phase III transporters can
be induced by xenobiotic exposure, which causes an increase in their activity and ultimately
affects the clearance and efficacy of the drug and other co-administered compounds [68].
The expression and activity of the phase I CYP enzymes have a large influence on the clearance
rate of drugs and can affect how slowly or quickly a compound is excreted by the body as this
is the first metabolic step an exogenous compound will undergo. The exposure to certain xeno-
biotics and pharmaceutical drugs can cause the induction of CYP genes, which up-regulates
their activity by increasing the rate of their transcription. Identifying commonly used phar-
maceutical drugs that induce CYP activity is critical to avoid drug-drug interactions (DDIs),
which can decrease the efficacy or increase the toxicity of additional medications taken at the
same time as an inducing drug. Medications such as phenobarbital, phenytoin, rifampicin, and
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dexamethasone are classic examples of CYP inducers that are implicated in many DDIs. CYP
induction is traditionally only studied in the context of adults, and it is assumed mechanisms of
enzyme induction are similar in infants and children. In adults, CYP induction is a temporary
and reversible event, and enzyme expression returns to basal levels once the inducer drug is
discontinued and fully excreted. However, our research has demonstrated that exposure to phe-
nobarbital during the neonatal stage of development may permanently up-regulate the expres-
sion of several hepatic CYPs in adult life, as explained in Chapter Three [159]. We therefore
contemplated whether neonatal phenobarbital exposure permanently impacts additional genes
important to liver function in adulthood.
Phenobarbital is known to up-regulate the expression of many other genes in addition to CYP
enzymes. Several in vitro studies in human hepatocyte cell lines have examined transcriptomic
and proteomic changes in response to phenobarbital treatment. In HepaRG cells, exposure to
phenobarbital caused significant induction of multiple CYPs and other genes involved in drug
metabolism, including phase II transferases and phase III transporters. Additionally, dozens
of other genes involved in lipid biosynthesis, hormone metabolism, digestion, carboxylic acid
metabolism were also induced as a result of phenobarbital exposure. Suppression occurred
in genes relating to cell adhesion, defense responses, and the regulation of cell proliferation
[160, 161]. It is hypothesized that phenobarbital is capable of affecting the expression of so
many genes due to its ability to activate both the CAR and PXR nuclear receptors, which act
as transcription factors for many target genes in the liver beyond CYP enzymes. However, it
is unknown whether neonatal exposure to phenobarbital permanently alters the expression of
other genes known to be induced by the drug.
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This study utilizes RNA-sequencing (RNA-seq) in a mouse model to characterize the long-
term consequences on gene expression in the adult liver following phenobarbital exposure at
the neonatal age in vivo. It is not feasible to study the developmental effects of phenobarbital
exposure in a cell model, so an animal model must be utilized. There are known differences
in the effects of the activation of murine CAR versus human CAR, and species differences in
the response to phenobarbital [162]. Therefore, this study will serve as proof of a concept that
exposure to phenobarbital at the neonatal age may cause permanent transcriptomic changes that
can impact the function of the liver through adulthood.
4.2 Materials and Methods
Animals. Eight-week-old C57Bl/6 mice were purchased from Jackson Laboratories (Bar Har-
bor, ME) and set up into breeding pairs. Mice were housed according to the Animal Care
Guidelines provided by the American Association for Animal Laboratory Sciences and were
bred under standard conditions in the Animal Care Facility at the University of Connecticut.
The use of these animals was approved by the Institutional Animal Care and Use Committee.
On day 5 after birth, male mice were administered either saline vehicle control (PBS) or 200
mg/kg phenobarbital (phenobarbital sodium salt) intraperitoneally (n = 3 for each group). At
age day 60 after birth, all mice were sacrificed and livers were collected and snap frozen in
liquid nitrogen. Samples were stored at -80 °C for further analyses.
Total RNA Extraction. Total RNAs were isolated from liver tissue using TRIzol reagent as
previously described in Chapter Three. The integrity of RNAs was evaluated on an Agilent
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2200 Tape Station (Agilent Technologies, Santa Clara, CA), and samples with RIN integrity
values of greater than 8.0 were acceptable for sequencing library construction.
cDNA Library Construction. cDNA libraries from all samples were prepared using an Illu-
mina TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA) with 3 g of total RNA used
for RNA input. Messenger RNAs were isolated from total RNAs by poly(A) selection using
poly(T) primers. RNA fragmentation, first-, and second-strand cDNA syntheses, end repair,
adapter ligation, and PCR amplification were performed according to the manufacturers pro-
tocol. Fragments of the cDNA library ranged from 220 to 500 bp with a peak size of 280 bp
(including the 120-bp adapter sequence). Quality of the cDNA libraries was evaluated using an
Agilent 2100 Bioanalyzer before sequencing.
RNA-sequencing. RNA-seq was performed on an Illumina HiSeq 2000 instrument (Perkin
Elmer, Branford, CT). Clusters of the cDNA libraries were generated on a TruSeq flow cell and
sequenced for 100-bp paired end reads (2 x 100) with a TruSeq 200-cycle SBS kit (Illumina).
A PhiX bacteriophage genome and a universal human reference RNA were used as controls
and sequences in parallel with other samples to ensure that the data generated for each run were
accurately calibrated during the image and data analysis. In addition, the PhiX was spiked onto
each cDNA sample at approximately 1% as an internal quality control.
RNA-seq Data Analysis. After the sequencing images were generated by the platform, the
pixel-level raw data collection, image analysis, and base calling were performed using Illu-
mina Real Time Analysis software. The output .bcl files were converted to qseq files by Illu-
mina BCL Converter 1.7 software and subsequently converted to .FASTQ files for downstream
analyses. The RNA-seq reads from the FASTQ files were mapped to the mouse reference
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genome (NCBI37/mm9) and splice junctions were identified by TopHat 1.2. The output files in
.BAM format were analyzed by Cufflinks 1.0.3 to estimate transcript abundance. The mRNA
abundance was expressed as the number of fragments per kilobase of exon per millions reads
mapped (FPKM).
Statistical Analysis. Differentially expressed genes in the phenobarbital-treated animals were
identified using the program Cuffdiff. Genes with an adjusted P-value 0.05 determined by one-
way ANOVA, FDR < 0.001, and log2 fold change ≥ 2 or ≤ −2 were considered significantly
differentially expressed. CummeRbund was utilized to visualize and integrate data produced
by Cuffdiff analysis.
Gene Ontology Analysis. Gene ontology (GO) was performed using the Database for Annota-
tion, Visualization, and Integrated Discovery (DAVID, v6.8). GO terms with a p-value < 0.05
and a FDR < 1 were considered statistically significantly enriched.
Transcription Factor Enrichment. Enriched transcription factors known to bind to the pro-
moter regions of selected genes were identified using the ENCODE ChIP-Seq Significance
Tool found at encodeqt.simple-encode.org. Lists of significantly up-regulated and significantly
down-regulated genes were input into the program and analyzed against the mm10 background
for transcription factors experimentally shown to bind within 2,000 bp upstream or 500 bp
downstream of the TSS 5‘ end. Q-values were calculated using the hypergeometric test accord-
ing to Benjamini-Hochberg.
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4.3 Results
4.3.1 Long-term effects on the liver transcriptome following neonatal phe-
nobarbital exposure.
Mice were treated with a single dose of either PBS vehicle control of 200 mg/kg phenobarbital
at the age of day 5 after birth. At age day 60 after birth, the mice were sacrificed and livers
were collected for transcriptome analysis by RNA-seq. A total of 10,499 genes were found to be
expressed in the liver. The similarity of the transcriptomes between samples were evaluated by
calculating correlations (Figure 4.1). The transcriptomes of control mice were more similar to
each other, while neonatal phenobarbital appeared to increase the variability in transcriptomes
of treated mice, as evidenced by the lower r-values of correlation between the treated mice.
We identified differentially expressed genes between the two groups of mice with the program
Cuffdiff. Genes with an adjusted p-value of < 0.05 and a FDR < 0.001 were considered
significantly differentially expressed. Based on this criteria, a total of 1,649 genes were found to
be differentially expressed in adult livers of mice treated with phenobarbital at the neonatal age.
Of these differentially expressed genes, 926 were up-regulated and 723 were down-regulated
in comparison to vehicle-treated mice. However, we narrowed these genes down further by
selecting for those that had a fold-change ≥ 2 or ≤ −2. Of these, 166 genes were up-regulated
by at least two-fold, and 57 were down-regulated by at least two-fold (Figure 4.2).
The most significantly up-regulated genes included CYPs, SULTs, and other genes involved in
detoxification such as Fmo3 and drug transporters. The CYPs with the greatest fold-changes,
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FIGURE 4.1: Correlation matrix of transcripte profiles among adult mice treated with
phenobarbital or control at the neonatal age. Overall correlation for the expression of each
gene expressed in the liver (in FPKM) was calculated for adult mice (n = 3) that received either
PBS (C 1, C 2, and C 3) or 200 mg/kg phenobarbital (PB 1, PB 2, and PB 3) at day 5 of age.
Blue represents r = 1, while red would represent r = -1.
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FIGURE 4.2: Summary of RNA-seq results. Summary of the results obtained from RNA-seq
analyses on adult livers following day 5 treatment with 200 mg/kg phenobarbital, compared to
age-matched mice that received vehicle control (PBS) on day 5 (n = 3 for both groups).
however, were genes not typically associated with drug metabolism in the mouse, and in-
cluded Cyp11b1, Cyp2b13, and Cyp2b9. In fact, these genes were not even expressed in
vehicle-treated mice. Interestingly, the gene with the highest fold-increase was the hydroxyl-
delta-5-steroid-dehydrogenase, 3 beta- and steroid delta-isomerase 1 (Hsd3b1). This enzyme
plays an important role in the biosynthesis of all hormonal steroids, including the catalysis
of pregnenolone to progesterone and DHEA to 4-androstenedione, along with the metabolism
of testosterone. This gene was not expressed in control males, but was up-regulated over 10-
fold in phenobarbital-treated mice. The gene with the greatest degree of suppression of was
Serpina4, also known as kallistatin. The protein functions as an inhibitor of kallikrein, which
has amdiolytic and kininogenase activity, to protect tissues against inflammation, fibrosis, and
oxidative stress [163].
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FIGURE 4.3: Comparison of the expression of all expressed cytochrome P450 enzymes
(FPKM > 1) in adult liver following neonatal phenobarbital treatment. Heatmap of ex-
pression profiles for all expressed CYPs (FPKM > 1) in adult livers.
4.3.2 Long-term effects on drug metabolism following neonatal pheno-
barbital exposure.
To evaluate global changes to genes involved in drug metabolism and transport, heatmaps were
created that included phase I and phase II enzymes and phase III transporters. When visualiz-
ing the data, red coloring represents gene expression higher than the average of all the samples,
while green coloring represents gene expression lower than the average of all the samples. Of
all phase I enzymes, 75 were significantly affected in adults by neonatal phenobarbital expo-
sure (Figure 4.3, Figure 4.4). Most were up-regulated, although a few genes, such as Aldh4,
Cyp2d40, and Pon2, were significantly down-regulated. There are also inconsistencies among
up- and down-regulated genes between the phenobarbital-treated samples. Specifically, the PB1
sample shows a more distint gene expression profile from the PB2 and PB3 samples, which are
more similar. There are a cluster of CYPs in the PB1 sample that are not up-regulated com-
pared to control mice, as in PB2 and PB3 samples. CYPs that were induced in all three samples
do include Cyp2b10, which was up-regulated 8-fold, and Cyp2c29 and Cyp3a11 which were
up-regulated 3- and 1.5-fold, respectively. While this confirms our observation from earlier
RT-PCR experiments that showed neonatal phenobarbital up-regulates CYP expression in adult
life, it does not reflect the large extent of enzyme induction that was observed in RT-PCR gene
expression evaluation. The Cyp4 enzymes also appear to be commonly down-regulated among
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all three phenobarbital-treated mice. Other phase I drug-metabolizing enzymes that were sig-
nificantly up-regulated included Cyp1a2 (0.7-fold), Aldh1a1 (1.3-fold), Fmo3 (8-fold), and
Ces2a (2.5-fold). There are also inconsistences in the rest of the phase I enzymes changed
by phenobarbital treatment, as many enzymes up-regulated in samples PB2 and PB3 are not
up-regulated in PB1. These data suggest that while phenobarbital treatment at the early age
definitely alters phase I drug-metabolizing enzymes in adult life, the changes in gene expres-
sion may not always be the same in all animals. Therefore, neonatal phenobarbital treatment
can increase variability in gene expression in adult life.
Additionally, 32 phase II enzymes were also significantly differentially expressed in phenobarbital-
treated mice (Figure 4.5). Again, most genes were up-regulated, but a few genes including
Ugt2a1 and Ugt2a3, were down-regulated. Many of the SULTs had the largest fold-increases
in expression, including Sult3a1, Sult2a1, Sult1e1, and Sult2a2, which had fold-changes of 9.6,
8.8, 8.7, and 8.6, respectively. Again, there was variability in the up- or down-regulation of spe-
cific phase II enzymes in response to neonatal phenobarbital treatment. Phase III transporters
were also impacted, with 27 showing significant differential expression in phenobarbital-treated
mice (Figure 4.6, Figure 4.7). However, the differences in expression were not as dramatic as
with phase I and phase II enzymes. SLC transporters appeared to be more significantly im-
pacted than ABC transporters, with Slc22a26 having the greatest fold-increase (6.5-fold).
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FIGURE 4.4: Comparison of expression of phase I enzymes in adult liver following neona-
tal phenobarbital exposure. Comparison of the expression of the rest of expressed phase I
enzymes (FPKM > 1, excluding CYPs) in adult livers following neonatal treatment with PBS
(C 1, C 2, C 3) or phenobarbital (PB 1, PB 2, PB 3).
4.3.3 Long-term effects on liver functions following neonatal phenobar-
bital exposure.
To further understand the major hepatic functions and pathways altered by neonatal phenobar-
bital treatment, we submitted the lists of differentially expressed genes for ontology analysis
by the program DAVID. For the genes up-regulated in adult liver by phenobarbital treatment
(Figure 4.8A), the most significantly enriched biological processes affected were the epoxy-
genase P450 pathway, oxidation-reduction process, digestion, steroid metabolic process, and
proteolysis. Many other processes the program identified were involved in lipid metabolism,
drug metabolism, detoxification, and hormone biosynthesis. Most of these genes in this list
had the molecular functions of steroid hydroxylase activity, iron ion binding, arachidonic acid
epoxygenase activity, and aromatase activity. The up-regulated genes were found to be sig-
nificantly involved in the steroid hormone biosynthesis, chemical carcinogenesis, pancreatic
secretion, and arachidonic acid metabolism KEGG pathways. We also examined the biologi-
cal processes that were enriched in genes that were down-regulated by neonatal phenobarbital
exposure (Figure 4.8B). Interestingly, the most significant process suppressed was circadian
rhythm and its regulation and effects on gene expression. The circadian rhythm and MAPK
signaling KEGG pathways were also identified as significantly enriched. Other processes that
were enriched were involved in gene transcription, cell differentiation, apoptosis, and liver de-
velopment. These genes involved in these processes mainly had transcription factor activity or
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FIGURE 4.5: Comparison of expression of phase II enzymes in adult liver following neona-
tal phenobarbital exposure. Comparison of the expression of all expressed phase II enzymes
(FPKM > 1) in adult livers following neonatal treatment with PBS (C 1, C 2, C 3) or pheno-
barbital (PB 1, PB 2, PB 3).
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FIGURE 4.6: Comparison of the expression of phase III ABC transporters in adult liver
following neonatal phenobarbital exposure. Comparison of the expression of all expressed
phase III transporters belonging to the ABC family (FPKM> 1) in adult livers following neona-
tal treatment with PBS (C 1, C 2, C 3) or phenobarbital (PB 1, PB 2, PB 3).
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FIGURE 4.7: Expression of phase III SLC transporters in adult liver following phenobar-
bital exposure at the neonatal age. Comparison of the expression of phase III transporters
belonging to the SLC family following neonatal treatment with PBS (C 1, C 2, C 3) or phe-
nobarbital (PB 1, PB 2, PB 3). Due to the large number of SLC transporters expressed, only
genes with FPKM > 15 are shown.
were involved in histone deacetylase and DNA binding functions.
We also submitted up- and down-regulated gene lists for transcription factor enrichment anal-
ysis (Figure 4.8C). This program identifies common transcription factors validated by chro-
matin immunoprecipitation experiments known to bind to the promoter regions of the genes
submitted. For up-regulated genes, signficant common transcription factors included p300
and CCCTC-binding factor (CTCF), which were experimentally shown to bind to over 50
of the genes were submitted. Of the down-regulated genes, common transcription factors
also included p300 and CTCF, along with ETS proto-oncogene 1 (ETS1), negative elonga-
tion factor complex member 3 (NELFe), MYC associated factor X (Max), and Max interactor
1 (Mxi1). Interestingly, even though fewer genes were significantly down-regulated by pheno-
barbital treatment, there was a greater number of common transcription factors shown to bind
to these genes. There was also overlap in the transcription factors that bound to both up- and
down-regulated genes, suggesting common mechanisms that activate as well as repress gene
transcription in response to phenobarbital.
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Biological Process
Number of 
genes
P-value FDR
Epoxygenase P450 pathways 14 3.15E-20 4.74E-17
Oxidation-reduction process 21 4.21E-07 6.34E-04
Digestion 6 5.92E-06 8.91E-03
Steroid metabolic process 7 5.61E-05 8.43E-02
Proteolysis 15 2.32E-04 3.48E-01
Lipid metabolic process 13 3.12E-04 4.68E-01
Sulfation 4 5.70E-05 8.57E-02
Biological Process
Number of 
genes
P-value FDR
Circadian rhythm 6 7.81E-06 1.09E-02
Circadian regulation of gene expression 5 1.72E-05 2.41E-02
Rhythmic process 6 1.79E-05 2.50E-02
Positive regulation of transcription 11 1.62E-04 2.26E-01
Regulation of transcription, DNA-templated 16 3.40E-04 4.75E-01
Transcription 
factor
Number of 
genes
Q-value
Pol2 109 5.58E-05
p300 56 6.10E-05
CTCF 66 1.20E-03
TCF12 12 1.06E-02
MyoD 9 3.88E-02
Transcription 
factor
Number of 
genes
Q-value
p300 35 4.95E-11
CTCF 40 8.61E-11
Pol2 51 3.74E-10
ETS1 23 1.62E-05
SRF 10 2.68E-04
BHLHE40 24 9.28E-04
Max 28 1.03E-03
MAZ 25 2.08E-03
CHD2 21 2.36E-03
CEBPB 7 4.27E-03
Mxi1 26 6.28E-03
NELFe 26 9.18E-03
E2F4 13 1.05E-02
GATA2 4 1.05E-02
JunD 6 1.11E-02
USF 7 1.11E-02
A
B
C
FIGURE 4.8: Gene ontology analysis of significantly differentially expressed genes in adult
mice following neonatal exposure to phenobarbital. Gene ontology analysis was performed
on significantly up-regulated genes (A) and down-regulated genes (B) in adult mice following
neonatal exposure to phenobarbital. Enriched biological processes with p < 0.05 and FDR <
0.1 are listed. Enriched transcription factors known to bind to the promoter region of differen-
tially expressed genes were also identfied (C) for up-regulated genes (left) and down-regulated
genes (right). Transcription factors with Q < 0.05 are listed.
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4.4 Discussion
Over the past 30 years, phenobarbital has been repeatedly shown to affect adult hepatic CYP ac-
tivity in rodents after it is administered at the neonatal stage [115, 119, 120]. The permanent in-
creases to CYP expression resulting from neonatal programming have also been shown to affect
the efficacy of other drugs and compounds administered in adulthood, such as omeprazole and
zolaxamine [86, 159], presumably due to increased clearance rates. Due to the ability of pheno-
barbital to activate the CAR nuclear receptor and affect the circulating concentrations of various
hormones, we hypothesized that neonatal phenobarbital exposure causes overall global alter-
ations to adult liver gene expression and function in addition to the permanent up-regulation of
drug-metabolizing CYPs. Therefore, we performed RNA-seq on liver samples from adult mice
that received a single dose of phenobarbital at the neonatal age, and compared gene expres-
sion to control mice to identify significantly differentially expressed transcripts. Gene ontology
analysis revealed multiple biological processes and pathways altered by neonatal phenobarbital
exposure in addition to all phases of drug metabolism. These results demonstrate that exposure
to a single dose of phenobarbital early in life may have the potential to alter various functions
of the liver in adulthood, including lipid metabolism, energy homeostasis, and steroid hormone
biosynthesis in adition to xenobiotic biotransformation.
Phenobarbital is known to cause the induction of multiple drug-metabolizing CYP enzymes via
the activation of the nuclear receptor CAR [164]. CAR is well-known for its role in regulat-
ing the expression of CYPs and other drug-metabolizing enzymes, which is evidenced by the
large amount of phase I, phase II, and transporter genes we found to be affected by neonatal
phenobarbital treatment. In addition, CAR has also been characterized for its involvement in
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glucose and lipid metabolism [165] and the promotion of hepatocyte differentiation [86]. This
would explain why we also found genes not related to drug metabolism, but rather involved in
digestion, lipid metabolism, and proteolysis, to be affected by phenobarbital treatment. CAR
activation, particularly by phenobarbital, has also been shown to promote liver tumorigenesis in
mice by altering the expression of genes involved in regulating cellular responses to DNA dam-
age and tumor promotion [166], suggesting CAR also plays an important role in the regulation
of cell growth and proliferation.
Upon its activation, CAR is translocated into the nuclear to promote the transcription of its
target genes. However, our common transcription factor analyses did not reveal CAR as a
significantly enriched transcription factor shown to bind to the genes we identified as signif-
icantly affected by neonatal phenobarbital exposure. However CAR is also known to recruit
a variety of co-activator proteins to the promoter of target genes to affect gene transcription.
Steroid receptor co-activator 3 (SRC-3) has been identified as a prominent co-activator that
is recruited with CAR to promote hepatocyte proliferation and induction of drug metabolism
upon TCPOBOP treatment [167], but was also not identified in our analyses. However, p300
a significant common transcription factor we identified, has been shown to be a key regula-
tor of various liver functions, including apoptosis, cell proliferation, gluconeogenesis, and liver
regeneration [168, 169]. p300 is also heavily involved in proper development including regulat-
ing hormone metabolism and cell differentiation [170], which are two processes also identified
by our gene ontology analyses. CTCF is also important for regulating epigenetic landscapes
during liver development and maturation to promote proper gene expression and function, and
was identified as an enriched transcription factor altered by neonatal phenobarbital treatment
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[171]. Perhaps changes in gene expression resulting from neonatal phenobarbital exposure are
due to other factors beyond CAR activation that are involved in more global liver maturation
regulation.
Phenobarbital does not directly bind CAR, but rather causes receptor activation through an
indirect mechanism that leads to its translocation into the nucleus. This mechanism by which
phenobarbital produces CAR activation was elusive for decades, until recently where it has been
shown that phenobarbital binds and antagonizes the epidermal growth factor receptor (EGFR),
which ultimately causes CAR activation [172]. Following EGFR binding and thus inhibition,
phosphorylation on the tyrosine of the scaffold protein RACK1 is abolished. Dephosphorylated
RACK1 is then able to activate protein phosphatase 2A (PP2A). The activated PP2A then de-
phosphorylates CAR, which causes the translocation of the nuclear receptor into the nucleus
where it is able to alter the transcription of its target genes, with the classic example being
CYP2B enzymes. However, there are many other signaling pathways that exist downstream
from EGFR activation or antagonism that can be affected by phenobarbital binding apart from
CAR activation [173–175]. It is likely that the permanent alterations to multiple hepatic bio-
logical pathways following neonatal phenobarbital exposure are also due to changes in EGFR
signaling, rather than just the activation of CAR.
EGFR, also known as ErbB-1, is a membrane receptor known for its role in promoting cell
proliferation, cell migration, and tumorigenesis. Following its activation by growth factor lig-
ands, downstream Ras-Raf-MEK-ERK1/2-STAT3/5 and PI3K-Akt-mTOR pathways become
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up-regulated, which leads to DNA synthesis and subsequent cell proliferation and the promo-
tion of cell survival. EGFR has been shown to be indispensible for proper gestational devel-
opment in rodents, and EGFR knockout mice are exhibit severe growth retardation [176]. The
abolishment of EGFR in hepatocytes specifically also causes whole body growth retardation
and body size reduction, indicating hepatic EGFR plays a role in energy homeostasis that con-
trols the growth of the entire body. EGFR is most highly expressed in the adult liver and is re-
quired for proper liver function and tissue regeneration following hepatic injury [177]. During
liver regeneration, growth hormone signaling can also indirectly regulate EGFR expression and
function. Down-regulation of the growth hormone receptor accompanies decreased expression
of EGFR on hepatocytes, which negatively affects proper hepatocyte proliferation and organ
growth [178]. Interestingly, neonatal phenobarbital treatment has been shown to permanently
alter growth hormone secretion in rodents [117]. Perhaps neonatal phenobarbital exposure
either permanently alters EGFR signaling, or the relationship between circualting growth hor-
mone and EGFR, which promotes the differentiation of hepatocytes during development, which
would explain the large number of drug-, lipid- and steroid-metabolizing enzymes affected by
phenobarbital treatment. Also in support of EGFR signaling modulation, EGFR inhibitors have
been shown to up-regulate p300 activity in cancer cells [179].
The regulation of circadian rhythm was the most significantly enriched process associated with
the down-regulated genes in phenobarbital-exposed mice. It is thought that circadian rhythm
evolved due to the increased production of reactive oxygen species (ROS) with the development
of redox reactions in the presence of daylight and oxygen. Therefore, it makes sense that the
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up-regulation of CYPs and other hepatic enzymes by phenobarbital treatment would affect cir-
cadian rhythm via the increased production of ROS through reactions involved in metabolism.
Glucose, lipid, and bile acid metabolism have also been shown to follow circadian patterns
[180]. Certain epigenetic modifications are also controlled by circadian rhythm, and it is possi-
ble that epigenetic alterations caused by phenobarbital treatment in neonates become permanent
and persist into adulthood, altering gene expression. However, the opposite might be true, in
which phenobarbital affects circadian rhythms, and this is in turn altering the expression of
the many genes involved in hepatic drug and energy metabolism. The circadian rhythm and
time of day of drug administration has been repeatedly shown to significantly affect patient
pharmacokinetics [181].
Most of the adverse effects associated with phenobarbital use are behavioral or cognitive and in-
clude attention deficits, problems with memory, impairment of judgment, sedation, and slowed
learning [182]. Growth defects have also been seen in children treated with phenbarbital, sug-
gesting a potential role of EGFR and/or growth hormone disturbances [183]. Long-term use
of phenobarbital is also associated with increased risks of liver cancer, decreased bone density,
metabolic issues, decreased serum concentrations of thyroid hormones, and even increased risk
of early death in adults [184–186]. It is interesting that many of the biological processes and
pathways enriched in the livers of mice neonatally exposed to phenobarbital are associated with
bone differentiation, energy metabolism, and hormone biosynthesis. Due to the propensity of
phenobarbital to cause adverse effects that are not well-tolerated, however, the medication is
usually not prescribed for long-term use. In light of this, our study highlights the possibility
of permanent effects on the liver following only a single dose of phenobarbital. Future studies
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will be necessary to determine whether the significantly increased or decreased gene transcripts
resulting from phenobarbital treatment are actually translated into protein and have functional
consequences in the liver, and whether these effects occur in humans.
Chapter 5
Long-term Effects of Neonatal Phenytoin
Exposure on Cytochrome P450 Expression
5.1 Introduction
Seizures, whether isolated or due to chronic epileptic conditions, are unfortunately a relatively
common occurrence in pediatric patients. Between two and four out of every 1,000 newborns
suffer from seizures following birth. It is crucial to control seizures immediately, utilizing ther-
apeutic interventions to prevent brain damage and other complications in young, developing
patients. Many AEDs, however, are known to induce CYP expression via the activation of
hepatic nuclear receptors, namely CAR and PXR. Following their activation, nuclear recep-
tors translocate into the nucleus to alter gene transcription by the recruitement of co-activator
100
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proteins, which alter the epigenetic landscape surrounding promoters. Increased levels of en-
zymes involved in catalyzing the addition or removal of epigenetic modifications to induce and
suppress gene transcription exist in the liver during early postnatal ages, which facilitates the
maturation of developing organs and proper programming of gene expression [187]. This may
also cause developing organs to be especially susceptible to alterations in normal gene expres-
sion ontogeny by xenobiotics that induce transcription via epigenetic modifications. It is also
possible for epigenetic modifications made during postnatal organ growth to become permanent
and alter cellular responses in adulthood [188].
We have already demonstrated in Chapters Three and Four that neonatal exposure to phenobar-
bital can permanently alter the expression of hundreds of genes in the liver in adult mice. In
particular, CYP genes involved in drug metabolism are up-regulated in response to phenobarbi-
tal exposure in early life, and this may affect the efficacy or toxicity of other drugs administered
in adulthood [120, 159]. It is now critical to investigate whether this phenomenon occurs fol-
lowing exposure to additional drugs at the neonatal age. Because neonates are more commonly
exposed to AEDs rather than other inducer drugs due to the frequency of infant seizures, we
decided to investigate the long-term effects of a different AED, phenytoin. Phenytoin is also
considered a first-line therapy for treating seizures and convulsions in pediatric patients, and is
even additionally used to treat arrhythmias.
Phenytoin is known to induce enzymes belonging to the CYP2B, CYP2C, and CYP3A families
in both rodents and humans, at least at the adult age. The induction of CYP2B6 by phenytoin
has been shown to be exclusively mediated by CAR [84]. The induction is temporary and the
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expression of these enzymes returns to basal levels once the inducing agent is ceased. Addi-
tionally, a study has shown that longer term, chronic administration of phenytoin even abolishes
inductive effects of CYP2B and CYP2C enzymes in rats [189]. However, no studies have ex-
amined whether neonatal exposure to phenytoin has any effect on CYP expression in the liver
in adulthood. Because we have already established that neonatal phenobarbital exposure results
in altered expression of drug-metabolizing CYPs in adult life that can diminish the efficacy of
other administered drugs, we hypothesized that neonatal phenytoin exposure would result in
the same consequences in adults. This is due to the common ability for both phenobarbital
and phenytoin to activate the nuclear receptor CAR to up-regulate CYP expression and drug
metabolism. We utilized the same mouse model and treated neonatal mice at the age of day 5
with a single dose of phenytoin, then measured the expression of drug-metabolizing CYPs in
adulthood at the mRNA, protein, and enzymatic activity levels.
5.2 Materials and Methods
Chemicals and Reagents. Phosphate buffered saline (PBS), 5,5-diphenylhydantoin salt (pheny-
toin, PHY), trifluoroacetic acid (TFA), formic acid, and acetonitrile were purchased from Sigma-
Aldrich (St. Louis, MO). Urea and dithiolthreitol (DTT) were obtained from Fisher Scientific
Co. (Pittsburgh, PA). Iodoacetamide (IAA) and ammonium bicarbonate were purchased from
Acros Organics (Morris Plains, NJ). TPCK-treated trypsin was obtained from Worthington Bio-
chemical Corporation (Freehold, NJ). Bovine serum albumin (BSA) standard was purchased
from Thermo Fisher Scientific (Waltham, MA).
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Animals. C57Bl/6 mice were housed in accordance with the animal care guidelines outlined
by the American Association for Animal Laboratory Sciences and were bred under standard
conditions in the Animal Resources Facility at the University of Connecticut. The use of these
animals was approved by the University of Connecticuts Institutional Animal Care and Use
Committee. At 12 weeks of age, mice were set up into breeding pairs. To study the long-term
effects of drug treatment at the neonatal age, mice were administered a single dose of pheny-
toin (100 mg/kg) or PBS vehicle control intraperitoneally at age day 5 after birth. Following
treatment, mice were sacrificed at different ages (day 10, 15, 20, 30, or 60 after birth) and liv-
ers without gallbladders were collected and stored at -80 °C. Re-challenge experiments were
also performed in which mice received phenytoin treatment at age day 5, and were then re-
challenged with a dose of phenytoin at day 60. For each age group, 4-6 livers from different
mice were collected and both male and female mice were included in this study.
Total RNA Extraction, Reverse Transcription, and RT-PCR. Total RNAs were isolated from
whole livers using TRIzol reagent, and reverse transcription was performed using iScript Re-
verse Transcription Supermix as previously described. RT-PCR was performed using a CFX-96
thermocycler system with TaqMan gene expression assays for Cyp2b10, Cyp2c29, Cyp3a11,
and Gapdh as an endogenous control.
Total Sample Preparation and LC-MS/MS-based Quantification. Liver microsomes were
obtained from S9 liver homogenates prepared from whole liver tissue samples. Protein concen-
tration was determined using a Pierce BCA protein assay kit (Thermo Fisher Scientific). Pro-
tein digestion was conducted according to a previously reported Lyc-C/Trypsin combinatorial
digestion protocol with minor modifications. Aliquots of 80µg protein from liver microsomes
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were mixed with 0.2µg of bovine serum albumin (BSA) internal standard. After adding ace-
tone, the mixture was incubated and centrifuged, then precipitated proteins were isolated and
washed with ethanol. Proteins were re-suspended in 4 mM DDT in 8 M urea solution contain-
ing 100 mM ammonium bicarbonate. Samples were sonicated, then incubated at 37 °C for 45
min. A solution of 20 mM IAA in 8 M urea/100 mM ammonium bicarbonate was then added.
Following an incubation for alkylation, the urea concentration was adjusted to 6 M by adding
ammonium bicarbonate. Lysyl endopeptidase (Wako Chemicals, Richmond, VA) was added in
a ratio of 100:1 to facilitate protein digestion for 6 hours at 37 °C. Samples were then diluted to
1.6 M urea and a second digestion step was carried out with trypsin at a ratio of 50:1 overnight
at 37 °C. Digestion was terminated by adding TFA.
Digested protein peptides were extracted and purified using Waters Oasis HLB columns (Wa-
ters Corporation, Milford, MA) according to the manufacturers instructions. Eluted peptides
were dried in a Speed Vac SPD1010 (Thermo Scientific, Hudson, NH) and reconstituted in
3% acetonitrile with 0.1% formic acid. The peptide samples were centrifuged and half of the
supernatant was collected and supplemented with synthetic iRT standard solutions (Biognosys
AG, Cambridge, MA) prior to LC-MS/MS analysis.
Digested protein peptides were analyzed on a TripleTOF 5600+ mass spectrometer (AB Sciex,
Framingham, MA) coupled with an Eksigent 2D plus LC system (Eksigent Technologies,
Dublin, CA). LC separation was performed via a trap-elute configuration including a trap-
ping column (ChromXP C18-CL, 120 A˚, 150 x 0.3 mm, 5µm, Eksigent Technologies, Dublin,
CA). The mobile phased consisted of water with 0.1% formic acid (phase A) and acetonitrile
with 0.1% formic acid (phase B) (Avantor, Center Valley, PA). A total of 6µg of protein was
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injected for analysis. Peptides were trapped and cleaned on the trapping column with phase A
delivered at a flow rate of 10 L/min for 3 min before being separated on the analytical column
with a gradient elution at a flow rate of 5 L/min. The gradient time program was set as follows
for phase B: 0 to 68 min: 3% to 30%, 68 to 73 min: 30% to 40%, 73 to 75 min: 40% to 80%,
75 min to 78 min: 80%, 78 to 79 min: 5% to 3%, and finally 79 to 90 min at 3% for column
equilibration. The TripleTOF instrument was operated in a positive ion mode with an ion spray
voltage floating at 5500 V, ion source gas one at 28 psi, ion source gas two at 16 psi, curtain
gas at 25 psi, and source temperature at 280 °C.
To generate the reference spectral library for SWATH (Sequential Window Acquisition of all
THeoretical mass spectra) data analysis, Information-Dependent Acquisition (IDA) was per-
formed on three pooled mouse liver microsomes samples of equal amounts. The IDA method
was set up with a 250 ms TOF-MS scan from 400 to 1250 Da, followed by an MS/MS scan
in high sensitivity mode from 100 to 1500 Da (50 ms accumulation time, 10 ppm mass toler-
ance, charge state from +2 to +5, rolling collision energy and dynamic accumulation) of the
top 30 precursor ions from the TOF-MS scan. The IDA data from the pooled mice liver micro-
somes were searched by MaxQuant (version 1.5.3.30, Max Planck Institute of Biochemistry,
Germany). The mouse FASTA database with 16,911 protein entries downloaded from Uniport
on 8/29/2016 was used at the reference sequences for the search. Tryspin/P was used as the
protease. Peptide length was between 7 and 25 residues with up to two missed cleavage sites
allowed. Carbamidomethyl (C) was set as a fixed modification. A false discovery rate of 0.01
was used as the cutoff for both peptide and protein identification.
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All microsomes samples were analyzing using a SWATH method comprised of a 250 ms TOF-
MS scan from 400 to 1250 Da, followed by MS/MS scans from 100 to 1500 Da performed
on all precursors in a cyclic manner. The accumulation time was 50 ms per isolation window,
resulting in a total cycle time of 2.8 s. The spectral alignment and target data extraction of the
SWATH data were performed on Skyline-daily (version 3.7.1.11271, University of Washington,
Seattle, WA) with the reference spectral library generated from the IDA searches. The isolation
scheme in Skyline-daily was set as SWATH (VW 100). The MS1 and MS/MS filtering were
both set as TOF mass analyzer with the resolution power of 30,000 and 15,000, respectively.
The retention time prediction was based on the auto-calculate regression implemented in the
iRT calculator. Proper peak selection was checked manually with the automated assistance
of Skyline-daily. The surrogate peptides used for the quantification of Cyp210, 2c29, 3a11,
and 3a16 are listed in Appendix A. These peptides were selected based on the uniqueness and
chromatographic performance. The peak areas of the top 3 to 5 fragment ions were summed up
and normalized to the internal standard BSA. The BSA-normalized peak area of each peptide
was further divided by the average of the 30 samples to calculate the relative abundance of the
peptide. The average of relative abundance of all surrogate peptides of a protein was used to
determine the relative abundance of the protein.
Evaluation of Enzymatic Activities. Liver tissues were homogenized in ice-cold mM phos-
phate buffered and S9 fractions were obtained by centrifugation. Protein concentrations were
determined using a Modified Lowry Protein Assay Kit (Thermo Fisher Scientific, Rockford,
IL). Pentoxyresorufin O-dealkylation, paclitaxel 6-hydroxylation, and midazolam 1-hydroxylation
were used as probes for Cyp2b10, 2c29, and 3a11 activities, respectively [120]. Incbuations
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were carried out in 1X phosphate-buffered saline (pH 7.4), containing 0.1 mg of mouse liver S9
protein and 30µM substrate for a final volume of 95µL. The reactions were initiated by adding
5µL of 20 mM NADPH and continued for 30 min for pentoxyresorufin and paclitaxel or 10
min for midazolam. Incubations were terminated by adding 100µL of ice-cold acetonitrile.
After centrifugation at 15,000 rpm, a 1.0µL aliquot was injected into a Waters Synapt G2-
S QTOFMS system (Milford, MA) for metabolic quantification analysis. Chromatographic
separation of metabolites was performed on an Acquity UPLC BEH C18 column (2.1 x 50 mm,
1.7µm, Waters). The mobile phase A (MPA) consisted of 0.1% formic acid in water and mobile
phase B (MPB) was 0.1% formic acid in acetonitrile. The gradient for aqueous extraction began
at 5% MPB and held for 0.5 min, followed by 5 min linear gradient to 95% MPB, held for 2 min,
and decreased 5% MPB for column equilibration. The flow rate of the mobile phase was 0.50
mL/min at the column temperature was maintained at 50 °C. The G2-S QTOFMS system was
operated in resolution mode (resolution ∼ 20, 000) with electrospray ionization. The source
and desolvation temperatures were set at 150 and 500 °C, respectively. Nitrogen was applied
as the cone gas (50 L/hr) and desolvation gas (800 L/hr). The capillary and cone voltages
were set at 0.8 kV and 40 V. The data were acquired in positive ionization mode. QTOFMS
was calibrated with sodium formate and monitored by the intermittent injection of lock mass
leucine encephalin (m/z = 556.2771) in real time. Quanlynx software (Waters, Milford, MA)
was used for the quantification of the concentration of metabolites.
Statistical Analysis. Data are presented as the mean ± S.E.M. Statistical analyses were per-
formed using GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA). Compar-
isons between groups were done using Students t-test and discovery was determined using the
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two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 1%. A p-
value of less than 0.05 was considered significant.
5.3 Results
5.3.1 Long-term effects of neonatal phenytoin exposure on the basal ex-
pression of cytochrome P450s.
At the age of 5 days following birth, both male and female mice were treated with a single dose
of either vehicle control (PBS) or 100 mg/kg phenytoin. These mice were allowed to grow to
specified ages (day 10, 15, 20, 30, or 60), at which point they were then sacrificed and livers
were harvested to investigate the long-term effects on CYP expression and activity. For RT-
PCR analyses, mice that were sacrificed before reaching the age of day 60 were not separated
based on sex, so both male and female samples were included for fold-change calculations.
Analyses performed on mice at the age of day 60 were executed separately for each sex, due
to mature hormonal influences on CYP expression. For protein quantification and enzymatic
activity assays, only male mice were utilized to ensure as little variability as possible.
The expressions and activities of three CYPs (Cyp2b10, Cyp2c29, and Cyp3a11) that contribute
significantly to murine drug metabolism and known to be induced by phenytoin treatment were
evaluated. Following treatment with phenytoin at age day 5, Cyp2b10 mRNA remained up-
regulated by roughly 25-fold compared to control mice at age day 10 (Figure 5.1A). At ages
day 15, 20, and 30, however, Cyp2b10 mRNA expression was not statistically significant from
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that of control mice. At age day 60, Cyp2b10 mRNA was up-regulated approximately 3-fold in
male mice that received phenytoin at age day 5, however there was no statistically significant
differences in Cyp2b10 expression in adult females. To determine whether the significant in-
crease in Cyp2b10 mRNA expression in males translated into significant differences in protein
expression, Cyp2b10 protein was quantified in male livers at the age of day 60 by SWATH-
MS method (n = 5). No statistically significant differences were found between adult control
and treated mice (Figure 5.1B). These results were confirmed by enzymatic activity assays in
adult male mice (n = 5). Again, there was no statistically significant difference in the rate of
pentoxyresorufin O-depentylation of microsomes isolated from control and treated male liv-
ers (Figure 5.1C). This indicates the slight up-regulation of Cyp2b10 mRNA at the adult age
following neonatal phenytoin treatment probably has no consequences on the function of the
Cyp2b10 protein in adulthood.
The expression of Cyp2c29 was also examined following phenytoin exposure at age day 5. At
ages day 20 and day 30, Cyp2c29 mRNA appeared to be slightly significantly up-regulated
compared to age-matched control mice, however any significant mRNA over-expression dis-
appears at age day 60 in both males and females (Figure 5.2A). Quantification of Cyp2c29
protein in adult males livers (n = 5) unexpectedly showed significantly down-regulated ex-
pression in phenytoin-treated mice (Figure 5.2B). The biological relevance of this observed
down-regulation of Cyp2c29 protein could not be validated with enzymatic activity analyses as
Cyp2c29 activity was too low in prepared microsomes.
The long-term effects on the expression and activity of Cyp3a11 were finally examined in re-
sponse to neonatal phenytoin exposure. Drug treatment did not appear to significantly impact
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FIGURE 5.1: Expression and activity of Cyp2b10 throughout postnatal development fol-
lowing phenytoin exposure at neonatal age. (A) Results of RT-PCR for Cyp2b10 expression
at different ages following treatment with 100 mg/kg phenytoin (PHY) at age day 5 after birth.
Fold-changes were calculated against age-matched mice that received PBS treatment on day
5. Males and females were evaluated collectively at ages before day 60 (left), while males and
females were evaluated separately at age day 60 (right). (B) Quantification of Cyp2b10 protein
at age day 60 following day 5 treatment with either PBS or 100 mg/kg phenytoin. (C) Rates of
pentoxyresorufin O-depentylation at age day 60 following day 5 treatment with either PBS or
PHY. *p < 0.05 **p < 0.01.
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FIGURE 5.2: Expression of Cyp2c29 throughout postnatal development following pheny-
toin exposure at the neonatal age.(A) Results of RT-PCR for Cyp2c29 gene expression at
different ages following treatment with 100 mg/kg phenytoin (PHY) at age day 5 after birth.
Fold-changes were calculated against age-matched mice that received PBS treatment on day
5. Males and females were evaluated collectively at ages before day 60 (left), while males and
females were evaluated separately at age day 60 (right). (B) Quantification of Cyp2c29 protein
at age day 60 following day 5 treatment with either PBS or PHY. *p < 0.05
the expression of Cyp3a11 mRNA at any age evaluated, in neither males nor females (Figure
5.3A). This observation was also verified by protein quantification method (Figure 5.3B) and
midazolam 1'-hydroxylation enzymatic activity (Figure 5.3C), both of which showed no sta-
tistically significant up-regulation in treated adult male mice compared to control (n = 5 for
both assays). However, Cyp3a11 protein and the enzymatic rate of midazolam metabolism do
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FIGURE 5.3: Expression and activity of Cyp3a11 throughotu postnatal development fol-
lowing phenytoin exposure at the neonatal age. (A) Results of RT-PCR for Cyp3a11 gene
expression at different ages following treatment with 100 mg/kg phenytoin (PHY) at age day
5. Fold-changes were calculated against age-matched mice that received PBS treatment on day
5. Males and females were evaluated collectively before age day 60 (left), while males and
females were evaluated separately at age day 60 (right). (B) Quantification of Cyp3a11 pro-
tein at age day 60 following day 5 treatment with either PBS or PHY. (C) Rates of midazolam
1’-hydroxylation at age day 60 following day 5 treatment with either PBS or PHY. *p < 0.05
appear to be slightly down-regulated in treated mice, however not significantly, which is inter-
esting due to the fact that Cyp2c29 protein is also significantly down-regulated in adults. In all
CYP enzymes evaluated, phenytoin treatment at the neonatal age does increase the variability
represented by the standard error of their expression at later ages compared to age-matched
control mice.
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5.4 Discussion
In this study, we aimed to examine the possibility of any permanent effects on CYP expres-
sion and activity in adulthood resulting from neonatal exposure to a single dose of phenytoin.
We hypothesized that, like phenobarbital, administration of phenytoin to mice at age day 5
would cause persistent up-regulation of the drug-metabolizing enzymes Cyp2b10, Cyp2c29,
and Cyp3a11 in adult mice. However, this was not the case. No significant up-regulation of
Cyp2c29 nor Cyp3a11 mRNA was observed at the adult age of day 60, and protein expres-
sion appeared to be even down-regulated, if anything. Cyp2b10 mRNA was significantly up-
regulated at age day 60 only in males, however there were no increases apparent in either protein
or enzymatic activity measurements. It is also interesting that both Cyp3a11 and Cyp2c29 pro-
tein were slightly down-regulated at age day 60, even though the decrease is only significant for
Cyp2c29. There was no significant down-regulation of Cyp2c29 mRNA, suggesting possible
enzyme inhibition perhaps at the protein, or post-translational, level. This mechanism will have
to be further investigated as well, as there are no studies that show decreased CYP transcription
or protein inhibition in response to phenytoin treatment.
We also measured CYP expression at various ages during postnatal development following day
5 phenytoin treatment. There was no mRNA induction greater than 3-fold found in any of
the CYPs at any postnatal ages tested, except for Cyp2b10 expression at age day 10, which
was found to be induced by an average of approximately 25-fold. The mechanism leading to
a five-day duration of Cyp2b10 induction will need to be further investigated, as the half-life
of phenytoin in mice is only around 16 hours, although this might not hold true in neonates
[190]. Cyp2c29 was observed to be at least slightly induced at ages day 20 and day 30 at the
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mRNA level, however whether the induction would translate into meaningful up-regulation of
enzymatic activity is left to be questioned.
Additional studies will be necessary to further determine why neonatal exposure to phenobar-
bital produces overexpression of Cyp2b10, 2c29, and 3a11 mRNA and protein, with conse-
quential up-regulation of activity, in adulthood, while neonatal exposure to phenytoin does not.
Phenobarbital up-regulates the transcription of CYPs through its indirect action on the nuclear
receptor CAR [191]. Previous work has shown that CAR activation using TCPOBOP, a murine-
specific CAR ligand, at the neonatal age also produces permanent alterations to CYP expres-
sion and function in adulthood, which altered the efficacy of zoxazolamine adminstered later in
life [86]. Phenobarbital exposure at the neonatal age also caused a decrease in the efficacy of
omeprazole adminstered to adult mice, suggesting its role in causing a non-conventional type of
DDI [159]. Due to the ability of phenytoin to also activate CAR, we hypothesized that neona-
tal exposure to this drug would also cause a similar permanent alteration to CYP expression;
however our hypothesis was incorrect. Unlike TCPOBOP, both phenobarbital and phenytoin
produce CAR activation indirectly. Whereas they are both classified as AEDs, these chemicals
each have distinct mechanisms of action for treating seizures. It is plausible that phenobarbi-
tal and phenytoin produce indirect CAR activation via separate mechanisms or pathways. A
pathway further upstream of CAR activation may be what is permanently affected following
neonatal phenobarbital treatment that is not impacted by phenytoin treatment.
Phenobarbital is known to indirectly activate CAR via its binding and antagonism of EGFR
[172]. The mechanism by which phenytoin activates CAR is not as clearly understood. Human
CAR has been shown to be necessary to induce CYP2B6 in response to phenytoin treatment in
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liver cells [84], and that murine CAR is necessary for induction of CYp2b10, 2c29, and 2c37
in mice [192, 193]. Beyond the fact that CAR is necessary to produce the induction of CYPs
in response to phenytoin, nothing else is known about how exactly phenytoin causes CAR
activation. However, it is also possible that CAR is not responsible for producing permanent
effects in response to neonatal phenobarbital exposure. Phenobarbital is also known to activate
several other hepatic nuclear receptors, including PXR and HNF4a, which all have roles in CYP
regulation [194], and perhaps these are the mechanisms producing permanent alterations to
CYP expression. However, another study administered the direct PXR ligand PCN to neonatal
mice and did not observe as drastic induction of drug-metabolizing CYPs as our previous study
has shown [71].
Further studies are necessary to determine exactly how phenytoin activates CAR, and how this
mechanism may differ from phenobarbital. It is also possible that the window of sensitivity
for neonatal programming may differ depending on the drug, and perhaps day 5 was not the
optimal age to treat mice with phenytoin to cause permanent alterations to CYP expression. Ex-
periments that expose mice to phenytoin at younger or older ages during postnatal development
will be critical. Additionally, only one dose of phenytoin was investigated in this particular
study. Perhaps multiple-day dosing of phenytoin is necessary to cause changes to CYP expres-
sion that exist into adulthood. It is also possible our chosen dose of 100 mg/kg bodyweight was
not sufficient to produce permanent effects, as our study with phenobarbital demonstrated that
the phenomenon is dose-dependent. However, 100 mg/kg was the highest dose we were able to
administer to neonatal mice without lethal effects. A dose of 100 mg/kg in mice is equivalent
to a human dose of 8 mg/kg, according to the FDA Guidance for Industry for species dose
Chapter 5 116
extrapolation. This is representative of a maintenance dose of phenytoin in humans, and it is
likely that newborns suffering from seizures would be treated with a dose closer to 20 mg/kg.
There may be species differences in tolerability to phenytoin, and administering a dose more
representative of what is used in the clinic may produce permanent changes to CYP expression
in mice.
Based on this data, we could suggest that phenytoin may be a better therapeutic choice for
treating neonatal seizures as it does not appear to permanently affect CYP expression at this
point. This could have a major impact in the clinic, as phenobarbital is currently the most
commonly used drug for treating neonatal seizures. Further animal studies and clinical human
testing will need to be performed in the future to validate this suggestion, however this study
could provide a basis and a proof-of-concept for those studies.
Chapter 6
Short-term Effects of Phenytoin Exposure
on Cytochrome P450 Expression
Throughout Postnatal Development
6.1 Introduction
The postnatal ontogeny of CYPs during human development has been established and corre-
sponds well to the postnatal ontogeny of orthologous CYP genes in rodent models [60, 141].
However, the induction of CYPs in response to drug treatment has not been thoroughly stud-
ied in pediatric populations at different stages of early development. It is largely unknown to
what extent CYP enzymatic activity can be induced in neonates and children in comparison to
adults. Whether the capacity for enzymatic induction varies at different stages during postnatal
117
Chapter 6 118
liver maturation is also not completely understood. Understanding CYP induction in pediatric
populations is critical to prevent DDIs and ADRs in infants and children. Many young patients
are exposed to multiple medications at once, especially those that are hospitalized or critically
ill [15]. However, DDIs in the context of pediatric patients are not as well understood as DDIs
in adults. This is mainly due to the lack of appropriate in vitro models and the fact that clinical
trials do not usually include infants and children [195]. Neonatal patients appear to be partic-
ularly susceptible to ADRs due to diminished clearance capabilities during the first two years
of life [196]. It is well-established that the neonatal liver is not fully developed at birth and
undergoes a period of postnatal maturation, during which metabolic function is not comparable
to that of adults. Drug metabolism by CYPs, in particular, varies greatly during the first two
years after birth [197]. Most drug-metabolizing CYPs, including CYp3A4, 2C9, and 2C19, are
expressed at low levels during gestation, at birth, and during early postnatal life, and do not
reach expression levels comparable to those of adults until at least two years of age [62, 65].
This causes an attenuated capacity for the metabolism of many drugs and is implicated in nu-
merous ADRS in infants [198]. Other enzymes, such as CYP3A7, are only expressed in the
fetal and early postnatal liver and become undetectable once the liver is fully matured [199].
How induction in response to xenobiotics corresponds to the drug-metabolizing CYP ontogenic
expression patterns is unknown.
The goal of this study was to examine the capacity for the postnatal liver to induce drug-
metabolizing CYP enzymes in response to inducer treatment at different ages spanning neona-
tal, infant, child, and adolescent stages in mouse. The short-term effects of exposure to a single
dose of phenytoin were investigated at multiple levels of CYP expression, including utilizing
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the novel quantitative proteomics technology sequential window acquisition of all theoretical
mass spectra (SWATH-MS) to determine CYP protein concentrations. Phenytoin was selected
as a model inducer drug for this study because, like phenobarbital, it is an antiepileptic drug
commonly used to treat neonatal seizures and is a potent inducer of drug-metabolizing CYPs in
humans and rodents. We also wanted to investigate whether phenytoin induces CYP enzymes
at young ages, because neonatal phenytoin treatment did not cause permanent alterations to
CYP expression as discussed in Chapter Five. Based on our previous work, we hypothesized
that the neonatal liver is particularly sensitive to CYP induction by drug treatment in early life,
and enzyme responses differ from those in adults.
6.2 Materials and Methods
Chemicals and Reagents. Phosphate buffered saline (PBS), 5,5-diphenylhydantoin salt (pheny-
toin, PHY), trifluoroacetic acid (TFA), formic acid, and acetonitrile were purchased from Sigma-
Aldrich (St. Louis, MO). Urea and dithiolthreitol (DTT) were obtained from Fisher Scientific
Co. (Pittsburgh, PA). Iodoacetamide (IAA) and ammonium bicarbonate were purchased from
Acros Organics (Morris Plains, NJ). TPCK-treated trypsin was obtained from Worthington Bio-
chemical Corporation (Freehold, NJ). Bovine serum albumin (BSA) standard was purchased
from Thermo Fisher Scientific (Waltham, MA).
Animals. C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were housed in accordance
with the animal care guidelines outlined by the American Association for Animal Laboratory
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Sciences and were bred under standard conditions in the Animal Resources Facility at the Uni-
versity of Connecticut. The use of these animals was approved by the University of Connecti-
cuts Institutional Animal Care and Use Committee. At 12 weeks of age, mice were set up
into breeding pairs. To study the short-term effects of drug treatment at different ages during
postnatal development, mice were administered a single dose of phenytoin (100 mg/kg) or PBS
vehicle control intraperitoneally at ages day 5, 10, 15, 20, 30, or 60 following birth. Twenty
fours after the treatment, mice were sacrificed and livers with gallbladders removed were col-
lected. Samples were snap frozen in liquid nitrogen then stored at -80 °C. For both control and
treatment groups, 4-6 mice were used for sufficient statistical power and both male and female
mice were included.
Total RNA Extraction, Reverse Transcription and RT-PCR. Total RNAs were isolated from
whole livers using TRIzol reagent, and reverse transcription was performed using iScript Re-
verse Transcription Supermix as previously described. RT-PCR was performed using a CFX-96
thermocycler system with TaqMan gene expression assays for Cyp2b10, Cyp2c29, Cyp2d22,
Cyp2e1, Cyp3a11, Cyp3a16, and Gapdh as an endogenous control.
Protein Sample Preparation and LC-MS/MS-based Quantification. The same procedures
used for protein quantification in Chapter Five were used in this study.
Evaluation of Enzymatic Activities. The same procedures used for enzymatic activity quan-
tification in Chapter Five were used in this study.
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Statistical Analysis. Data are presented as the mean ± S.E.M. Statistical analyses were per-
formed using GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA). Compar-
isons between groups were done using Students t-test and discovery was determined using the
two-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli with Q = 1%. A p-
value of less than 0.05 was considered significant.
6.3 Results
To evaluate the impact of phenytoin exposure on the expression and function of drug-metabolizing
CYPs throughout postnatal maturation, we continued to use the C57Bl/6 mouse model. Short-
term effects of drug treatment were evaluated by administering a single dose of phenytoin then
collected livers 24 hours later at different time points after birth. The expression of hepatic
murine Cyp2b10, 2c29, 2d22, 2e1, 3a11, and 3a16 isoforms were evaluated because of their
orthologous equivalence to human CYP2B6, 2C9/19, 2D6, 2E1, 3A4, and 3A7, respectively.
The effect of drug treatment on each enzyme was measured at the mRNA level using RT-PCR,
at the protein level using SWATH-MS quantification, and at the enzymatic activity level using
MS/MS to confirm function. Both male and female mice were evaluated collectively for data
presented at ages younger than day 30, however male and female data were evaluated separately
at age of day 60 due to hormonal influences on CYP expression. At each time point, mice that
received drug treatment were compared against age-matched mice that received vehicle control.
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6.3.1 Cyp2b10 induction and function following phenytoin exposure.
The extent of Cyp2b10 mRNA induction 24 hours following phenytoin administration was the
greatest of all CYPs measured, presumably however this may be due to established low con-
stitutive Cyp2b10 expression levels that inflate induction fold-changes. Mice at age of day 10
showed the greatest fold-change in mRNA expression when compared to control, age-matched
mice, whereas fold-changes at other ages were more comparable to those observed in adult
mice following phenytoin treatment. Adult males also had higher fold-changes than females
at day 60, however adult male mice are known to have lower basal Cyp2b10 expression than
females (Figure 6.1A). When comparing gene expression to Gapdh, which was unaffected by
phenytoin treatment, Cyp2b10 mRNA was much less abundant than Gapdh in control mice but
reached similar expression levels following drug exposure (Figure 6.1B). The surge in Cyp2b10
expression at age day 30 was also apparent and seemed to cause a corresponding peak in the
inducibility of the enzyme.
Cyp2b10 protein was also quantified 24 hours after treatment in neonatal mice at the age of
day 5 and in adult male mice at the age of day 60 (Figure 6.1C). Following vehicle treatment,
Cyp2b10 protein was nearly undetectable in both neonates and adults, however significant in-
duction of protein was evident at both ages following phenytoin treatment. The inductive po-
tential was far greater in adults than in neonates, however induced levels of Cyp2b10 in the
neonate significantly exceeded basal levels in the adult. This data also correlated well with re-
sorufin O-depentylation by microsomes prepared from neonatal and adult liver samples (Figure
6.1D), indicating functional consequences of induction by phenytoin at both ages tested.
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FIGURE 6.1: Short-term effects of phenytoin treatment on the expression and activity
of Cyp2b10 at different ages during postnatal development. Male and female mice were
treated with either vehicle (PBS) or 100 mg/kg phenytoin (PHY) at different ages following
birth and livers were collected 24 hours following treatment. Changes in Cyp2b10 gene ex-
pression were evaluated at the mRNA level using RT-PCR by calculating fold changes relative
to mice that received vehicle control (A). Both males and females were evaluated collectively
at ages day 30 and younger (left), but calculations were performed with males and females sep-
arate at age day 60 (right). Fold changes of mRNA were also calculated against the expression
of Gapdh, with the dotted line representing Gapdh expression set to 1 (B). Cyp2b10 protein was
quantified using an LC-MS/MS method in males following treatment at ages day 5 and day 60
(C). Enzymatic activity was evaluated by measuring the rate of resorufin O-depentylation in
microsomes prepared from male livers sample from mice treated at age day 5 and day 60 (D).
*p < 0.05, **p < 0.01, ***p < 0.001.
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6.3.2 Cyp2c29 induction and function following phenytoin exposure.
Induction of Cyp2c29 mRNA and protein expression 24 hours following phenytoin treatment
was also examined at different ages. The amount of mRNA was significantly greater in mice
that received phenytoin compared to mice that received vehicle at all ages tested, with age of
day 10 appearing to again by the most sensitive to enzyme induction (Figure 6.2A). When
evaluating Cyp2c29 mRNA expression relative to GAPDH expression, Cyp2c29 mRNA was
much less abundant in neonates at the age of day 5 in PBS treated control mice, but steadily
increased to levels comparable to GAPDH at day 20 (Figure 6.2B). Induced levels of Cyp2c29
mRNA exceeded GAPDH expression by around 10-fold at all ages except day 5, where it
remained minimally expressed even in the presence of phenytoin. This was also reflected in
Cyp2c29 protein quantified at age day 5 following 24 hour exposure duration to phenytoin
(Figure 6.2C). Phenytoin-mediated protein induction at age day 5 was significant, but minimal
compared to induction at the adult age of day 60. Induced levels of Cyp2c29 protein in the
neonate were significantly lower than even basal levels of the protein in adults. Enzymatic
activity of Cyp2c29 could not be evaluated in these experiments due to insufficient metabolic
activity detected from prepared microsomes.
6.3.3 Cyp3a11 induction and function following phenytoin exposure.
The short-term effects on Cyp3a11 mRNA induction following phenytoin treatment are evi-
dent across all ages studied during postnatal development. The greatest fold-change between
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FIGURE 6.2: Short-term effects of phenytoin treatment on the expression of Cyp2c29 at
different ages during postnatal developmentMale and female mice were treated with either
vehicle (PBS) or 100 mg/kg phenytoin (PHY) at different ages following birth and livers were
collected 24 hours following treatment. Changes in hepatic Cyp2c29 gene expression were
evaluated at the mRNA level using RT-PCR by calculating fold changes relative to mice that
received vehicle control (A). Both males and females were evaluated collectively at ages prior
to day 60 (left), while males and females were evaluated separately at age day 60 (right). Fold
changes of mRNA were also calculated against the expression of Gapdh, with the dotted line
representing Gapdh gene expression set to 1 (B). Cyp2c29 protein was quantified using an LC-
MS/MS method in males following treatment at ages day 5 and day 60 (C). *p < 0.05, **p <
0.01, ***p < 0.001.
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phenytoin-treated mice and control mice occurred in neonates at age day 5, presumably be-
cause this is when the basal expression of Cyp3a11 is the lowest (Fig. ). As mice matured
following birth, basal expression of Cyp3a11 mRNA increased and correlated with increased
induced levels of mRNA with age (Fig. ). Maximal induction occurred at adult ages (day 30
and 60), which correlated with protein expression (Fig. ). Protein quantification revealed that
induced levels of Cyp3a11 in the neonate at age day 5 were not statistically different from basal
levels of Cyp3a11 protein in the adult. This was also confirmed by enzymatic activity analyses
with midazolam in liver microsomes (Fig. ). At age of day 5, mice treated with phenytoin had
similar rates of 1-hydroxymidazolam metabolite formation as adult mice treated with vehicle
control, while adult mice treated with phenytoin produced the most metabolite overall.
6.3.4 Cyp3a16 repression following phenytoin exposure.
Cyp3a16 is considered to be the fetal isoform of the CYP3A subfamiliy of CYP enzymes.
Whereas it is highly expressed immediately after birth, its expression declines steadily through-
out postnatal maturation and is undetectable in the adult liver. Phenytoin treatment also ap-
peared to significantly affect the expression of Cyp3a16 in the short-term at different ages dur-
ing postnatal development. Twenty four hours following phenytoin administration, Cyp3a16
mRNA was significantly suppressed in mice at all ages examined (Figure 6.4A). The fold-
change in the decrease of expression was greatest at age day 20 and this correlated to the
age at which Cyp3a16 mRNA because undetectable in phenytoin-treated mice (Figure 6.4B).
Cyp3a16 mRNA was not detected by RT-PCR in mice at the ages of day 30 nor day 60, so the
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FIGURE 6.3: Short-term effects of phenytoin treatment on the expression and activity
of Cyp3a11 at different ages during postnatal development. Male and female mice were
treated with either vehicle (PBS) or 100 mg/kg phenytoin (PHY) at different ages following
birth, and livers were collected 24 hours following treatment. Changes in hepatic Cyp3a11
gene expression were evaluated at the mRNA level using RT-PCR by calculating fold changes
relative to mice that received vehicle control (A). Both males and females were evaluated col-
lectively at ages prior to day 60 (left), while males and females were evaluated separately at age
day 60 (right). Fold changes of Cyp3a11 mRNA were also calculated against the expression of
Gapdh, with the dotted line representing Gapdh gene expression set to 1 (B). Cyp3a11 protein
was quantified using an LC-MS/MS method in male livers following treatment at ages day 5
and day 60 (C). Cyp3a11 enzymatic activity was evaluated by measuring the rate of midazolam
1'-hydroxylation of microsome isolated from male livers treated at day 5 and day 60 of age (D).
*p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 6.4: Repression of Cyp3a16 expression following phenytoin treatment at different
ages during postnatal development. Male and female mice were treated with either vehicle
(PBS) or 100 mg/kg phenytoin (PHY) at different ages following birth, and livers were collected
24 hours following treatment. Changes in hepatic Cyp3a16 gene expression were evaluated
at the mRNA level using RT-PCR by calculating fold changes relative to mice that received
vehicle control (A). Fold decreases of Cyp3a16 expression were also calculated against Gapdh,
with the dotted line representing Gapdh gene expression set to 1 (B). Cyp3a16 mRNA was not
detected at ages day 30 or day 60, so data is not shown. Cyp3a16 protein was quantified using
an LC-MS/MS method in male livers following treatment at ages day 5 and day 60 (C). **p <
0.01, ***p < 0.001.
data is not shown. The decrease in Cyp3a16 in response to phenytoin treatment was also con-
firmed by protein quantification (Figure 6.4C). At age of day 5, Cyp3a16 protein was decreased
following drug exposure, however the different was not statistically significant. Cyp3a16 pro-
tein was not detectable in adults regardless of phenytoin administration.
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FIGURE 6.5: Repression of H19 and Igf2 gene expression following phenytoin treatment
during postnatal development. Male and female mice were treated with either vehicle (PBS)
or 100 mg/kg phenytoin (PHY) at different ages following birth, then livers were collected
24 hours after treatment. Changes in gene expression of H19 and Igf2 were measured using
RT-PCR and fold changes were calculated against PBS control mice.
6.3.5 Phenytoin represses H19/Igf2 expression during early postnatal life.
Due to the ability of phenytoin treatment to repress the expression of the fetal/neonatal-enriched
enzyme Cyp3a16, we also wondered whether phenytoin was able to repress the expression of
other liver genes that are enriched in early postnatal life. The insulin like growth-factor (Igf2) is
an important fetal growth factor produced by the liver in high amounts during fetal and neonatal
life, and becomes repressed in adulthood. The cis-neighboring gene, H19, is a long non-coding
RNA expressed highly in fetal and neonatal livers, and is repressed in adulthood unless liver
regeneration or hepatocellular carcinoma is occurring [59]. Treatment with phenytoin at the
ages of day 5, 10, and 15 repressed the gene expression of both H19 and Igf2 significantly
compared to age-matched control animals (Figure 6.5). At age day 20, there were no significant
differences in the expression of either gene between control and treated animals. No further
ages are shown due to low gene expression.
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6.4 Discussion
This study revealed the immediate effects on the expression and function of several drug-
metabolizing CYP enzymes following exposure to the AED phenytoin during murine postnatal
development. Short-term induction of Cyp2b10, 2c29, and 3a11 in response to phenytoin ad-
ministration appeared to vary in extent based on age, sex, and particular CYP enzyme. Younger
pups, such as those at ages of day 5 and day 10, had higher fold-changes relative to control for
CYP induction; however, these values are probably inflated due to the low basal expression of
CYPs in the neonatal liver. As basal expression of CYPs became greater with age, the extent
of induction was less extreme. For this reason, we also chose to evaluate mRNA expression of
each isoform in relation to Gapdh expression. Gapdh expression was not altered by drug treat-
ment and remained relatively consistent throughout postnatal life. Analyzing gene expression
in relation to Gapdh allowed the ontogeny of each CYP to be observed in basal and induced
conditons at each age. Induction of each enzyme (with the exception of Cyp3a16), appeared to
be proportional to the basal expression level of the enzyme; the higher the mRNA expression
of a CYP at a certain age, the greater its capacity for induction. On the other hand, Cyp3a16
appeared to be repressed to greater extents at older ages in postnatal development, which cor-
related with decreasing basal expression.
For both Cyp2b10 and 2c29, day 10 appeared to be the age most sensitive to the inductive
effects of phenytoin as evidenced by the greatest fold-changes in mRNA expression compared
to control mice. Interestingly, this corresponds with our previous data that shows a surge of
Cyp2b10 and 2c29 expression beginning at the same age [141]. Both of these enzymes are
primarily under the transcriptional control of CAR, while Cyp3a11 is known to be regulated
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primarily by PXR. The expression of PXR and CAR actually appear to be the highest during
early postnatal life in both mouse and infant humans [200]. The consequences of elevated
expression of these nuclear receptors at the neonatal stage on the expression and regulation
of CYPs are not understood. Perhaps, increased levels of CAR and/or PXR in the neonatal
liver contribute to the increased inducibility of Cyp2b10 and Cyp2c29 observed at this stage of
postnatal development.
The inducibility of other hepatic drug-processing genes utilizing direct activation of PXR and
CAR has also been shown to be age-dependent in mouse. Greater fold-changes in mRNA ex-
pression following xenobiotic treatment have been typically observed at the neonatal age. How-
ever, our study shows that despite the apparent greater extent of mRNA induction at younger
ages, protein expression and enzymatic activity following phenytoin treatment is still greater in
adults than in neonates. The expression of Cyp2b10, 2c29, and 3a11 proteins is several magni-
tudes higher in adults than in neonates following phenytoin treatment, suggesting the adult liver
has a greater capacity for enzyme induction following drug treatment than the infant liver. In
the case of Cyp2b10, protein expression in the neonate following phenytoin exposure exceeded
that of adults in basal conditions following vehicle treatment. The expression of Cyp2c29
protein following phenytoin treatment in the neonate, however, did not reach adult expression
levels. This data suggests that individual CYP enzymes are under unique transcriptional control
during postnatal development and their regulation must be evaluated independently. Only liver
samples from day 5 were used for protein and enzymatic activity analyses during early life, so
additional ages will need to be examined for protein and functional consequences in the future.
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The decrease in expression of Cyp3a16 in response to phenytoin treatment suggests drug treat-
ment is causing overall differentiation of the neonatal liver, rather than strictly induction of
drug-metabolizing enzymes. Cyp3a16, the murine equivalent of human CYP3A7, is expressed
only in fetal and neonatal livers, and signifies immature metabolic function. CYP3A7 has re-
duced metabolic capability compared to CYP3A4 (and CYP3A5), and does not contribute to
midazolam metabolism, as was tested for Cyp3a11 enzymatic activity [201]. The expression
of CYP3A7 in the developing liver is shown to be induced by glucocorticoids, including dex-
amethasone, cortisol, and cortisone, all of which activate the glucocorticoid receptor [202].
In contrast, our data shows that treatment with phenytoin, a CAR activator, has the ability to
down-regulate Cyp3a16 in mice. Additional studies have shown that the expression of Cyp3a16
is correlated with changes to histone modifications. As the mRNA expression of Cyp3a16 in
the liver decreases over the course of postnatal development, H3K27 methylation increases in
the genes promoter, which signifies transcriptional repression [67]. It is possible that phenytoin
is modifying the chromatin, in our experiments, which up-regulates the mature adult CYP en-
zyme, while down-regulating fetal CYP enzymes. There may, however, be species differences
in the regulation of the fetal forms of CYP3A enzymes.
The repression of H19 and Igf2 gene expression also indicate changes to epigenetic modifica-
tions as a result of phenytoin treatment. Both H19 and Igf2 are part of an imprinted genomic
region, meaning that the genes are only transcribed from one allele in a parent-of-origin fashion.
The transcription of these genes is regulated by differential DNA methylation in the imprinting
control region (ICR) of the domain. An unmethylated ICR allows the binding of CTCF, thus
impacting the transcription of the genes [203]. Proper methylation of this region is critical for
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proper fetal growth and organ development. Repression of both of these genes by phenytoin
suggests alterations to DNA methylation and CTCF binding resulting from drug treatment. This
could have body-wide impacts on organ growth and development.
The expression of CYPs in the human neonatal and infant liver follow distinct ontogenic pat-
terns that may be specific to each individual enzyme. Previous work from our laboratory has
defined the ontogenic profiles of all CYPs in the mouse liver from two days before birth through
age day 60 after birth [141]. The expression pattern of the murine enzymes investigated in this
study follow similar ontogenic trends to that of their human orthologous counterparts. It is
therefore plausible that human CYP enzymatic induction might also vary in extent at differ-
ent ages during early developmental periods following birth. Whereas most drugs currently
have recommendations for pediatric or infant dosing that is separate from adult regimens, it
might be necessary to further define pediatric dosing standards for specific ages based on the
CYP-mediated metabolism of a drug to best avoid ADRs and DDIs in young patients. Other
studies have also highlighted the need for pediatric pharmacokinetics to be evaluated in age-
and maturation-dependent models, rather than grouping all neonatal and infant guidelines into
a single pediatric category [204].
Phenytoin has a narrow therapeutic index with a large propensity to produce ADRs due to
patient interindividual variability. Adverse side effects of phenytoin are common and often
include rashes, headache, behavioral changes, Steven-Johnson syndrome, cardiovascular col-
lapse, and arrhythmias, especially with rapid intravenous administration, in both children and
adults [205, 206]. Many pediatric patients with severe epilepsy are often treated with poly-
therapy, and interactions between phenytoin and other AEDs and the resulting adverse effects
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have been documented. For example, concurrent treatment with phenytoin and valproic acid
produced phenytoin toxicity in an adolescent epileptic patient, despite adhering to pediatric
dosing guidelines for the medications [207]. SNPs in CYP2C9 and CYP2C19 have also been
shown to alter phenytoin metabolism in pediatric patients, leading to adverse reactions as well
[208]. However, genetic variation in CYP genes cannot explain the large amount of patients
that experience serious adverse effects while taking phenytoin [209]. A better understanding of
the additional mechanisms behind phenytoin-mediated CYP induction via CAR activation, es-
pecially throughout postnatal development, could help reduce the high-risk of adverse reactions
that commonly accompany phenytoin treatment.
Chapter 7
The Differential Effects of Phenytoin
Treatment on the Liver Proteome in
Neonates and Adults
7.1 Introduction
Phenytoin is one of the most common antiepileptic drugs (AEDs) administered to infants, chil-
dren, and adults for the treatment of acute seizures and to control chronic epilepsy. It is pre-
ferred over benzodiazepines and barbiturates due to its reduced sedative effect [210]. However,
phenytoin use is still associated with a high risk of adverse effects, and is the most common
of all AEDs in causing ADRs [211]. This is due to its narrow therapeutic window and wide
range of interindividual variation in patient responses. Minor to severe cutaneous reactions
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[212] are widely reported in adults. In pediatric patients, adverse reactions commonly reported
include poor scholastic performance, gum hypertrophy, headache, behavioral problems, drowsi-
ness [205]. There are also ample case reports of idiosyncratic adverse reactions to individual
pediatric patients despite adhering to dosing guidelines. Additionally, phenytoin treatment is
associated with hypersensitivty syndrome that includes fever, rash, lymphadenopathy, and hep-
atitis, suggesting an immune response or potential liver damage [213]. Phenytoin is also in-
volved in many DDIs due to its ability to induce drug-metabolizing enzymes in the liver [78].
Despite the extensive body of evidence that implicates many problems with phenytoin therapy,
the mechanisms by which phenytoin may cause changes to gene expression and liver function
are unknown.
Our previous study identified significant differences in the extent of CYP enzyme induction
in the liver following phenytoin treatment between neonatal and adult mice. Therefore, we
hypothesized that phenytoin may have differential effects on more proteins in the liver be-
tween neonates and adults. Additionally, we have previously shown that the AED phenobar-
bital has permanent effects on the expression of CYPs in the liver, as well the expression of
many other genes involved in various liver functions. Because of this, we also hypothesized
that neonatal phenytoin treatment would significantly affect the adult liver proteome. The fol-
lowing study utilized the novel mass-spectrometry (MS)-based proteomics method known as
SWATH-MS to quantify the expression of all proteins known to be expressed in the mouse liver.
SWATH-MS uses data-independent acquisition (DIA) to measure the concentration of unqiue
peptide fragments that correspond to proteins within a known library. This enables unbiased and
targeted data extractions that alleviates most constraints of current proteomic methods [214].
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Whereas SWATH-MS has been widely used to compare protein expression and alterations to
the epigenome, particularly in hepatocellular carcinoma [215], this method has not yet been
utilized to characterize the differences in drug response between neonates and adults in the
liver.
7.2 Materials and Methods
Chemicals and Reagents. Phosphate buffered saline (PBS), 5,5-diphenylhydantoin salt (pheny-
toin, PHY), trifluoroacetic acid (TFA), formic acid, and acetonitrile were purchased from Sigma-
Aldrich (St. Louis, MO). Urea and dithiolthreitol (DTT) were obtained from Fisher Scientific
Co. (Pittsburgh, PA). Iodoacetamide (IAA) and ammonium bicarbonate were purchased from
Acros Organics (Morris Plains, NJ). TPCK-treated trypsin was obtained from Worthington Bio-
chemical Corporation (Freehold, NJ). Bovine serum albumin (BSA) standard was purchased
from Thermo Fisher Scientific (Waltham, MA).
Animals. C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were housed in accordance
with the animal care guidelines outlined by the American Association for Animal Laboratory
Sciences and were bred under standard conditions in the Animal Resources Facility at the Uni-
versity of Connecticut. The use of these animals was approved by the University of Connecti-
cuts Institutional Animal Care and Use Committee. At 12 weeks of age, mice were set up
into breeding pairs. To study the short-term effects of drug treatment at different ages during
postnatal development, mice were administered a single dose of phenytoin (100 mg/kg) or PBS
vehicle control intraperitoneally at age day 5 or age day 60 following birth. Twenty fours after
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the treatment, mice were sacrificed and livers with gallbladders removed were collected. Sam-
ples were snap frozen in liquid nitrogen then stored at -80 °C. To study the long-term effects of
phenytoin treatment, a single dose of 100 mg/kg was administered intraperitoneally at age day
5, then livers were collected in the same manner at age day 60.
Protein Sample Preparation and LC-MS/MS-based Quantification. The same procedures
used for protein sample preparation and quantification in Chapter Five were used in this study.
However, for this experiment, unique peptide sequences of all known liver proteins were used
for quantification.
Protein Ontology Analysis. Ontology was performed using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID, v6.8). Biological processes and molecular
function terms with a p-value < 0.05 and a FDR < 1 were considered statistically significantly
enriched.
7.3 Results
To investigate global changes to liver function following phenytoin treatment, we performed
proteomics analysis rather than RNA-seq. This provided us with better insight into the func-
tional consequences of drug treatment, especially since earlier differences in gene expression
of CYPs based on RT-PCR did not always correlate with protein measurements, as seen in
Chapters Five and Six. We examined all proteins expressed in the liver of adult and neonatal
mice 24 hours after treatment with either vehicle control or 100 mg/kg phenytoin utilizing a
SWATH-MS mass spectrometry method. This allowed us to analyze the short-term effects of
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phenytoin treatment on the liver proteome. We also investigated long-term effects following
neonatal phenytoin exposure by treating mice at day 5 of age, then collecting livers for pro-
teome analysis at age day 60. Treatment schemes are illustrated in Figure 7.1A. Significantly
differentially expressed proteins were identified based on a p-value <0.05 and a fold-change
≥ 0.5 or≤ −0.5 in comparison to age-matched mice that received PBS vehicle control. Follow-
ing phenytoin treatment, 98 proteins were differentially expressed in the adult liver compared
to control. Of these, 57 were up-regulated and 41 were down-regulated. Following phenytoin
treatment in the neonate, however, 252 proteins were differentially expressed. Of these, only
69 were up-regulated while 183 were down-regulated. Our findings are summarized in Figure
7.1B. In total, there were only 25 common differentially expressed proteins between neonate
and adults following phenytoin treatment. The rest were specific to either adult or neonatal
livers. Additionally, of the 252 proteins affected by phenytoin treatment in neonates in the
short-term, only 12 of these proteins were commonly affected in the long-term by phenytoin
treatment at day 5. The other 42 proteins significantly differentially expressed in the long-term
were unique and did not overlap with neither neonate or adult short-term groups (Figure 7.1C).
7.3.1 Short-term effects on the adult liver proteome following phenytoin
exposure.
First, we verified that drug-metabolizing CYPs were identified and up-regulated in response
to 24-hour exposure to phenytoin in adults. Cyp2b10 was the most significantly up-regulated
protein in general, with a fold-increase of 5.4 compared to control mice. Cyp3a11 and Cyp2c29
were also significantly increased, with fold-changes of 2.3 and 1.3, respectively. In total, 15
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Animal Group
Total number of 
proteins
Up-regulated 
proteins
Down-regulated 
proteins
Adult short-term PHY 98 57 41
Neonate short-term PHY 252 69 183
Neonate long-term PHY 55 39 16
Short-term PHY, 
adult-specific
73 - -
Short-term PHY, neonate-
specific
228 - -
Short-term PHY, common 25 - -
A
B
C
Neonate 
short-term PHY
Adult
short-term PHY
Neonate
long-term PHY
FIGURE 7.1: Summary of differential protein expression in the liver following phenytoin
treatment in neonates and adults The groups of animal treatment schemes are illustrated in
(A). Short-term responses to a single dose of 100 mg/kg phenytoin (PHY) in neonates were
evaluated by collecting livers 24 hours following treatment and comparing the proteome to
mice that received PBS control. Short-term responses to a single dose of PHY in adults were
evaluated by collecting livers 24 hours following treatment and comparing the proteome to mice
that received PBS control. Long-term effects of a single dose of PHY were evaluated by treating
mice at day 5 of age, then collecting livers at day 60 of age, and comparing the proteome to
mice that received PBS control at day 5. The number of differentially expressed proteins in
PHY-treated groups compared to PBS-treated controls are summarized in (B). The overlap in
specific differentially expressed proteins between each treatment group are represented in (C).
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CYP proteins were differentially expressed. Most were up-regulated in response to pheny-
toin, and consisted of Cyp3a25, Cyp2c54, Cyp3a13, Cyp2c50, Cyp4a10, Cyp27a1, Cyp2b19,
Cyp8b1, and Cyp2c39 in addition. Three CYPs were down-regulated, including Cyp7b1,
Cyp51a1, and Cyp2c70. Other phase I enzymes such as Por, Ces1c, Ces1e, and Ces2a were
also significantly up-regulated in response to phenytoin treatment. Very few phase II enzymes
or transporters were affected by phenytoin treatment.
To gain a better understanding of the overall immediate effect of phenytoin treatment on liver
function, we also performed ontology analysis using the lists of differentially expressed pro-
teins. The up-regulated proteins were significantly enriched in biological processes such as
oxidation-reduction pathways, epoxygenase P450 pathway, fatty acid metabolism, and mito-
chondrial respiration and electron transport. Most of these proteins had the molecular function
of oxidoreductase activity, aromatase activity, heme binding, and other types of steroid hor-
mone metabolic activity. Down-regulated proteins were significantly enriched in the biological
processes of cholesterol biosynthesis, lipid biosynthesis, and receptor-mediated endocytosis.
The majority of these proteins functioned as molecular protein binders.
7.3.2 Short-term effects on the neonatal liver proteome following pheny-
toin exposure.
We observed strikingly different proteomic responses to phenytoin in neonatal mice compared
to adults. Our first step was to examine the expression of CYP proteins that were altered by
drug treatment. Cy2b10 and Cyp3a11 were again found to be up-regulated, but only by 1.3-
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Biological process
Number of 
proteins
P-value FDR
Oxidation-reduction 
pathway
28 3.34E-25 4.20E-22
Epoxygenase P450 
pathway
7 2.36E-10 2.97E-07
Fatty acid metabolic 
process
6 8.40E-05 1.05E-01
Transport 16 1.28E-04 1.61E-01
Lipid metabolic 
process
8 3.23E-04 4.05E-01
Respiratory electron 
transport chain
3 1.34E-03 7.76E-01
Biological process
Number of 
proteins
P-value FDR
Cholesterol 
biosynthetic process
5 1.40E-06 0.0019
Isoprenoid 
biosynthetic process
3 4.23E-04 0.56
Lipid biosynthetic 
process
3 4.23E-04 0.56
Receptor-mediated 
endocytosis
4 0.0079 10.02
A
B
Molecular 
Function
Number of 
proteins
P-value FDR
Oxidoreductase 
activity
24 1.06E-19 1.25E-16
Aromatase activity 10 1.35E-15 1.58E-12
Heme binding 14 6.71E-15 7.86E-12
Monooxygenase 
activity
12 2.89E-14 3.42E-11
Arachidonic acid 
epoxygenase
activity
8 1.19E-10 1.40E-07
Steroid 
hydroxylase 
activity
8 3.29E-10 3.88E-07
Electron carrier 
activity
6 6.61E-07 7.80E-04
Flavin adenine 
dinucleotide 
binding
5 7.76E-05 0.09
Molecular 
function
Number of 
proteins
P-value FDR
Protein 
binding
27 1.87E-02 19.70
Actin filament 
binding
3 3.38E-02 32.90
Poly(A) RNA 
binding
7 3.46E-02 33.50
SnoRNA
binding
2 4.51E-02 41.42
FIGURE 7.2: Ontology analysis of differentially expressed proteins in response to short-
term phenytoin treatment in adults. Protein ontology analyses were performed on both sig-
nificantly up-regulated (A) and down-regulated (B) proteins in response to phenytoin exposure
in adult male mice. Enriched biological processes and molecular functions with a p < 0.05
and FDR < 1 are listed. In the case of down-regulated proteins, all enriched terms are listed
regardless of FDR.
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and 1.5-fold, respectively. Cyp2c29 was not found to be up-regulated in the neonatal liver.
A total of 14 CYP proteins were found to be differentially expressed, however the extent of
CYP induction was not as great as in the adult liver. There appeared to be no difference in
the amount of CYPs either induced or repressed, with Cyp3a25, Cyp2d11, Cyp27a1 Cyp1a2,
Cyp3a13 being additionally up-regulated proteins, and Cyp2c40, Cyp3a16, Cyp4a10, Cyp4a12,
Cyp51a1, and Cyp2d26, being down-regulated. Additional phase I enzymes that exhibited
differential expression in response to phenytoin included Aldh5a1, Fmo1, Pon3, and Aox1. No
Ces proteins were significantly altered, and only a few phase II enzymes and transporters were
affected (Sult2a2, Sult1a1, Gstt3, Ugt16, Slc27a2). The protein with the greatest fold-induction
was tryptophan 2,3-dioxygenase (Tdo2), which is not involved in drug metabolism.
To gain a better understanding of the overall effect of phenytoin on proteins in the develop-
ing neonatal liver, we also performed ontology analyses on these differentially expressed pro-
teins lists (Figure 7.3). The biological processes enriched in up-regulated proteins were sim-
ilar to those of the adult samples and included oxidation-reduction, steroid metabolism, lipid
metabolism, and drug metabolism biological processes. However, additional processes that
were not identified in adults included ATP biosynthesis, cellular responses to glucagon, blood
coagulation, hemostasis, and fibrinolysis were also identified. The up-regulated proteins had
functions that were consistent with oxidoreductase activity, iron binding, and energy transport.
The majority of differentially expressed proteins in the neonatal samples were, however, down-
regulated. The protein with the greatest fold-reduction was thymidine kinase 1 (Tk1), which
was down-regulated by over 2-fold. The biological processes enriched for these proteins were
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quite different from the down-regulated proteins in adults and consisted of chromatin silenc-
ing, nucleosome assembly, translation, RNA splicing, and mRNA processing (Figure 7.3B).
The processes of steroid biosynthesis, oxidation-reduction reactions, cholesterol biosynthesis,
and lipid metabolism were also similarly enriched for repression. The molecular functions of
down-regulated proteins in the neonate showed enrichment for poly(A) RNA binding, riboso-
mal structure, RNA binding, DNA binding, and oxidoreductase activity functions. Strikingly,
many histone proteins (25 variants) were down-regulated in response to phenytoin neonates,
belonging to histone 1 and histone 2 submfamilies, and were identified for roles in chromatin
silencing and nucleosome assembly. This effect was absent in adults.
7.3.3 Long-term effects on the adult liver following phenytoin exposure
at the neonatal age.
Following neonatal exposure to phenytoin at age day 5, only 55 proteins were significantly
altered in the adult liver at age day 60. Only 12 proteins that were up-regulated in the short-
term by phenytoin were also significantly altered in these adult mice, and included apoptotic
chromatin condenstion inducer (Acin1), fibrinogen (Fga, Fgb), keratins (Krt6, Krt16), several
splicing factors (Srsfs), and small nuclear ribonuclear proteins (Snrps). The remainder of the
proteins altered in adults following neonatal exposure were unique to this group. The most
up-regulated protein was DExH-Box Helicase 9 (Dhx9), which had a 1.3-fold increase. Several
other heterogeneous ribonuclear proteins were also up-regulated. The most down-regulated
protein was glucosamine-6-phosphate deaminase 1 (Gnpda1), which had a 1.7-fold decrease.
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Biological process
Number of 
proteins
P-value FDR
Oxidation-reduction 
process
21 1.74E-13 2.48E-10
Steroid metabolic 
process
7 6.10E-07 8.68E-04
ATP biosynthetic 
process
5 1.36E-06 1.94E-03
Drug metabolic 
process
4 3.64E-05 5.19E-02
Lipid metabolic process 10 4.15E-05 5.91E-02
Cellular response to 
glucagon
3 1.30E-04 1.85E-01
Protein 
homotetramerization
5 1.54E-04 2.19E-01
Blood coagulation 5 2.51E-04 3.57E-01
Hemostasis 4 6.30E-04 8.94E-01
Biological process
Number of 
proteins
P-value FDR
Chromatin silencing 16 1.46E-16 1.67E-13
Nucleosome 
assembly
17 2.26E-14 3.43E-11
Translation 25 1.18E-11 1.79E-08
Steroid biosynthetic 
process
12 5.75E-11 8.70E-08
Oxidation-reduction 
process
18 4.92E-09 7.45E-06
RNA splicing 17 8.67E-09 1.31E-05
Cholesterol 
biosynthetic process
8 4.23E-08 6.39E-05
mRNA processing 18 8.61E-08 1.30E-04
Lipid metabolic 
process
17 4.22E-05 6.39E-02
Negative regulation of 
cell proliferation
12 3.21E-03 4.75
Histone H3-K27 
trimethylation
3 3.14E-03 4.64
Defense response to 
Gram-positive 
bacterium
7 5.24E-04 0.79
Molecular function
Number of 
proteins
P-value FDR
Oxidoreductase 
activity
20 6.84E-13 8.75E-10
Iron ion binding 12 4.66E-10 5.96E-07
Monooxygenase 
activity
8 1.83E-07 2.35E-04
Proton-transport ATP 
synthase activity
5 1.93E-07 2.47E-04
Aromatase activity 6 2.47E-07 3.15E-04
Amino acid binding 5 5.05E-06 6.46E-03
Electron carrier 
activity
5 5.05E-05 6.45E-02
Catalytic activity 10 8.55E-05 1.09E-01
ATPase activity 7 1.17E-04 1.50E-01
Metal ion binding 27 1.54E-04 1.96E-01
Flavin adenine 
dinucleotide binding
5 1.68E-04 2.14E-01
Molecular function
Number of 
proteins
P-value FDR
Poly(A) RNA binding 51 8.37E-18 1.13E-14
Structural constituent 
of ribosome
26 2.43E-16 3.00E-13
Oxidoreductase 
activity
27 4.32E-09 5.81E-06
Large ribosomal 
subunit rRNA binding
6 3.14E-07 4.22E-04
RNA binding 27 6.86E-07 9.24E-04
U1 snRNP binding 5 1.04E-06 1.41E-03
DNA binding 44 2.58E-06 3.47E-03
Enzyme binding 17 7.35E-06 9.90E-03
Estradiol 17-beta-
dehydrogenase 
activity
4 3.68E-04 4.94E-01
Monooxygenase 
activity
7 1.38E-03 1.84
Structural molecule 
activity
10 1.44E-03 1.92
A
B
FIGURE 7.3: Ontology analysis of differentially expressed proteins in response to short-
term phenytoin treatment in neonates. Protein ontology analyses were performed on both
significantly up-regulated (A) and down-regulated (B) proteins in response to phenytoin expo-
sure in neonatal mice. Enriched biological processes and molecular functions with p < 0.05
and FDR < 1 (in most cases) are listed.
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Overall, the long-term neonatal treated group had less drastic fold-changes in protein expression
compared to the other two groups.
Ontology analyses for the up-regulated proteins revealed biological processes such as RNA
splicing, mRNA processing, and mRNA transport as being enriched (Figure 7.4A). This sug-
gests possible permanent changes to transcriptional and translational regulation in the liver
following neonatal phenytoin treatment. This corresponds to the enriched molecular functions
of RNA binding, nucleotide binding, and structural molecule activity that were also identified.
Additionally, blood coagulation, platetel activation, fibrinolysis, and plasminogen activation
were processes identified to be significantly altered. No terms relating to drug metabolism,
CYP activity, or energy metabolism were found to be enriched. Significantly enriched bio-
logical processes of down-regulated proteins (Figure 7.4B) included nucleotide biosynthesis,
cellular response to lipids, cellular response to testosterone, heat generation, and regulation of
glucose metabolism. The molecular functions of these proteins that were enriched also included
small molecule binding and insulin-activated receptor activity. No terms or functions relating
to chromatin silencing, drug metabolism, or nucleosome assembly were identified, as in the
short-term neonatal group.
7.4 Discussion
This study revealed important differences in liver protein responses to phenytoin treatment
between neonatal and adult mice, and also identified many proteins that may be permanently
altered in adult mice following neonatal exposure to the drug. The use of the novel proteomics
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Biological Process
Number of 
proteins
P-value FDR
RNA splicing 14 7.95E-16 9.77E-13
mRNA processing 15 1.00E-15 1.25E-12
mRNA splicing 7 9.81E-08 1.24E-04
mRNA transport 5 3.06E-05 0.04
Blood coagulation 3 4.06E-05 0.05
Platelet activation 4 6.85E-05 0.09
Osteoblast differentiation 5 8.14E-05 0.10
Positive regulation of 
peptide hormone secretion
3 8.50E-05 0.11
Plasminogen activation 3 1.81E-04 0.23
Protein polymerization 3 3.13E-04 0.39
Fibrinolysis 3 4.21E-04 0.53
Molecular function
Number of 
proteins
P-value FDR
RNA binding 20 5.20E-16 6.22E-13
Poly(A) RNA binding 22 1.41E-15 1.62E-12
Nucleotide binding 21 6.22E-10 6.97E-07
Structural molecule 
activity
7 1.29E-05 0.014
mRNA binding 6 1.53E-05 0.017
Cell adhesion molecule 
binding
4 5.31E-04 0.59
Biological process
Number of 
proteins
P-value FDR
Nucleotide biosynthesis 3 3.29E-05 0.038
Cellular response to lipids 3 7.66E-05 0.088
Cellular response to 
testosterone
3 4.82E-05 0.055
Heat generation 3 7.66E-05 0.088
Positive regulation of 
glucose metabolism
3 1.53E-04 0.18
Locomotor rhythm 3 2.36E-04 0.27
Mitochondria 
morphogenesis
3 3.59E-04 0.41
Molecular function
Number of 
proteins
P-value FDR
Small molecule binding 4 3.75E-06 3.70E-03
Ribose phosphate 
diphosphokinase activity
3 1.34E-05 1.30E-02
Insulin-activated receptor 
activity
3 6.93E-05 6.84E-02
Pheromone binding 4 1.56E-04 0.15
A
B
FIGURE 7.4: Ontology analysis of differentially expressed proteins in adult mice in re-
sponse to long-term phenytoin treatment at the neonatal age. Protein ontology analyses
were performed on both significantly up-regulated (A) and down-regulated (B) proteins identi-
fied in the livers of adult mice following exposure to phenytoin at the neonatal age. Enriched
biological processes and molecular functions with p < 0.05 and FDR < 1 are listed.
method, SWATH-MS, allowed us to identify significant differences among all of the proteins
known to be expressed in the mouse liver between control and treatment groups. This is one
of the first studies that has looked at global changes to liver protein expression following drug
treatment in the mouse. This is also one of the only studies that has compared drug responses
in the adult mouse to drug responses in the neonatal mouse. This data supports the argument
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that drug responses vary considerably between pediatric and adult patients, and adult drug data
cannot be used to extrapolate drug responses to infants and children.
Alterations to proteins in the liver of adult mice exposed to phenytoin for 24 hours were as
expected and included proteins involved in oxidation-reduction pathways, CYP metabolism,
cholesterol metabolism, and lipid metabolism. Phenytoin, as previously discussed, is well
known to induce the expression of many drug-metabolizing enzymes in the liver, including
CYPs. Phenytoin has also been associated with changes in glucose and lipid metabolism, which
is supported by our data [216]. Long-term phenytoin treatment has also been associated with
changes in serum triglyceride and cholesterol levels [217]. Because phenytoin is known as an
enzyme inducer, it is also interesting to note the large amount of proteins acts to down-regulate,
which is an important consideration when predicting drug responses.
Alterations to proteins in the liver of neonatal mice exposed to phenytoin for 24 hours were
much more surprising. Biological processes found to be enriched included oxidation-reduction,
drug metabolism, and lipid metabolism, similar to adults, however ATP biosynthesis, steroid
biosynthesis, blood coagulation, and cellular response to glucagon were also up-regulated,
which was not observed in adult mice. Phenytoin has been shown to modulate estrogen re-
ceptor (ER) activity [218], as well as testosterone metabolism in the brain of rodents [219],
which makes sense due to the capacity for CYP enzymes to also metabolize steroid hormones.
Phenytoin has also been shown to increase serum glucagon levels [220], which may also be
related to the enriched ATP biosynthetic process our analyses identified due to altered energy
demands within liver cells. Hemorrhage has also been loosely linked to phenytoin exposure in
the newborn due to a vitamin K defiency that results from the up-regulation of liver enzymes
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[221]. This could explain the fact that blood coagulation was also a significantly altered process
resulting from phenytoin in our data.
The most striking differences in the response to phenytoin in the neonate was in the large num-
ber of down-regulated proteins, however. According to ontology analysis, biological processes
such as chromatin silencing, nucleosome assembly, translation, RNA splicing, steroid biosyn-
thesis, lipid biosynthesis, and histone modification were significantly down-regulated. None of
these terms were enriched in down-regulated proteins identified in our adult mice. This suggests
that phenytoin has significant effect on transcriptional and translational regulatory processes in
young mice only. This could also explain why a greater number of proteins were affected
following short-term phenytoin treatment in neonates, since general epigenetic changes, such
as chromatin silencing and mRNA processing, could affect the transcription and thus protein
expression of many target genes. A down-regulation of chromatin silencing would suggest an
increase in gene activation and transcription, and this could serve as a mechanism for enzyme
induction in neonates. At this point, no studies have identified an association between pheny-
toin treatment and chromatin modifications. A down-regulation of nucleosome assembly also
suggests diminished DNA synthesis and thus cell proliferation, which might affect hepatocyte
growth and liver development during postnatal maturation. In utero exposure to phenytoin is
known to cause a condition known as Fetal Hydantoin Syndrome, which is characterized by
growth retardation and alterations to developmental pathways [222]. It is possible that pheny-
toin treatment might still significantly interfere with developmental processes during postnatal
maturation as well.
Due to the propensity of phenobarbital to cause permanent changes to the liver transcriptome
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following neonatal exposure, we wondered if phenytoin treatment at the neonatal age might
also produce lasting effects on liver proteins. In adult mice that received phenytoin on day 5 of
age, 55 proteins were found to be differentially expressed compared to control mice. Only 12
of these proteins were also affected by short-term phenytoin treatment in neonates, suggesting
cellular mechanisms that occur later in life which alter the transcription or translation of genes
programmed by neonatal phenytoin treatment. Interestingly, proteins that are up-regulated in
adult mice include keratins, which are a classic marker for liver tumors and hepatic injury
[223]. This suggests that damage to the liver caused by neonatal phenytoin administration may
persist to adulthood and increase susceptibility for liver disease. Blood coagulation, a biological
processes identified as enriched in our mice, also plays a role in liver disease as the liver is
responsible for clearing coagulation factors from the blood [224]. This also supports the idea
that neonatal phenytoin treatment may increase the risk of liver disease or damage in later life.
It would be interesting to test susceptibility of adult mice to hepatotoxicants following neonatal
phenytoin treatment and compare liver damage to control animals. There are also permanent
changes to the expression of proteins involved in mRNA splicing, processing, and transport
following neonatal phenytoin exposure, which could impact global transcription regulation.
Perhaps this would affect enzyme induction in adulthood following exposure to inducing drugs.
However, this study showed no changes to adult basal drug metabolic processes following
neonatal phenytoin exposure. Lipid and glucose metabolism, however, were both observed
to be potentially down-regulated in adult livers, as well as cellular responses to testosterone.
Disturbances in the regulation of sex hormones, particularly testosterone, have been identified
in male epileptic patients taking AEDs [225], so it would be interesting to further explore the
link between neonatal AED exposure and potential hormonal imbalances later in life.
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Future studies will be necessary to determine whether the identified changes in protein ex-
pression following phenytoin exposure correspond to significant changes in liver function in
both neonates and adults. However, protein expression is typically more highly correlated to
enzyme activity, function, and biological consequences than mRNA expression [226]. Also,
our study only measured changes to protein expression following a single dosing concentration
and only at one timepoint. It would be interesting to see if there are any differences in liver
protein profiles following exposure to phenytoin at higher or lower doses than 100 mg/kg. It
would also be of value to measure protein expression following longer exposure, perhaps 48
hours, since it requires more time to observe significant changes in protein expression than
mRNA expression. In light of this, the present study highlights the fact that drug response can
vary drastically between neonates and adults, and the neonatal liver may be more susceptible
to epigenetic changes resulting from exposure to inducing drugs. Additionally, while neonatal
pheytoin exposure does not appear to signficantly affect drug-metabolizing proteins as pheno-
barbital dose, neonatal exposure to phenytoin may affect adult susceptibility to liver damage
and disease.
Chapter 8
Summary and Future Directions
The studies discussed in this dissertation highlight the significant differences between neona-
tal and adult responses to drug treatment, in particular the AEDs phenobarbital and phenytoin,
especially in regards to CYP expression and hepatic drug metabolism. Additionally, this work
also demonstrates the capability for neonatal drug exposure to affect gene and protein expres-
sion in the liver in adulthood, which could potentially affect drug efficacy and susceptibility
to liver diseases later in life. Because these studies were completed in a mouse model, future
studies will need to be completed in humans to verify our findings and determine inter-species
differences in the responses to these drugs. In light of this, our studies provide a solid basis
for the argument that adult drug response data cannot be directly extrapolated to predict drug
responses in infants and children. There is a significant need for pharmacokinetic evaluation of
specific drugs in infant and children populations, and to characterize CYP induction and drug
metabolic pathways for all drug compounds at multiple stages of postnatal development.
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Our work has demonstrated that neonatal phenobarbital treatment up-regulates the expression
of many drug-metabolizing enzymes, CYPs, and transporters in the adult mouse liver, which
can then affect drug efficacy later in life. Many other genes involved in hepatic processes such
as steroid metabolism, lipid metabolism, proteolysis, and circadian rhythm are also signifi-
cantly impacted. We hypothesized that this phenomenon was due to neonatal programming
of the CAR nuclear receptor, based on other work that described the necessity of CAR to pro-
duce permanent changes to CYP expression following neonatal treatment with the CAR agonist
TCPOBOP [86]. Future studies with Car-null mice and neonatal phenobarbital exposure would
be imperative to prove this speculation. Regardless, we subsequently predicted that neonatal
phenytoin exposure would also induce permanent up-regulation to CYP expression and drug
metabolism in adulthood due to the ability of the drug to activate CAR as well. However, this
did not occur. This suggests that CAR activation may not be the key factor enabling perma-
nent induction of CYP enzymes following drug treatment at the neonatal age. Whereas the
mechanism for the indirect activation of CAR by phenobarbital has been elucidated [172], the
mechanism of CAR activation by phenytoin is still unknown. There may be fundamental dif-
ferences in the way the two AEDs induce CYP expression, which warrants further examination
into the involvement of additional nuclear receptors and/or hormonal regulation. In addition,
it is also likely that different drugs may have specific windows of sensitivity and require high-
er/chronic doses in order to program gene expression in early postnatal life.
Neonatal exposure to phenytoin possibly induces differentiation of hepatocytes during postnatal
liver maturation. In addition to up-regulating several CYPs and drug-metabolizing enzymes,
phenytoin administration to neonatal mice also increases the expression of proteins involved in
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mature liver functions such as lipid metabolism, steroid metabolism, and energy homeostasis.
Phenytoin treatment also repressed the expression of fetal-specific genes such as Cyp3a16,
H19, and Igf2. Chromatin silencing via epigenetic modifications such as histone methylation
are known to be critical to maintaining proper gene expression during postnatal development,
and phenytoin treatment was also shown to down-regulate these processes in the neonatal liver.
Future studies on the impact of inducer treatment in early life on the proper differentiation and
maturation of the liver could provide valuable information on mechanisms underlying postnatal
liver development. Previous worked from our laboratory has shown that the loss of the nuclear
receptor Fxr in mice significantly affects the maturation of liver gene expression throughout
postnatal development [227]. It would be interesting to understand whether over-expressing
certain nuclear receptors, or the constant activation of nuclear receptors, in the liver would
affect the normal course of organ development and maturation.
Finally, consequences on functional processes and responses in the adult liver following neona-
tal drug exposure should be examined. It is possible that neonatal treatment with phenytoin
programs the liver to have exaggerated responses to chemical challenges later in life, as demon-
strated by Dr. Cherly Lyn Walker [129]. Adult re-challenges with other clinically utilized drugs
could be used to measure CYP induction, efficacy, and toxicity in relation to control animals.
Neonatal phenytoin exposure also caused up-regulation of various protein markers for liver dis-
ease in adulthood. It would be interesting to investigate whether these mice are more suscepti-
ble to liver damage by xenobiotics (e.g. acetaminophen, carbon tetrachloride) or to developing
liver diseases (e.g. NAFLD, fibrosis, hepatocellular carcinoma). Phenytoin also affects energy
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metabolism in additional to drug metabolism in the liver. It would also be valuable to better un-
derstand if neonatal phenytoin exposure has permanent effects on lipid or glucose metabolism
in adulthood and risk for developing obesity or diabetes.
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